// Drug Database for MLA Quiz PWA
// Extracted from app.js for better organization

const drugDatabase = {
            'aciclovir': {
                name: 'Aciclovir',
                class: 'Antiviral drugs',
                mechanism: 'Nucleoside analogue - inhibits viral DNA polymerase after phosphorylation by viral thymidine kinase',
                dosing: 'Herpes simplex: 200mg 5x daily for 5 days. Shingles: 800mg 5x daily for 7 days. IV: 5-10mg/kg TDS',
                contraindications: 'Hypersensitivity. Caution in renal impairment, dehydration',
                interactions: 'Nephrotoxic drugs (↑ nephrotoxicity), probenecid (↑ levels), mycophenolate',
                monitoring: 'Renal function, hydration status, neurological symptoms (high doses)',
                pregnancy: 'Safe - no evidence of teratogenicity',
                sideEffects: 'GI upset, headache, dizziness, acute kidney injury (IV), neurological effects (high doses)',
                pharmacokinetics: 'Variable oral absorption (15-30%), half-life: 2-3h, mainly renal excretion',
                clinicalPearls: 'Most effective when started within 72h of rash onset. Maintain good hydration',
                indication: 'Herpes simplex, varicella zoster, prophylaxis in immunocompromised'
            },
            'adenosine': {
                name: 'Adenosine',
                class: 'Antiarrhythmic (Purine nucleoside)',
                mechanism: 'Blocks AV node conduction by activating adenosine A1 receptors',
                dosing: 'Adult: rapid IV bolus 6mg via a large vein (immediate saline flush), if ineffective give 12mg then 18mg as per Resuscitation Council (tachycardia) guidance. Pediatric: 0.1mg/kg (see paediatric guidance)',
                contraindications: 'Severe asthma (relative contraindication because of bronchospasm risk), COPD, 2nd/3rd degree heart block, sick sinus syndrome, WPW with AF',
                interactions: 'Dipyridamole (↑ effect), theophylline (↓ effect), carbamazepine (↑ heart block)',
                monitoring: 'Continuous ECG, blood pressure, respiratory status',
                pregnancy: 'Use only if maternal benefit outweighs fetal risk; severe maternal asthma increases risk of bronchospasm. Refer to UK resuscitation guidance and seek specialist advice in pregnancy',
                sideEffects: 'Chest pain, dyspnea, flushing, transient AV block, bronchospasm',
                pharmacokinetics: 'Very short half-life <10 seconds. Rapid cellular uptake and metabolism',
                clinicalPearls: 'Give fast IV push followed by saline flush. Warn patient of chest discomfort',
                indication: 'SVT termination, diagnostic test for broad complex tachycardia'
            },
            'adrenaline': {
                name: 'Adrenaline (Epinephrine)',
                class: 'Emergency drugs',
                mechanism: 'Non-selective α and β adrenergic agonist causing vasoconstriction and inotropy',
                dosing: 'Anaphylaxis: 500mcg IM (0.5ml of 1:1000). Cardiac arrest: 1mg IV (10ml of 1:10,000)',
                contraindications: 'None in life-threatening situations. Caution with severe hypertension',
                interactions: 'β-blockers (unopposed α effects), tricyclics (arrhythmias), MAOIs',
                monitoring: 'Heart rate, blood pressure, ECG, blood glucose',
                pregnancy: 'Safe in life-threatening situations',
                sideEffects: 'Tachycardia, hypertension, arrhythmias, tremor, anxiety, hyperglycaemia',
                pharmacokinetics: 'Rapid onset, short duration: 5-10min, metabolised by COMT/MAO',
                clinicalPearls: 'First-line for anaphylaxis. IM route for anaphylaxis, IV for cardiac arrest. Check expiry dates',
                indication: 'Anaphylaxis, cardiac arrest, severe asthma (nebulised), local anaesthetic adjunct'
            },
            'alendronic acid': {
                name: 'Alendronic Acid',
                class: 'Bisphosphonates',
                mechanism: 'Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite',
                dosing: 'Osteoporosis: 70mg weekly on empty stomach. Paget\'s disease: 40mg daily for 6 months',
                contraindications: 'Oesophageal abnormalities, hypocalcaemia, severe renal impairment',
                interactions: 'Calcium/iron/antacids (↓ absorption - separate by 2h), NSAIDs (↑ GI irritation)',
                monitoring: 'Calcium, phosphate, vitamin D levels. Dental health. Atypical fractures',
                pregnancy: 'Avoid - crosses placenta and may affect fetal bone development',
                sideEffects: 'Oesophageal irritation, osteonecrosis of jaw (rare), atypical fractures (rare)',
                pharmacokinetics: 'Poor oral absorption (<1%), long bone half-life (10+ years)',
                clinicalPearls: 'Take on empty stomach with full glass water. Stay upright 30min. Weekly dosing improves compliance',
                indication: 'Osteoporosis treatment/prevention, Paget\'s disease, steroid-induced osteoporosis'
            },
            'allopurinol': {
                name: 'Allopurinol',
                class: 'Xanthine oxidase inhibitor',
                mechanism: 'Inhibits xanthine oxidase, decreasing uric acid synthesis',
                dosing: 'Start 100 mg OD; titrate by 100 mg every 2–4 weeks to target serum urate < 300 µmol/L (max 900 mg OD)',
                contraindications: 'Acute gout flare (delay initiation), known HLA-B*58:01 positivity (↑ risk of severe cutaneous reactions)',
                interactions: 'Azathioprine / mercaptopurine (↑ toxicity – reduce dose 75%), warfarin (↑ INR), ACEi (hypersensitivity)',
                monitoring: 'Urate, U&Es, LFTs, FBC; observe for rash or eosinophilia',
                pregnancy: 'Avoid if possible; limited safety data',
                sideEffects: 'Rash, Stevens-Johnson syndrome, hepatic dysfunction, bone-marrow suppression (rare)',
                pharmacokinetics: 'Oral bioavailability ≈ 90 %; active metabolite oxypurinol t½ ≈ 20 h; renal elimination',
                clinicalPearls: 'Test HLA-B*58:01 in patients of Han Chinese, Thai or Korean descent. Continue during intercurrent flares once established; co-prescribe prophylactic colchicine for first 3 months.',
                indication: 'Gout prophylaxis, hyperuricaemia, tumour-lysis-syndrome prevention'
            },
            'amiodarone': {
                name: 'Amiodarone',
                class: 'Antiarrhythmic drugs (Class III)',
                mechanism: 'Blocks potassium channels, prolongs action potential and refractory period',
                dosing: 'Loading: 200mg TDS for 1 week, then 200mg BD for 1 week. Maintenance: 200mg daily',
                contraindications: 'Sinus bradycardia, heart block, thyroid disease, iodine allergy',
                interactions: 'Warfarin (↑ INR), digoxin (↑ levels), β-blockers (bradycardia), many others',
                monitoring: 'TFTs and LFTs every 6 months; annual CXR; ECG at baseline and periodically; vision checks and ophthalmology referral if visual symptoms. Pre-treatment: TFTs, LFTs, CXR',
                pregnancy: 'Avoid in pregnancy - risk of neonatal hypothyroidism and bradycardia; UKTIS advises avoid unless essential',
                sideEffects: 'Pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, corneal deposits, skin discolouration',
                pharmacokinetics: 'Very long half-life: 20-100 days, extensive tissue distribution',
                clinicalPearls: 'Many serious side effects. Regular monitoring essential (TFTs/LFTs 6-monthly, CXR annually). Ophthalmology review if visual symptoms. Sun protection (photosensitivity)',
                indication: 'Life-threatening arrhythmias, AF (when other drugs fail), VT/VF'
            },
            'amlodipine': {
                name: 'Amlodipine',
                class: 'Calcium channel blockers',
                mechanism: 'Blocks L-type calcium channels in vascular smooth muscle and myocardium, causing vasodilation',
                dosing: 'Hypertension: Start 5mg daily, max 10mg daily. Elderly/hepatic impairment: start 2.5mg daily',
                contraindications: 'Hypersensitivity, unstable angina, significant aortic stenosis',
                interactions: 'Simvastatin (limit simvastatin to 20mg), CYP3A4 inhibitors (monitor for hypotension)',
                monitoring: 'Blood pressure, heart rate, signs of fluid retention, ankle oedema',
                pregnancy: 'Avoid unless essential - limited safety data',
                sideEffects: 'Ankle oedema (dose-related), flushing, dizziness, fatigue, gingival hyperplasia (rare)',
                pharmacokinetics: 'Peak: 6-12h, Half-life: 35-50h, Hepatic metabolism via CYP3A4',
                clinicalPearls: 'Long half-life allows once daily dosing. Ankle oedema not due to fluid retention. Preferred CCB in UK',
                indication: 'Hypertension, stable angina. Often used as add-on therapy'
            },
            'amitriptyline': {
                name: 'Amitriptyline',
                class: 'Tricyclic antidepressant (TCA)',
                mechanism: 'Inhibits serotonin and noradrenaline reuptake; antagonises muscarinic, histamine H₁, and α₁-adrenergic receptors',
                dosing: 'Depression: 25–75 mg nocte, titrate to max 150 mg. Neuropathic pain: 10–25 mg nocte (up to 75 mg).',
                contraindications: 'Recent MI, arrhythmias, mania, severe liver disease, concurrent MAOI use',
                interactions: 'Alcohol (↑ sedation), anticholinergics, QT-prolonging drugs, serotonergic agents',
                monitoring: 'ECG (QTc > 450 ms = caution), suicide risk (esp < 25 years), anticholinergic effects',
                pregnancy: 'Use with caution – neonatal withdrawal possible',
                sideEffects: 'Sedation, dry mouth, constipation, urinary retention, orthostatic hypotension, QT prolongation, arrhythmia in overdose',
                pharmacokinetics: 'Hepatic metabolism (CYP2D6); t½ ≈ 15 h',
                clinicalPearls: 'Start low and go slow. Cardiotoxic in overdose – dispense small quantities. Avoid in combination with SSRIs or tramadol (serotonin syndrome).',
                indication: 'Depression, neuropathic pain, migraine prophylaxis, nocturnal enuresis'
            },
            'amoxicillin': {
                name: 'Amoxicillin',
                class: 'Penicillins, broad-spectrum',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adults: 500mg TDS or 1g BD. Severe infections: 1g TDS. Children: 40-90mg/kg daily in 2-3 divided doses',
                contraindications: 'Penicillin allergy, infectious mononucleosis (high rash risk)',
                interactions: 'Methotrexate (↑ toxicity), combined oral contraceptive (↓ efficacy), probenecid (↑ levels)',
                monitoring: 'Signs of allergic reaction, C. difficile-associated diarrhoea, renal function in severe illness',
                pregnancy: 'Safe - suitable for use in pregnancy',
                sideEffects: 'GI upset, diarrhoea, rash (especially with EBV), CDAD, hypersensitivity reactions',
                pharmacokinetics: 'Onset: 1h, Peak: 1-2h, Half-life: 1h, Excretion: mainly renal',
                clinicalPearls: 'Broad spectrum penicillin. Good oral bioavailability. Reduce dose in severe renal impairment (CrCl <30)',
                coverage: 'Gram-positive: Streptococci, some Staphylococci. Gram-negative: E. coli, H. influenzae. No MRSA/Pseudomonas cover'
            },
            'apixaban': {
                name: 'Apixaban',
                class: 'Direct oral anticoagulant (DOAC) - Factor Xa inhibitor',
                mechanism: 'Direct, selective inhibition of factor Xa in coagulation cascade',
                dosing: 'AF: 5mg BD. Reduce to 2.5mg BD if the patient meets ≥2 of the following: age ≥80 years, body weight ≤60 kg, serum creatinine ≥133 µmol/L (see SmPC). Note: patients with severe renal impairment (CrCl 15–29 mL/min) also commonly require 2.5mg BD — check the local formulary/SmPC for details. VTE: 10mg BD for 7 days, then 5mg BD',
                contraindications: 'Active bleeding, severe hepatic impairment, pregnancy, prosthetic valves',
                interactions: 'Strong CYP3A4 inhibitors (↓ dose), P-gp inducers (avoid), warfarin (↑ bleeding)',
                monitoring: 'Renal function, hepatic function, signs of bleeding. No routine coagulation monitoring',
                pregnancy: 'Contraindicated in pregnancy — refer to the SmPC/Medicines.org.uk for pregnancy guidance',
                sideEffects: 'Bleeding, anaemia, nausea, hypotension',
                pharmacokinetics: 'Peak: 3-4h, Half-life: 12h, multiple elimination pathways',
                clinicalPearls: 'Can be taken with or without food. Less renal clearance than rivaroxaban',
                indication: 'Atrial fibrillation stroke prevention, VTE treatment and prophylaxis'
                ,
                reversal: 'Life-threatening bleeding: andexanet alfa where available; if not available or contraindicated consider 4-factor PCC. For non-life-threatening bleeding consider local protocols. Avoid routine bridging with heparin when stopping for procedures unless high thrombotic risk.'
            },
            'aspirin': {
                name: 'Aspirin',
                class: 'Antiplatelet drug (COX-1 inhibitor)',
                mechanism: 'Irreversibly inhibits cyclo-oxygenase-1 (COX-1), preventing thromboxane A₂ formation and platelet aggregation',
                dosing: 'Secondary prevention: 75 mg OD. Acute MI/ACS: 300 mg stat PO then 75 mg OD with a P2Y₁₂ inhibitor (dual therapy typically for 12 months post-ACS). Pain/fever: 300–900 mg QDS.',
                contraindications: 'Active GI bleeding, severe HF, children <16 years (Reye’s syndrome risk)',
                interactions: 'Warfarin or DOACs (↑ bleeding), methotrexate (↑ toxicity), ACEi/diuretics (↓ efficacy)',
                monitoring: 'Bleeding signs, Hb if long-term, renal function in elderly',
                pregnancy: 'Low-dose safe (preeclampsia prophylaxis); avoid high-dose in 3rd trimester (ductus arteriosus closure)',
                sideEffects: 'Dyspepsia, GI ulcer/bleed, bronchospasm in aspirin-sensitive asthma, tinnitus (high dose)',
                pharmacokinetics: 'Irreversible platelet inhibition lasting 7–10 days; hepatic metabolism',
                clinicalPearls: 'Always consider PPI cover if age > 65 or on anticoagulant. Stop 7 days pre-surgery unless indicated by cardiology.',
                indication: 'Secondary prevention after MI/stroke, post-PCI dual therapy, stable angina, ACS'
            },
            'atorvastatin': {
                name: 'Atorvastatin',
                class: 'Statins',
                mechanism: 'Competitively inhibits HMG-CoA reductase, rate-limiting enzyme in cholesterol synthesis',
                dosing: 'Adults: Start 20mg daily, usual dose 20-80mg daily. High-intensity: 40-80mg daily. Take any time of day',
                contraindications: 'Active liver disease, pregnancy, breastfeeding, unexplained persistent ↑ ALT/AST',
                interactions: 'Ciclosporin (↑ statin levels), warfarin (↑ INR), digoxin (↑ levels), grapefruit juice',
                monitoring: 'LFTs before treatment and at 3 months, lipids at 3 months, CK if muscle symptoms. For suspected statin intolerance consider dose reduction, alternate statin, or specialist referral. Stop statin if CK > 5× ULN or severe myopathy',
                pregnancy: 'Contraindicated - stop 3 months before conception',
                sideEffects: 'Myalgia (common), hepatotoxicity (rare), rhabdomyolysis (very rare), new-onset diabetes (slight ↑)',
                pharmacokinetics: 'Peak: 1-2h, Half-life: 14h, Metabolism: CYP3A4, active metabolites',
                clinicalPearls: 'High-intensity statin. NICE preferred high-intensity option. Can take any time due to long half-life. Manage intolerance with dose adjustments or switch; consider specialist input for recurrent myopathy',
                targets: 'Primary prevention: 20mg daily. Secondary prevention: 80mg daily. Target >40% LDL-C reduction'
            },
            'atropine': {
                name: 'Atropine',
                class: 'Antimuscarinic',
                mechanism: 'Competitive antagonist at muscarinic acetylcholine receptors',
                dosing: 'Bradycardia: 500mcg IV, repeat if necessary (max 3mg). Pre-med: 300-600mcg IM',
                contraindications: 'Narrow-angle glaucoma, prostatic enlargement, paralytic ileus',
                interactions: 'Tricyclics (↑ antimuscarinic effects), antihistamines (↑ sedation)',
                monitoring: 'Heart rate, blood pressure, pupil size, mental state',
                pregnancy: 'Safe - crosses placenta but no evidence of harm',
                sideEffects: 'Dry mouth, blurred vision, urinary retention, confusion, tachycardia',
                pharmacokinetics: 'Rapid onset: 1-2min IV, Duration: 30min-4h depending on dose',
                clinicalPearls: 'Antidote for organophosphate poisoning. May cause paradoxical bradycardia at low doses',
                indication: 'Symptomatic bradycardia, organophosphate poisoning, pre-medication'
            },
            'azithromycin': {
                name: 'Azithromycin',
                class: 'Antibiotic (Macrolide)',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adult: 500mg daily for 3 days PO or 500mg daily IV. Pneumonia: 500mg x 5 days',
                contraindications: 'Macrolide allergy, severe liver disease, QT prolongation',
                interactions: 'Warfarin (↑ INR), digoxin (↑ levels), simvastatin (↑ myopathy), QT drugs',
                monitoring: 'QT interval, liver function, infection resolution, hearing (high dose)',
                pregnancy: 'Generally considered compatible in pregnancy; UKTIS advises azithromycin may be used if indicated (e.g., chlamydia), but avoid unnecessary use',
                sideEffects: 'GI upset, QT prolongation, hepatotoxicity, hearing loss (rare)',
                pharmacokinetics: 'Long tissue half-life 68h. Good intracellular penetration. Hepatic metabolism',
                clinicalPearls: 'Once daily dosing. Good atypical coverage. Short course therapy',
                indication: 'Atypical pneumonia, COPD exacerbations, chlamydia, URTI, skin infections'
            },
            'beclomethasone': {
                name: 'Beclomethasone',
                class: 'Inhaled corticosteroid',
                mechanism: 'Synthetic glucocorticoid with anti-inflammatory effects in airways',
                dosing: 'Adults: 200-800mcg daily in divided doses. Children: 100-400mcg daily. Use spacer device',
                contraindications: 'Hypersensitivity. Caution in active pulmonary TB',
                interactions: 'Few significant interactions due to low systemic absorption',
                monitoring: 'Growth in children, oral candidiasis, signs of systemic effects (high doses)',
                pregnancy: 'Safe - inhaled route minimises systemic exposure',
                sideEffects: 'Oral candidiasis, hoarse voice, growth retardation (children with high doses)',
                pharmacokinetics: 'Low systemic bioavailability (~20%), extensive first-pass metabolism',
                clinicalPearls: 'Brown/red preventer inhaler. Rinse mouth after use. Use spacer device. Regular use essential',
                indication: 'Asthma prophylaxis, COPD (in combination inhalers)'
            },
            'bendroflumethiazide': {
                name: 'Bendroflumethiazide',
                class: 'Diuretics, thiazide and thiazide-like',
                mechanism: 'Inhibits sodium-chloride cotransporter in distal convoluted tubule',
                dosing: 'Hypertension: 2.5mg daily (morning). Oedema: 5-10mg daily initially',
                contraindications: 'Anuria, severe renal/hepatic impairment, hypersensitivity to sulfonamides',
                interactions: 'Lithium (↑ toxicity), digoxin (hypokalaemia ↑ toxicity), NSAIDs (↓ effect)',
                monitoring: 'U&Es, glucose, uric acid, blood pressure',
                pregnancy: 'Avoid - may cause neonatal thrombocytopenia',
                sideEffects: 'Hyponatraemia, hypokalaemia, hyperuricaemia, glucose intolerance, impotence',
                pharmacokinetics: 'Onset: 2h, Peak: 4-6h, Duration: 12-18h',
                clinicalPearls: 'Historically commonly used, but NICE NG136 prefers thiazide-like diuretics (e.g., indapamide or chlortalidone) as first-line for hypertension; bendroflumethiazide is not considered first-line for HTN under current NICE guidance. Take in morning. 2.5mg often sufficient',
                indication: 'Hypertension, mild heart failure, oedema'
            },
            'benzylpenicillin': {
                name: 'Benzylpenicillin',
                class: 'Penicillins, narrow-spectrum',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adult: 0.6-2.4g QDS IV/IM. Meningitis: 2.4g 4-hourly. Severe infections: up to 14.4g/day',
                contraindications: 'Penicillin allergy, previous severe allergic reaction',
                interactions: 'Probenecid (↑ levels), methotrexate (↑ toxicity), oral contraceptives (↓ efficacy)',
                monitoring: 'Signs of infection resolution, allergic reactions, renal function if high dose',
                pregnancy: 'Generally considered compatible in pregnancy for indicated infections; consult local guidance or UKTIS for detailed advice',
                sideEffects: 'Allergic reactions (rash to anaphylaxis), diarrhea, injection site reactions',
                pharmacokinetics: 'Good tissue penetration. t½ 30min. Mainly renal excretion',
                clinicalPearls: 'First-line for streptococcal infections. Give IV for serious infections',
                indication: 'Meningitis, cellulitis, pneumonia, endocarditis, necrotizing fasciitis'
            },
            'bisoprolol': {
                name: 'Bisoprolol',
                class: 'Beta-blockers',
                mechanism: 'Selective antagonist of cardiac beta-1 adrenoreceptors',
                dosing: 'Heart failure: Start 1.25mg daily, titrate to 10mg daily. Hypertension: 5-10mg daily',
                contraindications: 'Asthma, severe COPD, cardiogenic shock, severe bradycardia, severe heart failure',
                interactions: 'Calcium channel blockers (↑ bradycardia), insulin (masks hypoglycemia), NSAIDs',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, renal function, glucose',
                pregnancy: 'Use only if the potential maternal benefit outweighs fetal risk; avoid in first trimester if possible and consult UKTIS/specialist guidance. Monitor fetal growth and consider alternative agents if planning pregnancy',
                sideEffects: 'Bradycardia, hypotension, fatigue, cold extremities, bronchospasm',
                pharmacokinetics: 'Good oral bioavailability. t½ 10-12h. 50% hepatic, 50% renal elimination',
                clinicalPearls: 'Most cardioselective beta-blocker. Evidence-based for heart failure',
                indication: 'Heart failure, post-MI, hypertension, angina, atrial fibrillation'
            },
            'bumetanide': {
                name: 'Bumetanide',
                class: 'Loop diuretics',
                mechanism: 'Inhibits Na+-K+-2Cl- transporter in the thick ascending limb of the loop of Henle',
                dosing: 'IV/PO: 0.5-2mg once daily (usual IV bolus 1-2mg). Higher doses (up to 10mg) may be used in resistant oedema; titrate to effect',
                contraindications: 'Anuria, severe electrolyte depletion, hypersensitivity to sulfonamides',
                interactions: 'Aminoglycosides (↑ ototoxicity), ACE inhibitors/ARBs (↑ renal dysfunction), NSAIDs (↓ diuretic effect), digoxin (↑ arrhythmia risk with hypokalaemia)',
                monitoring: 'U&Es (especially K+, Na+, creatinine) 1–2 weeks after initiation/titration, blood pressure, weight, fluid balance. Monitor for hearing changes if high IV doses or rapid administration',
                pregnancy: 'Use with caution; consider specialist advice',
                sideEffects: 'Hypokalaemia, hyponatraemia, dehydration, hypotension, dizziness. Ototoxicity can occur with high or rapid IV doses and with concomitant aminoglycosides',
                pharmacokinetics: 'Rapid onset (IV), short half-life ~1-1.5h; hepatic metabolism and renal excretion',
                clinicalPearls: 'More potent than furosemide mg-for-mg (≈40× stronger). Useful when oral absorption of furosemide unreliable or in diuretic resistance. Monitor electrolytes closely. Beware ototoxicity with rapid/high-dose IV administration and when combined with aminoglycosides',
                indication: 'Acute pulmonary oedema, chronic heart failure with fluid overload, peripheral oedema'
            },
            'oxycodone': {
                name: 'Oxycodone',
                class: 'Opioid analgesic',
                mechanism: 'μ-opioid receptor agonist',
                dosing: 'Oral immediate-release: 5-10mg every 4-6 hours PRN. Modified-release: 10-20mg BD for chronic pain. Reduce dose in elderly/renal impairment',
                contraindications: 'Severe respiratory depression, acute or severe bronchial asthma, paralytic ileus, known hypersensitivity',
                interactions: 'CNS depressants (↑ sedation and respiratory depression), MAOIs (avoid), CYP3A4 inhibitors (↑ oxycodone levels)',
                monitoring: 'Respiratory rate, sedation, bowel function, pain control',
                pregnancy: 'Avoid near term; prolonged use may cause neonatal withdrawal',
                sideEffects: 'Nausea, constipation, sedation, pruritus, respiratory depression, dependence with long-term use',
                pharmacokinetics: 'Well absorbed orally, hepatic metabolism (CYP3A4/CYP2D6), half-life ~3-4h',
                clinicalPearls: 'Good oral alternative to morphine for moderate-severe pain. Always prescribe laxative when used regularly. Adjust for opioid-tolerant patients',
                indication: 'Moderate to severe acute or chronic pain, breakthrough pain in opioid-treated patients'
            },
            'lisinopril': {
                name: 'Lisinopril',
                class: 'ACE inhibitor',
                mechanism: 'Inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II and aldosterone',
                dosing: 'Start 5-10mg once daily (usual maintenance 20-40mg daily). Lower starting doses in elderly or renal impairment',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, history of ACE inhibitor–induced angioedema',
                interactions: 'Potassium-sparing diuretics/ACEi/ARBs (↑ hyperkalaemia), NSAIDs (↓ antihypertensive effect), lithium (↑ toxicity)',
                monitoring: 'BP, serum creatinine and potassium 1-2 weeks after initiation or dose changes. An acceptable rise in creatinine/eGFR is generally ≤30% from baseline; monitor and consider dose change if larger increases occur',
                pregnancy: 'Contraindicated — fetal toxicity',
                sideEffects: 'Dry cough, hyperkalaemia, hypotension, renal impairment, angioedema (rare)',
                pharmacokinetics: 'Not metabolised, excreted unchanged by kidneys; half-life ~12h',
                clinicalPearls: 'Start low and titrate; check renal function and K+ after initiation. Substitute with ARB if cough troublesome',
                indication: 'Hypertension, heart failure, post-MI, diabetic nephropathy'
            },
            'co-trimoxazole': {
                name: 'Co-trimoxazole (Trimethoprim + Sulfamethoxazole)',
                class: 'Antibacterial combination (folate synthesis inhibitors)',
                mechanism: 'Sequential blockade of folate synthesis pathway (trimethoprim inhibits dihydrofolate reductase; sulfamethoxazole inhibits dihydropteroate synthase)',
                dosing: 'Uncomplicated UTI (where susceptible): 160/800mg (one DS tablet) BD for 3 days. PCP prophylaxis: 160/800mg three times weekly or daily dosing as indicated',
                contraindications: 'Severe hepatic impairment, megaloblastic anaemia due to folate deficiency, sulfonamide allergy',
                interactions: 'Warfarin (↑ INR), methotrexate (↑ toxicity), ACEi/ARBs (↑ hyperkalaemia risk), trimethoprim may ↑ creatinine (functional)',
                monitoring: 'U&Es, FBC and LFTs for prolonged therapy; watch for rash and signs of bone marrow suppression',
                pregnancy: 'Avoid near term; caution in pregnancy due to folate antagonism',
                sideEffects: 'Rash (including SJS/TEN rare), GI upset, cytopenias, hyperkalaemia, photosensitivity',
                pharmacokinetics: 'Well absorbed orally; renal excretion of metabolites; half-lives differ between components',
                clinicalPearls: 'Check local resistance patterns for UTI use. Can potentiate warfarin — monitor INR closely',
                indication: 'UTI (where susceptible), PCP prophylaxis/treatment, certain systemic infections'
            }
            ,
            'calcium-gluconate': {
                name: 'Calcium Gluconate',
                class: 'Mineral replacement/Antidote',
                mechanism: 'Provides calcium ions essential for cardiac, skeletal muscle function and nerve transmission',
                dosing: 'Hypocalcemia: 10-20ml of 10% solution IV. Hyperkalemia: 10ml of 10% IV. Mg toxicity: 10-20ml IV',
                contraindications: 'Hypercalcemia, calcium kidney stones, digoxin toxicity',
                interactions: 'Digoxin (↑ toxicity), thiazides (↑ calcium), levothyroxine (↓ absorption)',
                monitoring: 'Serum calcium, phosphate, magnesium, ECG, signs of extravasation',
                pregnancy: 'Safe when clinically indicated. Essential mineral',
                sideEffects: 'Hypercalcemia, tissue necrosis (extravasation), bradycardia, hypotension',
                pharmacokinetics: 'IV: immediate effect. Calcium distributed to bones, excreted via kidneys',
                clinicalPearls: 'Preferred over calcium chloride peripherally. Give slowly to avoid arrhythmias',
                indication: 'Hypocalcemia, hyperkalemia, hypermagnesemia, calcium channel blocker overdose'
            },
            'carbamazepine': {
                name: 'Carbamazepine',
                class: 'Antiepileptic drug',
                mechanism: 'Blocks voltage-gated sodium channels, stabilizes neuronal membranes',
                dosing: 'Start 100-200mg BD, increase slowly to 800-1200mg daily in divided doses',
                contraindications: 'AV block, porphyria, bone marrow depression',
                interactions: 'Warfarin (↓ effect), contraceptives (↓ efficacy), numerous CYP450 interactions',
                monitoring: 'FBC, LFTs, sodium levels, carbamazepine levels (4-12mg/L)',
                pregnancy: 'Teratogenic - folate supplementation recommended; seek UKTIS/specialist advice. Women of childbearing potential: folic acid 5 mg daily',
                sideEffects: 'Diplopia, ataxia, hyponatraemia, blood dyscrasias, Stevens-Johnson syndrome',
                pharmacokinetics: 'Induces own metabolism, half-life decreases with time',
                clinicalPearls: 'Start low, go slow. Monitor for hyponatraemia. Screen for HLA-B*1502 in people of Asian ancestry where relevant prior to initiation. Many drug interactions',
                indication: 'Epilepsy, trigeminal neuralgia, bipolar disorder (second-line)'
            },
            'cefalexin': {
                name: 'Cefalexin',
                class: 'Cephalosporins and carbapenems',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adults: 250-500mg QDS. Severe infections: 1-1.5g QDS. Children: 25mg/kg BD (max 1g BD)',
                contraindications: 'Cephalosporin hypersensitivity. Caution if penicillin allergy (cross-reactivity 1-3%)',
                interactions: 'Probenecid (↑ levels), warfarin (may ↑ INR), metformin (monitor)',
                monitoring: 'Signs of allergic reaction, C.difficile-associated diarrhoea, renal function',
                pregnancy: 'Safe - no increased risk of congenital abnormalities',
                sideEffects: 'GI upset, diarrhoea, allergic reactions, CDAD, transient rise in LFTs',
                pharmacokinetics: 'Well absorbed orally, Half-life: 1h, mainly renal excretion',
                clinicalPearls: 'Good oral bioavailability. First-line for cellulitis in UK. Take with food if GI upset',
                indication: 'Skin/soft tissue infections, UTI, respiratory tract infections, prophylaxis'
            },
            'ceftriaxone': {
                name: 'Ceftriaxone',
                class: 'Cephalosporins and carbapenems',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adult: 1-2g daily IV/IM. Severe infections: 2g BD. Meningitis: 2g BD. Max 4g/day',
                contraindications: 'Hypersensitivity to cephalosporins, premature neonates, hyperbilirubinemia',
                interactions: 'Calcium-containing solutions (precipitation), warfarin (↑ INR), probenecid (↑ levels)',
                monitoring: 'Signs of infection resolution, renal function, LFTs, FBC, C.diff surveillance',
                pregnancy: 'Generally considered compatible in pregnancy; consult UKTIS or SmPC for details',
                sideEffects: 'Diarrhea, rash, injection site reactions, gallbladder sludging, C.diff',
                pharmacokinetics: 'Good tissue penetration including CSF. t½ 6-9h. 50% renal excretion',
                clinicalPearls: 'Excellent CNS penetration. Once daily dosing. Avoid calcium solutions',
                indication: 'Pneumonia, meningitis, sepsis, gonorrhea, cellulitis, intra-abdominal infections'
            },
            'cetirizine': {
                name: 'Cetirizine',
                class: 'Second-generation antihistamine (H1 antagonist)',
                mechanism: 'Selective peripheral H1 receptor antagonist with minimal CNS penetration',
                dosing: 'Adults: 10mg daily. Children 6-12 years: 5mg daily or 2.5mg BD. Children 2-6 years: 2.5mg daily',
                contraindications: 'End-stage renal disease, hypersensitivity to cetirizine or hydroxyzine',
                interactions: 'Minimal interactions due to limited metabolism. Alcohol (↑ sedation)',
                monitoring: 'Sedation level (less than first-generation), renal function in elderly',
                pregnancy: 'Generally considered compatible in pregnancy; use when clinically indicated and consult UKTIS if concerned',
                sideEffects: 'Drowsiness (10%), dry mouth, headache, fatigue, GI upset',
                pharmacokinetics: 'Good oral absorption, Half-life: 8-11h, 60% renal excretion unchanged',
                clinicalPearls: 'Less sedating than chlorphenamine. Reduce dose in renal impairment. Available OTC',
                indication: 'Allergic rhinitis, chronic urticaria, allergic conjunctivitis, atopic dermatitis'
            },
            'chlorphenamine': {
                name: 'Chlorphenamine',
                class: 'First-generation antihistamine (H1-receptor antagonist)',
                mechanism: 'H1-receptor antagonist with anticholinergic and sedative properties',
                dosing: 'Adults: 4mg TDS-QDS. Children 1-2y: 1mg BD. Children 2-6y: 1mg QDS. IV: 10-20mg slowly',
                contraindications: 'MAOIs, severe liver disease, porphyria',
                interactions: 'Alcohol (↑ sedation), anticholinergics (↑ effects), MAOIs (avoid)',
                monitoring: 'Sedation level, anticholinergic effects, driving ability',
                pregnancy: 'Appears safe - no increased malformation risk',
                sideEffects: 'Sedation, dry mouth, blurred vision, urinary retention, confusion (elderly)',
                pharmacokinetics: 'Well absorbed, half-life: 12-15h, hepatic metabolism',
                clinicalPearls: 'Useful for acute allergic reactions. IM/IV route available for anaphylaxis adjunct',
                indication: 'Allergic reactions, urticaria, hay fever, insomnia (short-term)'
            },
            /* earlier duplicate ciprofloxacin entry removed — canonical MHRA-updated entry retained later in file */
            'citalopram': {
                name: 'Citalopram',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Selective inhibition of serotonin reuptake with minimal effect on other neurotransmitters',
                dosing: 'Adults: Start 20mg daily, usual dose 20mg, max 40mg daily (20mg if >65 years or hepatic impairment)',
                contraindications: 'MAOIs, QT prolongation, recent MI, severe heart failure',
                interactions: 'MAOIs (serotonin syndrome), drugs prolonging QT interval, warfarin',
                monitoring: 'ECG if cardiac risk factors, electrolytes, mood, suicide risk',
                pregnancy: 'Use if benefit outweighs risk - potential pulmonary hypertension in neonate',
                sideEffects: 'Nausea, dry mouth, drowsiness, sexual dysfunction, QT prolongation (dose-related)',
                pharmacokinetics: 'Half-life: 35h, CYP2C19 and CYP3A4 metabolism',
                clinicalPearls: 'Lowest interaction profile of SSRIs. Dose reduction needed in elderly. ECG if >40mg or cardiac risk',
                indication: 'Depression, panic disorder (unlicensed but effective)'
            },
            'clarithromycin': {
                name: 'Clarithromycin',
                class: 'Macrolide antibiotic',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adults: 250-500mg BD. Severe infections: 500mg BD. H.pylori: 500mg BD with PPI and amoxicillin',
                contraindications: 'Macrolide hypersensitivity, myasthenia gravis, severe hepatic impairment',
                interactions: 'Warfarin (↑ INR), simvastatin (rhabdomyolysis risk), digoxin (↑ levels)',
                monitoring: 'LFTs if prolonged use, signs of cardiac arrhythmias, drug interactions',
                pregnancy: 'Use only if essential - crosses placenta but no evidence of harm',
                sideEffects: 'GI upset, metallic taste, QT prolongation, hepatotoxicity (rare)',
                pharmacokinetics: 'Well absorbed, Half-life: 3-7h, hepatic metabolism (CYP3A4)',
                clinicalPearls: 'Part of triple therapy for H.pylori. Good tissue penetration. Many drug interactions via CYP3A4',
                indication: 'Respiratory tract infections, H.pylori eradication, skin infections, atypical pneumonia'
            },
            'clindamycin': {
                name: 'Clindamycin',
                class: 'Clindamycin',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adult: 150-450mg QDS PO or 0.6-2.7g daily IV in divided doses. Max 4.8g/day IV',
                contraindications: 'Previous C.diff colitis, severe liver disease, lincomycin allergy',
                interactions: 'Neuromuscular blockers (↑ paralysis), warfarin (↑ INR), ciclosporin',
                    monitoring: 'Diarrhea/C.diff symptoms, liver function, infection resolution',
                    clinicalPearls: 'Excellent bone penetration. High risk of C. difficile infection — follow antimicrobial stewardship (NICE NG199) and stop if diarrhoea develops; use only when indicated',
                pregnancy: 'Generally considered compatible in pregnancy; seek UKTIS for specific scenarios',
                sideEffects: 'C.diff colitis, diarrhea, rash, metallic taste, liver dysfunction',
                pharmacokinetics: 'Good tissue/bone penetration. t½ 2-3h. Hepatic metabolism',
                clinicalPearls: 'Excellent bone penetration. High C.diff risk. Stop if diarrhea develops',
                indication: 'Bone/joint infections, anaerobic infections, skin/soft tissue, dental infections'
            },
            'clopidogrel': {
                name: 'Clopidogrel',
                class: 'Antiplatelet drugs, ADP-receptor antagonists',
                mechanism: 'Irreversibly inhibits P2Y12 ADP receptor on platelets',
                dosing: 'Acute coronary syndrome: 600mg loading dose, then 75mg daily. Stroke prevention: 75mg daily',
                contraindications: 'Active bleeding, severe hepatic impairment',
                interactions: 'Warfarin (↑ bleeding), Omeprazole/Esomeprazole reduce activation via CYP2C19—avoid; if gastroprotection needed prefer pantoprazole. Other strong CYP2C19 inhibitors may ↓ activation',
                monitoring: 'Signs of bleeding, FBC, hepatic function',
                pregnancy: 'Avoid - limited safety data, bleeding risk',
                sideEffects: 'Bleeding, dyspepsia, rash, thrombotic thrombocytopenic purpura (rare)',
                pharmacokinetics: 'Prodrug requiring CYP2C19 activation, irreversible platelet inhibition',
                clinicalPearls: 'Dual antiplatelet therapy with aspirin post-ACS. Genetic testing for CYP2C19 variants',
                indication: 'Acute coronary syndromes, stroke prevention, peripheral vascular disease'
            },
            'co-amoxiclav': {
                name: 'Co-amoxiclav',
                class: 'Penicillins, broad-spectrum',
                mechanism: 'Amoxicillin inhibits cell wall synthesis, clavulanic acid protects against beta-lactamases',
                dosing: 'Adults: 625mg TDS or 1g BD. Severe infections: 1.2g TDS IV. Available as 375mg, 625mg tablets',
                contraindications: 'Penicillin allergy, previous cholestatic jaundice with co-amoxiclav',
                interactions: 'Warfarin (↑ INR), methotrexate (↑ toxicity), probenecid (↑ levels)',
                monitoring: 'LFTs (risk of cholestatic jaundice), signs of C.difficile colitis',
                pregnancy: 'Safe - no increased risk of congenital abnormalities',
                sideEffects: 'GI upset, diarrhoea, cholestatic jaundice (rare), skin reactions',
                pharmacokinetics: 'Well absorbed, Half-life: 1h, mainly renal excretion',
                clinicalPearls: 'Broad spectrum including beta-lactamase producers. Take with food to ↓ GI upset. Monitor LFTs',
                indication: 'Respiratory tract infections, skin/soft tissue infections, dental infections, UTI'
            },
            'co-codamol': {
                name: 'Co-codamol',
                class: 'Opioid/paracetamol combination analgesic',
                mechanism: 'Codeine acts on μ-opioid receptors, paracetamol inhibits COX enzymes centrally',
                dosing: 'Adults: 8/500mg or 30/500mg, 1-2 tablets every 4-6 hours (max 8 tablets/24h). Children >12 years: 8/500mg only',
                contraindications: 'Children <12 years, acute respiratory depression, paralytic ileus, severe hepatic impairment',
                interactions: 'Alcohol (↑ sedation), MAOIs, other CNS depressants, warfarin (paracetamol component)',
                monitoring: 'Signs of respiratory depression, constipation, dependence with long-term use',
                pregnancy: 'Use with caution - potential neonatal withdrawal if used near term',
                sideEffects: 'Constipation, nausea, drowsiness, dizziness, dry mouth, potential for dependence',
                pharmacokinetics: 'Codeine: prodrug converted to morphine by CYP2D6. Half-life: 3-4h',
                clinicalPearls: 'Popular UK combination. 8/500mg available OTC. 30/500mg prescription only. Maximum 3 days OTC use',
                indication: 'Moderate pain where paracetamol alone insufficient. Post-operative pain, dental pain'
            },
            'codeine': {
                name: 'Codeine',
                class: 'Opioid analgesic',
                mechanism: 'Prodrug converted to morphine by CYP2D6, mu-opioid receptor agonist',
                dosing: 'Pain: 15-60mg QDS PRN. Cough: 15-30mg QDS. Diarrhoea: 30mg TDS-QDS',
                contraindications: 'Children <12 years, breastfeeding, severe respiratory disease, acute abdomen',
                interactions: 'Alcohol/sedatives (↑ sedation), MAOIs (avoid), CYP2D6 inhibitors (↓ efficacy)',
                monitoring: 'Respiratory rate, sedation level, bowel function, signs of dependence',
                pregnancy: 'Avoid near term - risk of neonatal respiratory depression',
                sideEffects: 'Constipation, nausea, sedation, respiratory depression, dependence',
                pharmacokinetics: 'Prodrug, 10% converted to morphine, half-life: 3-4h',
                clinicalPearls: 'Variable efficacy due to CYP2D6 polymorphisms. Always prescribe laxatives for regular use',
                indication: 'Mild to moderate pain, dry cough, diarrhoea'
            },
            'colecalciferol': {
                name: 'Colecalciferol (Vitamin D3)',
                class: 'Vitamin supplement',
                mechanism: 'Precursor to active vitamin D, essential for calcium absorption and bone health',
                dosing: 'Deficiency: 6000 units daily for 8 weeks. Maintenance: 800-2000 units daily',
                contraindications: 'Hypercalcaemia, severe renal impairment, sarcoidosis',
                interactions: 'Thiazides (↑ hypercalcaemia risk), digoxin (hypercalcaemia ↑ toxicity)',
                monitoring: 'Serum calcium, 25-OH vitamin D levels',
                pregnancy: 'Safe - 400 units daily recommended',
                sideEffects: 'Hypercalcaemia, hypercalciuria, nausea, constipation (overdose)',
                pharmacokinetics: 'Fat-soluble, stored in adipose tissue, half-life: 2-3 weeks',
                clinicalPearls: 'Increasingly prescribed due to widespread deficiency. Take with fatty meal for absorption',
                indication: 'Vitamin D deficiency, osteoporosis prevention, general health maintenance'
            },
            'cyclizine': {
                name: 'Cyclizine',
                class: 'Antihistamine antiemetic',
                mechanism: 'H1 receptor antagonist with anticholinergic properties, acts on vestibular system',
                dosing: 'Adults: 50mg TDS PO/IM/IV. Children 6-12 years: 25mg TDS. Motion sickness: 50mg 30min before travel',
                contraindications: 'Severe heart failure, porphyria, known hypersensitivity',
                interactions: 'CNS depressants (↑ sedation), anticholinergics (↑ effects), MAOIs',
                monitoring: 'Sedation level, anticholinergic effects, cardiac function in elderly',
                pregnancy: 'Generally considered compatible in pregnancy for short-term use; RCOG green-top guidance supports use for nausea and vomiting in pregnancy when indicated (refer to UKTIS for detailed guidance)',
                sideEffects: 'Drowsiness, dry mouth, blurred vision, constipation, urinary retention',
                pharmacokinetics: 'Good oral absorption, Half-life: 20h, hepatic metabolism',
                clinicalPearls: 'Excellent for motion sickness and vertigo. Less sedating than promethazine',
                indication: 'Motion sickness, vertigo, nausea/vomiting, pregnancy sickness'
            },
            'dexamethasone': {
                name: 'Dexamethasone',
                class: 'Corticosteroid (glucocorticoid)',
                mechanism: 'Potent synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects',
                dosing: 'Cerebral oedema: 4mg QDS. COVID-19: 6mg daily for 10 days. Croup: 150mcg/kg single dose',
                contraindications: 'Systemic infection (unless covering antimicrobials), live vaccines',
                interactions: 'Similar to prednisolone - warfarin, NSAIDs, vaccines',
                monitoring: 'Blood glucose, blood pressure, mood changes, infection signs',
                pregnancy: 'Use if essential - crosses placenta more than prednisolone',
                sideEffects: 'Similar to prednisolone but more potent - hyperglycaemia, immunosuppression',
                pharmacokinetics: 'Long half-life: 36-72h, potency: 25x hydrocortisone',
                clinicalPearls: '4x more potent than prednisolone. Minimal mineralocorticoid activity. Use tapering for prolonged courses to avoid adrenal suppression. COVID-19: 6 mg once daily for up to 10 days (RECOVERY trial)',
                indication: 'Cerebral oedema, severe COVID-19, croup, severe inflammatory conditions'
            },
            'diazepam': {
                name: 'Diazepam',
                class: 'Benzodiazepines',
                mechanism: 'Enhances GABA-A receptor activity, increasing chloride influx and neuronal inhibition',
                dosing: 'Anxiety: 2-5mg TDS. Status epilepticus: 10-20mg IV slowly. Muscle spasm: 2-15mg daily',
                contraindications: 'Respiratory depression, severe hepatic impairment, myasthenia gravis, sleep apnoea',
                interactions: 'Alcohol (↑ sedation), opioids (respiratory depression), phenytoin (variable)',
                monitoring: 'Respiratory function, level of sedation, signs of dependence',
                pregnancy: 'Avoid - risk of floppy baby syndrome and withdrawal in neonate',
                sideEffects: 'Sedation, ataxia, confusion (elderly), dependence, respiratory depression',
                pharmacokinetics: 'Long half-life: 20-100h (including active metabolites), hepatic metabolism',
                clinicalPearls: 'Long-acting benzodiazepine. High dependence potential. Flumazenil reverses effects',
                indication: 'Status epilepticus, severe anxiety, alcohol withdrawal, muscle spasm'
            },
            'diclofenac': {
                name: 'Diclofenac',
                class: 'Non-steroidal anti-inflammatory drug (NSAID)',
                mechanism: 'Non-selective COX inhibitor, reducing prostaglandin synthesis',
                dosing: 'Oral: 50 mg TDS or 75 mg BD with food. Topical 1–2 % gel TDS-QDS to affected area.',
                contraindications: 'Active peptic ulcer, established IHD, PAD, cerebrovascular disease, NYHA II–IV HF, severe renal impairment',
                interactions: 'ACEi/ARBs (renal risk), anticoagulants (↑ bleeding), corticosteroids (↑ ulcer risk)',
                monitoring: 'BP, renal function (U&Es 1–2 weeks after initiation), GI symptoms, CV risk review',
                pregnancy: 'Avoid, especially 3rd trimester (premature ductus closure)',
                sideEffects: 'GI bleeding, fluid retention, hypertension, ↑ CV event risk',
                pharmacokinetics: 't½ 1–2 h; hepatic metabolism; renal excretion',
                clinicalPearls: 'Oral diclofenac contraindicated in established CVD or moderate–severe HF (MHRA 2015). Topical formulation preferred for local pain.',
                indication: 'Short-term pain/inflammation when lower-risk NSAIDs ineffective (topical preferred)'
            },
            'digoxin': {
                name: 'Digoxin',
                class: 'Digoxin',
                mechanism: 'Inhibits Na+/K+-ATPase pump, increases intracellular Ca2+, ↑ contractility, ↓ AV conduction',
                dosing: 'Loading: 10-15 micrograms/kg IV or PO. Maintenance: 125-250 micrograms daily (reduce in elderly/renal impairment)',
                contraindications: 'Ventricular arrhythmias, heart block, hypertrophic cardiomyopathy with outflow obstruction',
                interactions: 'Amiodarone (↑ levels), diuretics (hypokalaemia ↑ toxicity), verapamil, quinidine',
                monitoring: 'Digoxin levels (6h post-dose), U&Es, heart rate, rhythm, signs of toxicity',
                pregnancy: 'Safe - no teratogenic effects, adjust dose due to increased clearance',
                sideEffects: 'Nausea, vomiting, visual disturbances, arrhythmias, confusion (toxicity)',
                pharmacokinetics: 'Half-life: 36h (longer in renal impairment), mainly renal excretion',
                clinicalPearls: 'Narrow therapeutic window. Target level 1.0-2.0 micrograms/L. Toxicity common in elderly',
                indication: 'AF (rate control), heart failure (symptom control). No mortality benefit'
            },
            'domperidone': {
                name: 'Domperidone',
                class: 'Antiemetic (Dopamine antagonist)',
                mechanism: 'Selective D2 receptor antagonist at CTZ, prokinetic effect on upper GI tract',
                dosing: 'Adults: 10mg TDS (maximum 30 mg/day) before meals for up to 7 days (MHRA restriction). Not licensed for children <12 years or weight <35 kg',
                contraindications: 'Known cardiac conduction disorders, significant ventricular arrhythmia, moderate–severe hepatic impairment, prolactinoma, congenital or acquired QT prolongation',
                interactions: 'CYP3A4 inhibitors (↑ levels), other QT-prolonging drugs, anticholinergics',
                monitoring: 'Consider ECG in patients with cardiac risk factors or on concomitant QT-prolonging drugs. Check hepatic function if prolonged use. Monitor for extrapyramidal signs and signs of hyperprolactinaemia if used longer than recommended',
                pregnancy: 'Use only if essential and after specialist/UKTIS advice — limited safety data',
                sideEffects: 'QT prolongation and rare serious arrhythmias, galactorrhoea, gynaecomastia, extrapyramidal effects (rare)',
                pharmacokinetics: 'Poor oral bioavailability (~15%), Half-life: 7-9h, hepatic metabolism',
                clinicalPearls: 'MHRA guidance: restrict use to short-term symptomatic treatment (max 7 days). Maximum 30 mg/day. Contraindicated under 12 years or <35 kg. Avoid combinations with other QT-prolonging drugs and strong CYP3A4 inhibitors; consider alternatives in cardiac risk',
                indication: 'Nausea and vomiting (short-term use only), selected gastroparesis after specialist advice'
            },
            'doxycycline': {
                name: 'Doxycycline',
                class: 'Tetracyclines and glycylcyclines',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 30S ribosomal subunit',
                dosing: 'Adults: 200mg on day 1, then 100mg daily. Acne: 40mg daily modified-release. Malaria prophylaxis: 100mg daily',
                contraindications: 'Pregnancy, breastfeeding, children <12 years, myasthenia gravis',
                interactions: 'Antacids/iron (↓ absorption), warfarin (↑ INR), penicillins (antagonistic)',
                monitoring: 'LFTs if prolonged use, signs of C.difficile colitis, photosensitivity',
                pregnancy: 'Contraindicated - risk of dental staining and bone growth inhibition in fetus',
                sideEffects: 'GI upset, photosensitivity, oesophageal irritation, vaginal thrush',
                pharmacokinetics: 'Well absorbed, Half-life: 18-22h, Hepatic metabolism and renal excretion',
                clinicalPearls: 'Take with food, avoid dairy 2h before/after. Stay upright 30min after dose. First-line for atypical pneumonia',
                indication: 'Respiratory tract infections, acne, chlamydia, malaria prophylaxis, Lyme disease'
            },
            'empagliflozin': {
                name: 'Empagliflozin',
                class: 'Sodium-glucose co-transporter 2 inhibitors',
                mechanism: 'Inhibits sodium-glucose co-transporter 2 in proximal renal tubules',
                dosing: 'Type 2 diabetes: 10mg daily, may increase to 25mg. Heart failure: 10mg daily',
                contraindications: 'Type 1 diabetes, ketoacidosis, severe renal impairment (eGFR <30)',
                interactions: 'Diuretics (↑ volume depletion), insulin (↑ hypoglycaemia risk)',
                monitoring: 'eGFR, genital infections, volume status. Consider ketone monitoring if clinically unwell',
                pregnancy: 'Avoid - limited safety data',
                sideEffects: 'Genital infections, UTI, volume depletion, diabetic ketoacidosis (rare)',
                pharmacokinetics: 'Long half-life: 12h, renal excretion, minimal drug interactions',
                clinicalPearls: 'Cardiovascular and renal benefits: recommended as an add-on in T2DM with CVD and in HFrEF/CKD where indicated. See NICE guidance (NG136/NG17 and NG238) for specific pathways. Monitor renal function; consider patient education on volume status',
                indication: 'Type 2 diabetes (with CVD benefits), heart failure with reduced ejection fraction, chronic kidney disease as per guideline indications'
            },
            'enoxaparin': {
                name: 'Enoxaparin',
                class: 'Heparins and fondaparinux',
                mechanism: 'Enhances antithrombin III activity, preferentially inhibiting factor Xa',
                dosing: 'VTE prophylaxis: 40mg daily SC. VTE treatment: 1.5mg/kg daily or 1mg/kg BD SC',
                contraindications: 'Active bleeding, thrombocytopenia, severe renal impairment',
                interactions: 'Anticoagulants (↑ bleeding), NSAIDs (↑ bleeding), antiplatelets',
                monitoring: 'Anti-Xa levels (if required), platelet count, signs of bleeding',
                pregnancy: 'Safe - does not cross placenta. Preferred anticoagulant in pregnancy',
                sideEffects: 'Bleeding, thrombocytopenia (HIT), injection site reactions, osteoporosis',
                pharmacokinetics: 'Subcutaneous bioavailability 90%, half-life: 4-7h, renal excretion',
                clinicalPearls: 'More predictable than unfractionated heparin. Pregnancy anticoagulant of choice',
                indication: 'VTE prophylaxis/treatment, acute coronary syndromes, pregnancy anticoagulation'
            },
            'erythromycin': {
                name: 'Erythromycin',
                class: 'Macrolide antibiotic',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 50S ribosomal subunit',
                dosing: 'Adults: 250-500mg QDS. Children: 25-50mg/kg daily in divided doses. Take before food',
                contraindications: 'Hypersensitivity to macrolides, concurrent use with ergot alkaloids',
                interactions: 'Warfarin (↑ INR), theophylline (↑ levels), carbamazepine (↑ levels), QT-prolonging drugs',
                monitoring: 'LFTs with prolonged use, signs of C.difficile colitis, hearing (high doses)',
                pregnancy: 'Safe - drug of choice for chlamydia in pregnancy',
                sideEffects: 'GI upset, QT prolongation, cholestatic hepatitis, tinnitus',
                pharmacokinetics: 'Variable oral absorption, half-life: 1-4h, hepatic metabolism',
                clinicalPearls: 'Take before food to improve absorption. Many drug interactions via CYP3A4',
                indication: 'Respiratory tract infections, skin infections, chlamydia, legionella'
            },
            'ferrous sulfate': {
                name: 'Ferrous Sulfate',
                class: 'Iron',
                mechanism: 'Provides elemental iron for haemoglobin synthesis and correction of iron deficiency',
                dosing: 'Adults: 200mg (65mg elemental iron) BD-TDS on empty stomach. Prophylaxis: 200mg daily',
                contraindications: 'Haemochromatosis, haemosiderosis, non-iron deficiency anaemia',
                interactions: 'Tetracyclines (↓ absorption both), levothyroxine (separate by 4h), antacids (↓ absorption)',
                monitoring: 'FBC, iron studies, signs of iron overload with prolonged use',
                pregnancy: 'Safe and recommended - increased iron requirements',
                sideEffects: 'GI upset, constipation, diarrhoea, black stools, nausea',
                pharmacokinetics: 'Best absorbed on empty stomach, vitamin C enhances absorption',
                clinicalPearls: 'Take with orange juice (vitamin C). Black stools are normal. Continue 3 months after Hb normal',
                indication: 'Iron deficiency anaemia, prophylaxis in pregnancy/menorrhagia'
            },
            'fexofenadine': {
                name: 'Fexofenadine',
                class: 'Second-generation antihistamine (H1 antagonist)',
                mechanism: 'Selective peripheral H1 receptor antagonist with no CNS penetration',
                dosing: 'Adults: 120mg daily (seasonal rhinitis) or 180mg daily (urticaria). Children 6-12 years: 30mg BD',
                contraindications: 'Hypersensitivity to fexofenadine, severe renal impairment',
                interactions: 'Antacids (↓ absorption), fruit juices may ↓ absorption',
                monitoring: 'Effectiveness for allergic symptoms, minimal side effects',
                pregnancy: 'Use only if maternal benefit outweighs fetal risk; check UKTIS/SmPC for up-to-date evidence',
                sideEffects: 'Headache, drowsiness (2%), nausea, dyspepsia',
                pharmacokinetics: 'Good oral absorption, Half-life: 14h, minimal metabolism, renal/biliary excretion',
                clinicalPearls: 'Least sedating antihistamine. No cardiotoxicity. Take on empty stomach',
                indication: 'Seasonal allergic rhinitis, chronic idiopathic urticaria, allergic skin conditions'
            },
            'flucloxacillin': {
                name: 'Flucloxacillin',
                class: 'Penicillins, narrow-spectrum',
                mechanism: 'β-lactam antibiotic - inhibits cell wall synthesis, resistant to β-lactamases',
                dosing: 'Oral: 250-500mg QDS on empty stomach. IV: 0.25-2g QDS. Severe infections: up to 8g daily',
                contraindications: 'Penicillin allergy, previous flucloxacillin-induced hepatitis',
                interactions: 'Warfarin (may ↑ INR), methotrexate (↑ toxicity), probenecid (↑ levels)',
                monitoring: 'LFTs (risk of cholestatic hepatitis), signs of allergic reaction',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'GI upset, allergic reactions, cholestatic hepatitis (rare but serious), CDAD',
                pharmacokinetics: 'Variable oral absorption, half-life: 1h, mainly renal excretion',
                clinicalPearls: 'First-line for staphylococcal infections. Take on empty stomach. Monitor LFTs',
                indication: 'Staphylococcal infections (cellulitis, bone/joint infections), endocarditis prophylaxis'
            },
            'fluconazole': {
                name: 'Fluconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal cytochrome P450 enzyme 14α-demethylase, disrupting ergosterol synthesis',
                dosing: 'Vaginal candidiasis: 150mg single dose. Oral candidiasis: 50mg daily for 7-14 days. Systemic: up to 400mg daily depending on indication',
                contraindications: 'Hypersensitivity to azoles, concurrent terfenadine/astemizole, significant hepatic impairment without specialist advice',
                interactions: 'Warfarin (↑ INR), phenytoin (↑ levels), rifampicin (↓ fluconazole levels), many CYP3A4 substrates/inhibitors',
                monitoring: 'LFTs with prolonged or high-dose therapy, signs of hepatotoxicity, review drug interactions',
                pregnancy: 'Avoid high or prolonged doses in pregnancy due to a malformation signal. A single 150mg dose for vaginal candidiasis is unlikely to increase risk but should be used only if clearly indicated — follow UKTIS guidance',
                sideEffects: 'GI upset, headache, skin rashes, hepatotoxicity (rare), QT prolongation',
                pharmacokinetics: 'Excellent oral bioavailability (~90%), CSF penetration, renal excretion',
                clinicalPearls: 'Single 150mg dose appropriate for uncomplicated vulvovaginal candidiasis; avoid prolonged or high-dose therapy in pregnancy. For systemic infections, specialist guidance and monitoring required',
                indication: 'Candidiasis (vaginal, oral, systemic), cryptococcal meningitis, fungal prophylaxis'
            },
            'fluoxetine': {
                name: 'Fluoxetine',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Inhibits serotonin reuptake at synaptic cleft, increasing serotonin availability',
                dosing: 'Depression: Start 20mg daily, usual dose 20mg, max 60mg daily. Take in morning',
                contraindications: 'MAOIs (within 14 days), mania, severe hepatic impairment',
                interactions: 'MAOIs (serotonin syndrome), warfarin (↑ bleeding), tramadol (↑ seizure risk)',
                monitoring: 'Mood, suicide risk (especially <25 years), weight, sodium levels',
                pregnancy: 'Use if benefit outweighs risk - potential neonatal adaptation syndrome',
                sideEffects: 'Nausea, headache, insomnia, sexual dysfunction, weight loss, hyponatraemia',
                pharmacokinetics: 'Long half-life: 4-6 days (active metabolite: 4-16 days), CYP2D6 metabolism',
                clinicalPearls: 'Longest half-life SSRI - less withdrawal symptoms. May initially increase anxiety. Monitor under 25s weekly',
                indication: 'Depression, panic disorder, OCD, bulimia nervosa, premenstrual dysphoric disorder'
            },
            'folic acid': {
                name: 'Folic Acid',
                class: 'Vitamin supplement',
                mechanism: 'Synthetic form of folate, essential for DNA synthesis and red cell production',
                dosing: 'Deficiency: 5mg daily. Pregnancy: 400mcg daily (5mg if high risk). With methotrexate: 5mg weekly',
                contraindications: 'Megaloblastic anaemia until B12 deficiency excluded',
                interactions: 'Methotrexate (antagonistic - given on different days), phenytoin (↓ levels)',
                monitoring: 'FBC, B12 levels (must exclude B12 deficiency first)',
                pregnancy: 'Essential - prevents neural tube defects. Start pre-conception',
                sideEffects: 'Generally well tolerated. May mask B12 deficiency',
                pharmacokinetics: 'Well absorbed, stored in liver, renal excretion',
                clinicalPearls: 'Always check B12 before treating megaloblastic anaemia. Take with methotrexate day+1',
                indication: 'Folate deficiency, pregnancy/pre-conception, with methotrexate therapy'
            },
            'furosemide': {
                name: 'Furosemide',
                class: 'Diuretics, loop',
                mechanism: 'Inhibits Na+/K+/2Cl- co-transporter in ascending limb of loop of Henle',
                dosing: 'Heart failure: Start 20-40mg daily, titrate to response. Oedema: 20-80mg daily. IV dose = half oral dose',
                contraindications: 'Anuria, severe electrolyte imbalance, hepatic coma',
                interactions: 'Lithium (↑ toxicity), digoxin (hypokalaemia ↑ toxicity), NSAIDs (↓ effect)',
                monitoring: 'U&Es (check 1–2 weeks after initiation/titration), fluid balance, weight, hearing (especially after high IV doses). If giving IV infusion, administer at ≤4 mg/min to reduce ototoxicity risk; monitor renal function and electrolytes closely',
                pregnancy: 'Use with caution; consult UKTIS for guidance',
                sideEffects: 'Hypokalaemia, hyponatraemia, dehydration, ototoxicity (especially with high IV doses or rapid administration), gout',
                pharmacokinetics: 'Oral onset: 1h, Peak: 1-2h, Duration: 6h. IV onset: 5min',
                clinicalPearls: 'Take in morning to avoid nocturia. Monitor K+ closely. Ototoxicity with high IV doses; IV infusion rate should not exceed 4 mg/min. Ensure renal function and electrolytes monitored after initiation/titration',
                indication: 'Heart failure, pulmonary oedema, hypertension (rarely used), ascites'
            },
            'gabapentin': {
                name: 'Gabapentin',
                class: 'Gabapentinoids',
                mechanism: 'Binds to voltage-gated calcium channel α2δ subunit, reducing neurotransmitter release',
                dosing: 'Neuropathic pain: Start 300mg daily, increase to 300mg TDS, max 3600mg daily in divided doses',
                contraindications: 'Hypersensitivity to gabapentin',
                interactions: 'Antacids (↓ absorption), opioids (↑ sedation), alcohol (↑ CNS depression)',
                monitoring: 'Pain scores, mood changes, renal function, signs of abuse/dependence',
                pregnancy: 'Use only if the maternal benefit outweighs fetal risk; consult UKTIS/SmPC',
                sideEffects: 'Drowsiness, dizziness, fatigue, peripheral oedema, weight gain, ataxia',
                pharmacokinetics: 'Dose-dependent absorption, Half-life: 5-7h, renal excretion unchanged',
                clinicalPearls: 'Gradual dose escalation needed. Reduce dose in renal impairment. Potential for abuse. In the UK gabapentin is classed as a Schedule 3 controlled drug (since 2019); prescribers should record supply and be cautious with repeat prescriptions',
                indication: 'Neuropathic pain, epilepsy, restless leg syndrome (unlicensed)'
            },
            'gentamicin': {
                name: 'Gentamicin',
                class: 'Aminoglycoside',
                mechanism: 'Inhibits bacterial protein synthesis by binding to 30S ribosomal subunit',
                dosing: 'Adult: 5-7mg/kg daily IV/IM. Adjust for renal function. Monitor levels - trough <2mg/L',
                contraindications: 'Myasthenia gravis, previous 8th nerve damage, severe renal impairment',
                interactions: 'Loop diuretics (↑ ototoxicity), vancomycin (↑ nephrotoxicity), muscle relaxants',
                monitoring: 'Renal function, hearing, balance, drug levels (peak/trough), urine output',
                pregnancy: 'Avoid in pregnancy due to fetal risk (see SmPC/UKTIS); specialist advice required if exposure occurs',
                sideEffects: 'Nephrotoxicity, ototoxicity (vestibular/auditory), neuromuscular blockade',
                pharmacokinetics: 'Poor oral absorption. Good tissue penetration. t½ 2-3h. 95% renal excretion',
                clinicalPearls: 'Once daily dosing preferred. Synergistic with beta-lactams. Monitor levels',
                indication: 'Serious gram-negative infections, endocarditis, sepsis, UTI, pneumonia'
            },
            'gliclazide': {
                name: 'Gliclazide',
                class: 'Sulfonylurea',
                mechanism: 'Stimulates insulin release from pancreatic β-cells by blocking K-ATP channels',
                dosing: 'Standard release: 40-80mg daily with breakfast, max 320mg daily. MR: 30-120mg daily',
                contraindications: 'Type 1 diabetes, ketoacidosis, severe renal/hepatic impairment',
                interactions: 'Alcohol (↑ hypoglycaemia), β-blockers (mask hypoglycaemia), steroids (↑ glucose)',
                monitoring: 'Blood glucose, HbA1c, weight, signs of hypoglycaemia',
                pregnancy: 'Switch to insulin - crosses placenta',
                sideEffects: 'Hypoglycaemia, weight gain, GI upset, skin reactions',
                pharmacokinetics: 'Half-life: 10-20h, hepatic metabolism, renal excretion',
                clinicalPearls: 'Second-line after metformin. Take with food. Lower hypoglycaemia risk than glibenclamide. Driving advice: inform DVLA if recurrent hypoglycaemia; provide hypoglycaemia education and arrange follow-up',
                indication: 'Type 2 diabetes (when metformin contraindicated/not tolerated or as add-on)'
            },
            'glyceryl-trinitrate': {
                name: 'Glyceryl Trinitrate (GTN)',
                class: 'Nitrates',
                mechanism: 'Releases nitric oxide causing smooth muscle relaxation and vasodilation',
                dosing: 'Angina: 400-800mcg SL PRN. IV: 10-200mcg/min. Topical: 2.5-5mg patches daily',
                contraindications: 'Severe aortic stenosis, hypertrophic cardiomyopathy, PDE5 inhibitor use',
                interactions: 'Sildenafil/PDE5 inhibitors (severe hypotension), alcohol (↑ hypotension)',
                monitoring: 'Blood pressure, heart rate, headache severity, nitrate tolerance',
                pregnancy: 'Use if benefits outweigh risks. Limited data but generally considered safe',
                sideEffects: 'Headache, hypotension, flushing, dizziness, nitrate tolerance',
                pharmacokinetics: 'SL: onset 2-5min, duration 30min. Patches: onset 30min, duration 12-14h',
                clinicalPearls: 'Nitrate-free period needed to prevent tolerance. Keep tablets in original container',
                indication: 'Angina, heart failure, hypertensive emergency, anal fissure'
            },
            'haloperidol': {
                name: 'Haloperidol',
                class: 'Antipsychotic (First-generation, typical)',
                mechanism: 'Potent dopamine D2 receptor antagonist in mesolimbic and mesocortical pathways; also blocks α1-adrenergic and 5-HT2 receptors',
                dosing: 'Psychosis/schizophrenia: 1.5–3 mg twice daily (max 30 mg/day). Acute agitation: 2.5–10 mg IM repeated q30 min if needed (max 18 mg/24 h). Elderly: start 0.5 mg twice daily and titrate cautiously',
                contraindications: 'Parkinson’s disease, Lewy-body dementia, prolonged QTc, CNS depression, comatose states',
                interactions: 'QT-prolonging agents (macrolides, fluoroquinolones), CNS depressants, carbamazepine (↓ levels)',
                monitoring: 'Baseline ECG (QTc < 450 ms), electrolytes, weight, BP, extrapyramidal symptoms, prolactin',
                pregnancy: 'Use only if benefit outweighs risk; neonatal extrapyramidal symptoms possible',
                sideEffects: 'Extrapyramidal symptoms, tardive dyskinesia, QT prolongation, neuroleptic malignant syndrome, hyperprolactinaemia, sedation',
                pharmacokinetics: 'Onset 30–60 min PO, t½ ≈ 20 h, hepatic metabolism (CYP3A4, 2D6)',
                clinicalPearls: 'Avoid in dementia-related psychosis (↑ mortality). Always use the lowest effective dose for the shortest duration. ECG before initiation and after dose increases',
                indication: 'Schizophrenia, acute psychosis, delirium, short-term control of severe agitation, Tourette syndrome'
            },
            'heparin': {
                name: 'Heparin',
                class: 'Heparins and fondaparinux',
                mechanism: 'Binds to antithrombin III, enhancing inactivation of thrombin and factor Xa',
                dosing: 'DVT/PE: Loading 80 units/kg IV, then 18 units/kg/h. Monitor APTT. Prophylaxis: 5000 units SC BD-TDS',
                contraindications: 'Active bleeding, severe thrombocytopenia, previous HIT, severe liver disease',
                interactions: 'Aspirin, warfarin (↑ bleeding risk), NSAIDS (↑ bleeding risk)',
                monitoring: 'APTT (target 1.5-2.5x control), platelet count (HIT screening), signs of bleeding',
                pregnancy: 'Safe - does not cross placenta. First-line anticoagulant in pregnancy',
                sideEffects: 'Bleeding, HIT, osteoporosis (long-term), alopecia, skin necrosis',
                pharmacokinetics: 'IV: immediate onset, t½ 1-2h. SC: onset 1-2h. Metabolism hepatic',
                clinicalPearls: 'Monitor for HIT. Reverse with protamine. Use anti-Xa levels if APTT unreliable',
                indication: 'DVT/PE treatment, ACS, AF, cardiac surgery, dialysis, stroke prevention'
            },
            'hydrocortisone': {
                name: 'Hydrocortisone',
                class: 'Corticosteroids, topical',
                mechanism: 'Anti-inflammatory glucocorticoid effects via cytoplasmic receptors',
                dosing: 'Topical: Apply thinly BD-QDS. Oral: 20-30mg daily in divided doses',
                contraindications: 'Viral skin infections, rosacea, perioral dermatitis (topical)',
                interactions: 'Minimal with topical use. Oral form: similar to prednisolone',
                monitoring: 'Skin atrophy with prolonged topical use, HPA axis suppression',
                pregnancy: 'Safe topically. Oral use: similar precautions to prednisolone',
                sideEffects: 'Topical: skin atrophy, striae. Oral: similar to other corticosteroids',
                pharmacokinetics: 'Topical absorption varies by site. Oral: short half-life 8-12h',
                clinicalPearls: 'Mildest topical steroid. Available OTC in low concentrations. Safe for face/children',
                indication: 'Eczema, dermatitis, insect bites, adrenal insufficiency (oral)'
            },
            'hyoscine': {
                name: 'Hyoscine (Scopolamine)',
                class: 'Anticholinergic/Antimuscarinic',
                mechanism: 'Competitive antagonist of muscarinic acetylcholine receptors',
                dosing: 'Motion sickness: 0.3mg patch behind ear. Palliative care: 0.4-0.6mg SC/IV TDS-QDS',
                contraindications: 'Narrow-angle glaucoma, prostatic enlargement, myasthenia gravis, intestinal obstruction',
                interactions: 'Anticholinergic drugs (↑ effects), phenothiazines, tricyclics',
                monitoring: 'Anticholinergic effects, confusion in elderly, respiratory secretions',
                pregnancy: 'Generally considered compatible for short-term use in pregnancy for nausea; consult UKTIS for guidance',
                sideEffects: 'Dry mouth, drowsiness, blurred vision, confusion, hallucinations',
                pharmacokinetics: 'Crosses blood-brain barrier, Half-life: 4-8h, hepatic metabolism',
                clinicalPearls: 'Patches for motion sickness. Excellent for respiratory secretions in palliative care',
                indication: 'Motion sickness, excessive respiratory secretions, smooth muscle spasm'
            },
            'ibuprofen': {
                name: 'Ibuprofen',
                class: 'Non-steroidal anti-inflammatory drug (NSAID)',
                mechanism: 'Non-selective cyclooxygenase (COX) inhibitor, reducing prostaglandin synthesis',
                dosing: 'Adults: 400mg TDS-QDS with food (max 2.4g daily). Children >6 months: 20-30mg/kg daily in 3-4 divided doses',
                contraindications: 'Active peptic ulceration, severe heart failure, severe renal impairment, pregnancy (3rd trimester)',
                interactions: 'ACE inhibitors (↓ antihypertensive effect), warfarin (↑ bleeding risk), lithium (↑ toxicity), methotrexate (↑ toxicity)',
                monitoring: 'Renal function, blood pressure, signs of GI bleeding, fluid retention',
                pregnancy: 'Avoid in 3rd trimester - risk of oligohydramnios and premature closure of ductus arteriosus',
                sideEffects: 'GI bleeding/perforation, acute kidney injury, fluid retention, hypertension, bronchospasm (aspirin-sensitive asthma)',
                pharmacokinetics: 'Onset: 30min, Peak: 1-2h, Half-life: 2-4h, Hepatic metabolism',
                clinicalPearls: 'Most widely used NSAID in UK. Always take with food. Use lowest effective dose for shortest time',
                indication: 'Pain and inflammation, particularly musculoskeletal conditions, fever, dysmenorrhoea'
            },
            'insulin': {
                name: 'Insulin (soluble/regular; e.g., Actrapid/Humulin S)',
                class: 'Short-acting insulin',
                mechanism: 'Replaces endogenous insulin to facilitate cellular glucose uptake and inhibit hepatic glucose output',
                dosing: 'SC pre-meal dosing individualised (often part of basal-bolus regimens). IV infusion for DKA/HHS per local protocol (e.g., 0.1 units/kg/h).',
                contraindications: 'Hypoglycaemia',
                interactions: 'Beta-blockers (mask hypos), steroids (↑ glucose), alcohol (hypo risk)',
                monitoring: 'Capillary glucose, ketones if unwell, electrolytes in IV therapy',
                pregnancy: 'Safe; first-line in gestational diabetes if needed',
                sideEffects: 'Hypoglycaemia, weight gain, injection-site reactions',
                pharmacokinetics: 'Onset ~30 min SC; peak 2–4 h; duration 6–8 h',
                clinicalPearls: 'Use IV only in monitored settings per protocol. Educate on hypo recognition and treatment; driving advice per DVLA.',
                indication: 'Type 1 and Type 2 diabetes (as part of regimens); DKA/HHS (IV)'
            },
            'ipratropium': {
                name: 'Ipratropium',
                class: 'Short-acting muscarinic antagonist (SAMA)',
                mechanism: 'Competitive antagonist of muscarinic receptors in bronchial smooth muscle',
                dosing: 'MDI: 40mcg QDS. Nebuliser: 250-500mcg QDS. Acute exacerbation: 500mcg nebulised',
                contraindications: 'Hypersensitivity to atropine or derivatives',
                interactions: 'Other anticholinergics (↑ anticholinergic effects)',
                monitoring: 'Bronchodilator response, anticholinergic side effects, eye symptoms',
                pregnancy: 'Safe - minimal systemic absorption',
                sideEffects: 'Dry mouth, cough, headache, paradoxical bronchospasm (rare)',
                pharmacokinetics: 'Minimal systemic absorption, onset: 15min, duration: 3-6h',
                clinicalPearls: 'Additive effect with beta-2 agonists. Avoid contact with eyes (glaucoma risk)',
                indication: 'COPD, severe asthma (add-on therapy), acute exacerbations'
            },
            'ketamine': {
                name: 'Ketamine',
                class: 'Dissociative Anaesthetic/Analgesic',
                mechanism: 'NMDA receptor antagonist causing dissociative anaesthesia and analgesia',
                dosing: 'Anaesthesia: 1-2mg/kg IV, 4-6mg/kg IM. Analgesia: 0.1-0.3mg/kg IV. Depression: 0.5mg/kg',
                contraindications: 'Severe hypertension, raised ICP, psychotic disorders, porphyria',
                interactions: 'CNS depressants, sympathomimetics (↑ hypertension), theophylline',
                monitoring: 'Blood pressure, heart rate, respiratory rate, emergence reactions',
                pregnancy: 'Use only if benefit outweighs risk; consult UKTIS or SmPC as needed',
                sideEffects: 'Emergence reactions, hallucinations, hypertension, tachycardia, laryngospasm',
                pharmacokinetics: 'Rapid onset 1-2min IV. t½ 2-3h. Hepatic metabolism to active metabolites',
                clinicalPearls: 'Maintains airway reflexes. Good for unstable patients. Pre-treat with benzodiazepine',
                indication: 'Emergency anaesthesia, procedural sedation, severe asthma, treatment-resistant depression'
            },
            'lactulose': {
                name: 'Lactulose',
                class: 'Osmotic laxative',
                mechanism: 'Non-absorbable disaccharide, osmotically active, acidifies colon reducing ammonia absorption',
                dosing: 'Adults: 15ml BD initially, adjust to 1-2 soft stools daily. Hepatic encephalopathy: 30-50ml TDS',
                contraindications: 'Galactosaemia, intestinal obstruction, fructose intolerance',
                interactions: 'No significant drug interactions',
                monitoring: 'Stool frequency/consistency, electrolyte balance, dehydration risk',
                pregnancy: 'Generally considered compatible in pregnancy; minimal systemic absorption',
                sideEffects: 'Flatulence, abdominal cramps, nausea, electrolyte disturbance (overdose)',
                pharmacokinetics: 'Not absorbed in small intestine, fermented by colonic bacteria',
                clinicalPearls: 'Safe in pregnancy and elderly. Takes 2-3 days for full effect. Sweet taste',
                indication: 'Constipation, hepatic encephalopathy, preparation for procedures'
            },
            'lansoprazole': {
                name: 'Lansoprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Irreversibly inhibits gastric H+/K+-ATPase (proton pump)',
                dosing: 'GORD: 30mg daily. Peptic ulcer: 30mg daily for 4-8 weeks. H.pylori: 30mg BD with antibiotics',
                contraindications: 'Hypersensitivity to PPIs',
                interactions: 'Similar to omeprazole - clopidogrel, warfarin, digoxin',
                monitoring: 'Similar to omeprazole - B12, magnesium with long-term use',
                pregnancy: 'Generally safe - no increased malformation risk',
                sideEffects: 'Similar to omeprazole - headache, GI upset, long-term risks',
                pharmacokinetics: 'Enteric-coated, acid-labile, hepatic metabolism',
                clinicalPearls: 'Alternative to omeprazole. Take before food. Orodispersible tablets available',
                indication: 'GORD, peptic ulcer disease, H.pylori eradication, Zollinger-Ellison syndrome'
            },
            'levodopa': {
                name: 'Levodopa/Carbidopa (Co-careldopa)',
                class: 'Dopaminergic drug for Parkinson\'s disease',
                mechanism: 'Levodopa converted to dopamine in brain; carbidopa prevents peripheral conversion',
                dosing: 'Start 62.5mg (50mg levodopa + 12.5mg carbidopa) TDS, increase gradually',
                contraindications: 'Narrow-angle glaucoma, melanoma, MAOIs',
                interactions: 'MAOIs (hypertensive crisis), antipsychotics (antagonism), iron (↓ absorption)',
                monitoring: 'Motor symptoms, dyskinesias, psychiatric symptoms, blood pressure',
                pregnancy: 'Use only if essential - limited safety data',
                sideEffects: 'Nausea, dyskinesias, psychiatric symptoms, postural hypotension',
                pharmacokinetics: 'Short half-life: 1-3h, extensive first-pass metabolism',
                clinicalPearls: 'Take 30min before food. Wearing-off effects develop over time. Protein meals reduce absorption',
                indication: 'Parkinson\'s disease, restless legs syndrome'
            },
            'levonorgestrel': {
                name: 'Levonorgestrel',
                class: 'Synthetic progestogen',
                mechanism: 'Progesterone receptor agonist, prevents/delays ovulation and affects endometrium',
                dosing: 'Emergency contraception: 1.5mg STAT (within 72h). IUS: 52mg over 5 years',
                contraindications: 'Pregnancy, severe liver disease, undiagnosed vaginal bleeding',
                interactions: 'Enzyme inducers (↓ efficacy - may need higher dose), ritonavir',
                monitoring: 'Pregnancy test if period late, BP with IUS, bleeding patterns',
                pregnancy: 'Contraindicated - stop if pregnancy occurs',
                sideEffects: 'Nausea, headache, breast tenderness, irregular bleeding, mood changes',
                pharmacokinetics: 'Rapid absorption, half-life: 24-32h, hepatic metabolism',
                clinicalPearls: 'Most effective within 12h of unprotected intercourse. Available OTC as emergency contraception',
                indication: 'Emergency contraception, long-term contraception (IUS), menorrhagia'
            },
            'levothyroxine': {
                name: 'Levothyroxine',
                class: 'Thyroid hormones',
                mechanism: 'Synthetic L-thyroxine (T4) hormone, converted to active T3 in peripheral tissues',
                dosing: 'Adults <50yrs: 1.6micrograms/kg daily. >50yrs or cardiac disease: 25-50micrograms daily, increase by 25-50micrograms every 3-4 weeks',
                contraindications: 'Untreated adrenal insufficiency, acute myocardial infarction, thyrotoxicosis',
                interactions: 'Iron/calcium (take 4h apart), warfarin (↑ anticoagulant effect), carbamazepine (↑ metabolism)',
                monitoring: 'TSH every 6-8 weeks until stable, then annually. Free T4 if pituitary disease suspected',
                pregnancy: 'Safe - essential in pregnancy. Increase dose by 25-50micrograms. Monitor TSH each trimester',
                sideEffects: 'Over-replacement: palpitations, insomnia, tremor, weight loss, heat intolerance, AF, osteoporosis',
                pharmacokinetics: 'Peak: 2-4h, Half-life: 7 days, Steady state: 6-8 weeks',
                clinicalPearls: 'Take on empty stomach 30-60min before breakfast. Consistent brand/timing. TSH target 0.4-4.0 mU/L',
                indication: 'Primary hypothyroidism, secondary hypothyroidism, thyroid cancer (TSH suppression)'
            },
            'lidocaine': {
                name: 'Lidocaine',
                class: 'Local anaesthetic (amide type)',
                mechanism: 'Blocks voltage-gated sodium channels, preventing nerve conduction',
                dosing: 'Local infiltration: max 4.5mg/kg (7mg/kg with adrenaline). Topical: 2-5% preparations',
                contraindications: 'Heart block, severe cardiac failure, hypersensitivity to amides',
                interactions: 'Beta-blockers (↑ toxicity), cimetidine (↑ levels), class I antiarrhythmics',
                monitoring: 'Signs of systemic toxicity, cardiac rhythm (IV use)',
                pregnancy: 'Safe for local use - does not cross placenta significantly',
                sideEffects: 'Local: burning, swelling. Systemic: CNS toxicity, cardiac arrhythmias',
                pharmacokinetics: 'Rapid onset: 2-5min, duration: 1-3h, hepatic metabolism',
                clinicalPearls: 'Most common local anaesthetic. Adrenaline prolongs duration. IV form for arrhythmias',
                indication: 'Local anaesthesia, topical anaesthesia, ventricular arrhythmias (IV)'
            },
            'lithium': {
                name: 'Lithium carbonate',
                class: 'Mood stabiliser',
                mechanism: 'Unclear - affects neurotransmitter function and cellular signalling',
                dosing: 'Start 200-400mg daily, target level 0.6-1.0mmol/L for maintenance, 0.8-1.2mmol/L acute',
                contraindications: 'Severe renal/cardiac disease, Addison\'s disease, dehydration, pregnancy (1st trimester)',
                interactions: 'Diuretics (↑ toxicity), ACE inhibitors (↑ levels), NSAIDs (↑ levels), theophylline (↓ levels)',
                monitoring: 'Lithium levels weekly until stable, then 3-monthly. TFTs, U&Es, weight',
                pregnancy: 'Avoid 1st trimester (Ebstein\'s anomaly). Use with caution thereafter',
                sideEffects: 'Tremor, polyuria, weight gain, hypothyroidism, nephrotoxicity, teratogenicity',
                pharmacokinetics: 'Narrow therapeutic window, renal excretion, half-life: 12-27h',
                clinicalPearls: 'Regular level monitoring essential. Toxicity >1.5mmol/L. Maintain good hydration',
                indication: 'Bipolar disorder (acute treatment and prophylaxis), treatment-resistant depression'
            },
            'loperamide': {
                name: 'Loperamide',
                class: 'Opioid antidiarrhoeal agent',
                mechanism: 'Mu-opioid receptor agonist in GI tract, slows intestinal motility',
                dosing: 'Adults: 4mg initially, then 2mg after each loose stool (max 16mg daily). Children >4 years: weight-based dosing',
                contraindications: 'Acute dysentery, acute ulcerative colitis, bacterial enterocolitis, children <4 years',
                interactions: 'P-glycoprotein inhibitors (↑ CNS effects), quinidine, ritonavir',
                monitoring: 'Stool frequency, abdominal pain, signs of toxic megacolon',
                pregnancy: 'Safe - limited systemic absorption, no increased malformation risk',
                sideEffects: 'Constipation, abdominal cramps, drowsiness, dry mouth, nausea',
                pharmacokinetics: 'Poor oral absorption, minimal CNS penetration, Half-life: 10-14h',
                clinicalPearls: 'Available OTC (max 2 days). Does not cross blood-brain barrier at therapeutic doses',
                indication: 'Acute diarrhoea, chronic diarrhoea, IBS with diarrhoea'
            },
            'loratadine': {
                name: 'Loratadine',
                class: 'Second-generation antihistamine (H1 antagonist)',
                mechanism: 'Selective peripheral H1 receptor antagonist, minimal CNS and anticholinergic effects',
                dosing: 'Adults: 10mg daily. Children 2-12 years: 5mg daily (<30kg) or 10mg daily (>30kg)',
                contraindications: 'Hypersensitivity to loratadine, severe hepatic impairment',
                interactions: 'CYP3A4 inhibitors (ketoconazole, erythromycin) may ↑ levels but no clinical significance',
                monitoring: 'Sedation level, effectiveness for allergic symptoms',
                pregnancy: 'Generally considered compatible in pregnancy; preferred antihistamine in many cases, see UKTIS',
                sideEffects: 'Headache, drowsiness (3%), dry mouth, fatigue, nervousness',
                pharmacokinetics: 'Rapidly absorbed, Half-life: 8h (active metabolite 28h), hepatic metabolism',
                clinicalPearls: 'Non-sedating antihistamine. Once daily dosing. Available OTC. No dose adjustment in renal disease',
                indication: 'Allergic rhinitis, chronic idiopathic urticaria, allergic skin conditions'
            },
            'lorazepam': {
                name: 'Lorazepam',
                class: 'Short-acting benzodiazepine',
                mechanism: 'Enhances GABA-A receptor activity, increasing neuronal inhibition',
                dosing: 'Anxiety: 1-4mg daily in divided doses. Status epilepticus: 4mg IV slowly',
                contraindications: 'Respiratory depression, severe hepatic impairment, myasthenia gravis',
                interactions: 'Alcohol (↑ sedation), opioids (respiratory depression), phenytoin',
                monitoring: 'Respiratory function, sedation level, signs of dependence',
                pregnancy: 'Avoid - risk of floppy baby syndrome, neonatal withdrawal',
                sideEffects: 'Sedation, confusion (elderly), dependence, respiratory depression',
                pharmacokinetics: 'Intermediate half-life: 10-20h, conjugated (safer in elderly)',
                clinicalPearls: 'Shorter-acting than diazepam. Less affected by hepatic impairment. High dependence risk',
                indication: 'Short-term anxiety, status epilepticus, premedication'
            },
            'losartan': {
                name: 'Losartan',
                class: 'Angiotensin receptor blockers',
                mechanism: 'Selective antagonist of angiotensin II at AT1 receptors',
                dosing: 'Hypertension: Start 50mg daily, max 100mg daily. Heart failure: Start 12.5mg daily, target 150mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, severe renal impairment',
                interactions: 'NSAIDs (↓ efficacy), potassium supplements (hyperkalemia), lithium (↑ levels)',
                monitoring: 'eGFR, potassium, blood pressure. Check 1-2 weeks after starting',
                pregnancy: 'Contraindicated - teratogenic in 2nd/3rd trimester',
                sideEffects: 'Dizziness, hyperkalemia, dry cough (less than ACE-I), angioedema (rare)',
                pharmacokinetics: 'Prodrug, active metabolite half-life: 6-9h, hepatic metabolism',
                clinicalPearls: 'Alternative to ACE inhibitor if cough. Less cough than ACE-I but more expensive',
                indication: 'Hypertension, heart failure, diabetic nephropathy, post-MI (ACE-I intolerant)'
            },
            'magnesium-sulfate': {
                name: 'Magnesium Sulfate',
                class: 'Mineral supplement/Antiarrhythmic',
                mechanism: 'Essential cofactor for enzymes, membrane stabilizer, calcium channel blocker',
                dosing: 'Hypomagnesemia: 8mmol IV over 24h. Torsades: 8mmol IV over 10-15min. Eclampsia: 4g IV then 1g/h',
                contraindications: 'Severe renal impairment, myasthenia gravis, heart block',
                interactions: 'Digoxin (↓ efficacy), neuromuscular blockers (↑ paralysis), calcium channel blockers',
                monitoring: 'Serum magnesium, reflexes, respiratory rate, urine output, renal function',
                pregnancy: 'Safe and indicated for eclampsia/pre-eclampsia. Standard treatment',
                sideEffects: 'Hypotension, respiratory depression, areflexia, cardiac arrest (overdose)',
                pharmacokinetics: 'Onset 1-5min IV. Excreted unchanged by kidneys. t½ 3-4h',
                clinicalPearls: 'Check reflexes before each dose. Have calcium gluconate ready as antidote',
                indication: 'Eclampsia, torsades de pointes, hypomagnesemia, severe asthma'
            },
            'meropenem': {
                name: 'Meropenem',
                class: 'Antibiotic (Carbapenem)',
                mechanism: 'Inhibits bacterial cell wall synthesis, stable to most beta-lactamases',
                dosing: 'Adult: 0.5-1g TDS IV. Severe infections/meningitis: 2g TDS. Infuse over 15-30min',
                contraindications: 'Carbapenem allergy, severe penicillin allergy (cross-reactivity)',
                interactions: 'Probenecid (↑ levels), valproate (↓ seizure threshold), ganciclovir',
                monitoring: 'Renal function, seizure activity, infection resolution, C.diff surveillance',
                pregnancy: 'Generally considered compatible where benefits outweigh risks; consult UKTIS/SmPC',
                sideEffects: 'Diarrhea, nausea, headache, seizures (high dose/renal impairment), C.diff',
                pharmacokinetics: 'Excellent tissue penetration including CSF. t½ 1h. 70% renal excretion',
                clinicalPearls: 'Broad spectrum including ESBL producers. Lower seizure risk than imipenem',
                indication: 'Severe sepsis, complicated UTI, intra-abdominal infections, meningitis'
            },
            'metformin': {
                name: 'Metformin',
                class: 'Biguanide (oral hypoglycaemic)',
                mechanism: 'Reduces hepatic gluconeogenesis, increases insulin sensitivity and reduces intestinal glucose absorption',
                dosing: 'Immediate-release: start 500 mg once or twice daily with food, titrate up to 1 g twice daily as tolerated. Modified-release: start 500 mg once daily, up to 2 g once daily depending on formulation. Adjust dose for renal impairment—see SmPC and local guidance.',
                contraindications: 'eGFR <30 mL/min/1.73 m² (contraindicated); acute or chronic metabolic acidosis including diabetic ketoacidosis; conditions associated with hypoxia',
                interactions: 'Iodinated contrast (withhold around procedure and check eGFR), drugs that alter renal function (NSAIDs, ACEi/ARBs, diuretics) may ↑ metformin accumulation',
                monitoring: 'Baseline and periodic eGFR (at least annually; more often if eGFR 45–60 or if risk factors present). Check B12 periodically if anaemia or neuropathy. HbA1c every 3–6 months.',
                pregnancy: 'Used in pregnancy for gestational diabetes and PCOS in some circumstances; specialist/obstetric guidance and UKTIS advice recommended',
                sideEffects: 'GI upset (nausea, diarrhoea), metallic taste, reduced B12 absorption leading to deficiency, rare risk of lactic acidosis in severe renal impairment or hypoxic states',
                pharmacokinetics: 'Not metabolised; renally excreted unchanged. Oral bioavailability variable; half-life ~6 hours in plasma but longer clinical effect',
                clinicalPearls: 'Withhold before and for 48 hours after iodinated contrast or major procedures if renal function may be compromised; consider restarting when eGFR stable. Use lowest effective dose in elderly with declining renal function. Counsel regarding GI effects and slow titration. Consider alternative agents in significant CKD.',
                efficacy: 'Effective first-line therapy for type 2 diabetes; reduces HbA1c and has favourable weight and CV profile'
            },
            'methotrexate': {
                name: 'Methotrexate',
                class: 'Methotrexate',
                mechanism: 'Inhibits dihydrofolate reductase, interfering with folate metabolism',
                dosing: 'Rheumatoid arthritis: 7.5-25mg weekly. Always prescribe folic acid 5mg weekly (day after MTX)',
                contraindications: 'Pregnancy, breastfeeding, severe renal/hepatic impairment, immunodeficiency',
                interactions: 'NSAIDs (↑ toxicity), trimethoprim (↑ toxicity), PPIs (↑ levels)',
                monitoring: 'FBC, LFTs, U&Es weekly initially, then monthly. CXR annually',
                pregnancy: 'Contraindicated - teratogenic and abortifacient',
                sideEffects: 'Bone marrow suppression, hepatotoxicity, pulmonary fibrosis, mucositis',
                pharmacokinetics: 'Variable absorption, renal excretion, polyglutamate forms accumulate',
                clinicalPearls: 'Always prescribe with folic acid. Stop if infection/illness. DMARD monitoring essential',
                indication: 'Rheumatoid arthritis, psoriasis, cancer (various), ectopic pregnancy'
            },
            'metoclopramide': {
                name: 'Metoclopramide',
                class: 'Antiemetic/Prokinetic (Dopamine antagonist)',
                mechanism: 'Blocks dopamine D2 receptors in CTZ and enhances GI motility',
                dosing: 'Adult: 10mg TDS PO/IV/IM. Max 5 days treatment. Reduce dose in elderly/renal impairment',
                contraindications: 'GI obstruction, perforation, pheochromocytoma, prolactinoma, Parkinson\'s disease',
                interactions: 'Dopamine agonists (antagonism), CNS depressants, digoxin (↑ absorption)',
                monitoring: 'Neurological symptoms (tardive dyskinesia), cardiac conduction, renal function',
                pregnancy: 'Generally considered compatible and commonly used for hyperemesis gravidarum; consult UKTIS as required',
                sideEffects: 'Extrapyramidal effects, tardive dyskinesia, drowsiness, depression, galactorrhea',
                pharmacokinetics: 'Onset 30min PO, 10min IV. t½ 4-6h. Hepatic metabolism, renal excretion',
                clinicalPearls: 'Limit to 5 days to reduce tardive dyskinesia risk. Give procyclidine for dystonia',
                indication: 'Nausea/vomiting, gastroparesis, migraine-associated nausea, postoperative nausea'
            },
            'metronidazole': {
                name: 'Metronidazole',
                class: 'Nitroimidazole (antibacterial/antiprotozoal)',
                mechanism: 'Forms reactive metabolites that damage DNA in anaerobic bacteria and certain protozoa',
                dosing: 'Oral: 400 mg TDS for 5–7 days for most indications. IV: 500 mg TDS. For C. difficile infection metronidazole is no longer first-line for initial episodes — NICE recommends oral vancomycin or fidaxomicin; metronidazole may be used in specific circumstances (e.g. where oral therapy is not possible) typically 400 mg TDS for 10–14 days',
                contraindications: 'Hypersensitivity to nitroimidazoles; avoid concurrent disulfiram or alcohol (disulfiram-like reaction)',
                interactions: 'Warfarin (may ↑ INR), alcohol (disulfiram-like reaction), caution with lithium — monitor levels if co-prescribed',
                monitoring: 'Check for signs of peripheral neuropathy during prolonged courses; LFTs if used long-term or in hepatic impairment',
                pregnancy: 'Use specialist/UKTIS advice if required. Avoid in first trimester where possible; may be used later in pregnancy if benefits outweigh risks',
                sideEffects: 'Metallic taste, nausea, GI upset, headache, peripheral neuropathy with prolonged use, rarely hepatic dysfunction or seizures',
                pharmacokinetics: 'Well absorbed orally with good tissue and CNS penetration; hepatic metabolism with renal excretion of metabolites',
                clinicalPearls: 'Avoid alcohol during treatment and for 48 hours afterwards. Not first-line for initial C. difficile per current NICE guidance — use oral vancomycin/fidaxomicin where indicated. Prolonged therapy risks peripheral neuropathy and should prompt review',
                indication: 'Anaerobic infections, bacterial vaginosis, H. pylori eradication (as part of combination therapy), giardiasis/trichomoniasis, limited/alternative role in C. difficile infection'
            },
            'midazolam': {
                name: 'Midazolam',
                class: 'Benzodiazepine (short-acting)',
                mechanism: 'Positive allosteric modulator at GABA-A receptors causing sedation, anxiolysis and amnesia',
                dosing: 'Seizure rescue (IV): 0.1–0.2 mg/kg (max 5 mg) IV bolus; IM/IN: 0.2 mg/kg (max 10 mg). Procedural/conscious sedation: 1–2.5 mg IV incremental doses. Anaesthesia induction: 0.15–0.3 mg/kg IV. Adjust for elderly and hepatic impairment.',
                contraindications: 'Severe respiratory depression, acute narrow-angle glaucoma, hypersensitivity to benzodiazepines',
                interactions: 'Additive CNS and respiratory depression with opioids, alcohol and other sedatives; CYP3A4 inhibitors may increase effect',
                monitoring: 'Continuous monitoring of respiratory rate, oxygen saturation and level of consciousness during and after administration; observe until baseline mental state',
                pregnancy: 'Avoid if possible; use only if benefits outweigh risks and follow specialist/UKTIS guidance for neonate monitoring if used near delivery',
                sideEffects: 'Respiratory depression, hypotension, paradoxical agitation, prolonged sedation in elderly/renal impairment',
                pharmacokinetics: 'Rapid onset (IV: minutes), short acting; hepatic metabolism (CYP3A4) with active metabolites in some populations',
                clinicalPearls: 'Have airway equipment and reversal (flumazenil) available where clinically indicated. Intranasal and buccal routes useful for prehospital/seizure rescue. Reduce dose in older adults and those with hepatic impairment.',
                indication: 'Seizure control (status epilepticus), conscious sedation, procedural sedation, premedication, ICU sedation'
            },
            'mirtazapine': {
                name: 'Mirtazapine',
                class: 'Noradrenergic and specific serotonergic antidepressant (NaSSA)',
                mechanism: 'Blocks α2-adrenergic autoreceptors and 5-HT2/5-HT3 receptors, enhancing noradrenaline and serotonin',
                dosing: 'Adults: Start 15mg at night, increase after 1-2 weeks to 30mg, max 45mg daily',
                contraindications: 'MAOIs, mania, severe hepatic impairment',
                interactions: 'MAOIs, warfarin, alcohol (↑ sedation), tramadol',
                monitoring: 'FBC (especially first few months), weight, mood, sedation level',
                pregnancy: 'Use if benefit outweighs risk - limited safety data',
                sideEffects: 'Sedation (dose-related), weight gain, dry mouth, constipation, blood dyscrasias (rare)',
                pharmacokinetics: 'Half-life: 20-40h, hepatic metabolism',
                clinicalPearls: 'Paradoxical effect: more sedating at lower doses. Good for depression with insomnia/weight loss',
                indication: 'Depression (especially with anxiety, insomnia, or weight loss)'
            },
            'montelukast': {
                name: 'Montelukast',
                class: 'Leukotriene receptor antagonist',
                mechanism: 'Selective antagonist of cysteinyl leukotriene (CysLT1) receptors',
                dosing: 'Adults: 10mg daily at bedtime. Children 6-14 years: 5mg daily. Children 2-5 years: 4mg daily',
                contraindications: 'Hypersensitivity to montelukast, acute asthma attacks',
                interactions: 'CYP2C8 inducers (rifampicin) may ↓ levels. CYP2C8/2C9 interactions possible',
                monitoring: 'Asthma control, mood changes, neuropsychiatric symptoms, liver function',
                pregnancy: 'Generally considered compatible; continue if clinically required and consult UKTIS for specific drug guidance',
                sideEffects: 'Headache, GI upset, neuropsychiatric effects (mood changes, sleep disturbances)',
                pharmacokinetics: 'Rapid absorption, Half-life: 3-6h, extensive hepatic metabolism',
                clinicalPearls: 'Add-on therapy in asthma step 3. Take at bedtime. Monitor for mood changes',
                indication: 'Asthma prophylaxis, allergic rhinitis, exercise-induced bronchospasm'
            },
            'morphine': {
                name: 'Morphine',
                class: 'Opioid analgesic (strong opioid)',
                mechanism: 'μ-opioid receptor agonist producing analgesia, sedation, and respiratory depression',
                dosing: 'Oral (immediate-release): opioid‑naïve 2.5–5 mg PO every 4 h PRN (adjust to context). Oral modified‑release for chronic pain individualized (e.g., 10–30 mg BD). SC/IM: 2.5–5 mg titrated to effect; IV bolus 2.5–5 mg (titrate carefully). PCA and infusion dosing depend on local protocols; typical PCA bolus 1 mg with lockout, infusion rates individualized.',
                contraindications: 'Respiratory depression, acute severe asthma, paralytic ileus, significant CNS depression, known hypersensitivity',
                interactions: 'Other CNS depressants (benzos, gabapentinoids, alcohol) ↑ risk of respiratory depression; MAOIs (dangerous interactions), CYP interactions via metabolites',
                monitoring: 'Pain scores, sedation score, respiratory rate and oxygenation, bowel function, renal function (metabolite accumulation), signs of tolerance/dependence',
                pregnancy: 'Use only if necessary; avoid near term where possible (risk neonatal respiratory depression/withdrawal); liaise with obstetrics',
                sideEffects: 'Constipation, nausea, vomiting, pruritus, sedation, respiratory depression, urinary retention',
                pharmacokinetics: 'Hepatic metabolism to M3G/M6G; renally excreted metabolites accumulate in CKD—reduce dose or use alternative (e.g., oxycodone/fentanyl) in severe renal impairment',
                clinicalPearls: 'Co-prescribe laxative and consider antiemetic for initiation; start low and titrate. Use caution with concomitant sedatives and in the elderly. Naloxone reverses opioid toxicity—titrate to restore ventilation rather than full reversal. For PCA/infusions, follow local policies and monitor closely.',
                indication: 'Moderate to severe acute pain, chronic severe pain, palliative care'
            },
            'naloxone': {
                name: 'Naloxone',
                class: 'Opioid antagonist',
                mechanism: 'Competitive antagonist at μ‑opioid receptors, rapidly reversing opioid-induced respiratory depression',
                dosing: 'Intranasal (pre-filled spray): 400 mcg per spray — may repeat every 2–3 minutes as necessary. IM/SC: 400 mcg–2 mg (commonly 400 mcg increments), repeat every 2–3 minutes. IV: 100–400 mcg boluses titrated to effect; if large opioid burden, consider infusion (e.g. 4 mcg/kg/h) after initial bolus titration. In community opioid rescue kits, follow local protocols (often 400 mcg IN).',
                contraindications: 'Hypersensitivity to naloxone; use with caution in opioid-dependent patients because of precipitating acute withdrawal',
                interactions: 'Reverses opioid analgesia and may precipitate withdrawal; may interact indirectly with drugs that affect cardiovascular stability',
                monitoring: 'Continuous monitoring of respiratory rate, oxygenation, consciousness and haemodynamics. Observe for re‑sedation after initial response because naloxone duration may be shorter than some opioids; monitor for at least 2 hours (longer if long‑acting opioids suspected).',
                pregnancy: 'Safe to use in pregnancy in opioid overdose; maternal resuscitation takes priority',
                sideEffects: 'Acute opioid withdrawal (nausea, vomiting, agitation), tachycardia, hypertension, arrhythmias, pulmonary oedema (rare)',
                pharmacokinetics: 'Rapid onset IV/IN; relatively short duration (30–120 minutes) requiring observation and possible repeat dosing',
                clinicalPearls: 'Titrate to restore adequate spontaneous ventilation rather than full reversal to avoid severe withdrawal. Community kits commonly use intranasal formulations (400 mcg). Ensure plan for transfer to ED after reversal and consider need for repeat dosing or infusion for long-acting opioids.',
                indication: 'Opioid overdose with respiratory depression, reversal of opioid-induced respiratory depression in clinical settings'
            },
            'naproxen': {
                name: 'Naproxen',
                class: 'Non-steroidal anti-inflammatory drug (NSAID)',
                mechanism: 'Non-selective COX inhibitor with longer half-life than other NSAIDs',
                dosing: 'Adults: 250-500mg BD with food. Acute pain: 500mg initially, then 250mg TDS',
                contraindications: 'Active peptic ulceration, severe heart failure, severe renal/hepatic impairment',
                interactions: 'ACE inhibitors (↓ effect), warfarin (↑ bleeding), lithium (↑ toxicity)',
                monitoring: 'Renal function, blood pressure, signs of GI bleeding, cardiovascular events',
                pregnancy: 'Avoid in 3rd trimester. Use lowest dose for shortest time if essential',
                sideEffects: 'GI bleeding, cardiovascular events, renal impairment, fluid retention',
                pharmacokinetics: 'Good oral absorption, Half-life: 12-15h, hepatic metabolism',
                clinicalPearls: 'Longer half-life allows BD dosing. Lower GI toxicity than some NSAIDs',
                indication: 'Inflammatory conditions, musculoskeletal pain, dysmenorrhoea, acute gout'
            },
            'nitrofurantoin': {
                name: 'Nitrofurantoin',
                class: 'Nitrofurantoin',
                mechanism: 'Inhibits bacterial enzymes involved in carbohydrate metabolism',
                dosing: 'UTI treatment: 100mg BD for 3 days (women) or 7 days (men). Prophylaxis: 50-100mg at night',
                contraindications: 'eGFR <45ml/min/1.73mÂ², pregnancy at term, G6PD deficiency, acute porphyria',
                interactions: 'Magnesium salts (↓ absorption), probenecid (↑ toxicity)',
                monitoring: 'Renal function, LFTs, signs of pulmonary toxicity (chronic use)',
                pregnancy: 'Safe except at term (risk of neonatal haemolysis)',
                sideEffects: 'GI upset, pulmonary toxicity (chronic use), peripheral neuropathy, hepatotoxicity',
                pharmacokinetics: 'Rapidly absorbed, concentrated in urine, Half-life: 20min',
                clinicalPearls: 'Excellent for uncomplicated UTI. Take with food. Avoid if eGFR <45. Urine may turn brown',
                indication: 'UTI treatment and prophylaxis. Not effective for pyelonephritis'
            },
            'noradrenaline': {
                name: 'Noradrenaline',
                class: 'Sympathomimetic (Alpha/Beta agonist)',
                mechanism: 'Potent α1 and moderate β1 agonist causing vasoconstriction and increased contractility',
                dosing: 'IV infusion: 0.01-3mcg/kg/min via central line. Titrate to MAP >65mmHg',
                contraindications: 'Hypovolemia (relative), pregnancy (unless life-threatening), peripheral vascular disease',
                interactions: 'TCAs (↑ pressor response), MAOIs (↑ hypertensive crisis), halothane (arrhythmias)',
                monitoring: 'Blood pressure, heart rate, urine output, peripheral perfusion, ECG',
                pregnancy: 'Avoid unless life-threatening. May reduce uterine blood flow',
                sideEffects: 'Hypertension, arrhythmias, peripheral ischemia, tissue necrosis (extravasation)',
                pharmacokinetics: 'IV only. Onset immediate, duration 1-2min after stopping. Metabolized by COMT/MAO',
                clinicalPearls: 'First-line vasopressor in septic shock. Give via central line. Have phentolamine ready',
                indication: 'Septic shock, cardiogenic shock, severe hypotension, cardiac arrest'
            },
            'olanzapine': {
                name: 'Olanzapine',
                class: 'Antipsychotics, second-generation (atypical)',
                mechanism: 'Dopamine D2, serotonin 5-HT2A receptor antagonist with multiple receptor activity',
                dosing: 'Schizophrenia: Start 10mg daily, range 5-20mg. Bipolar: 15mg daily, adjust 5-20mg',
                contraindications: 'Comatose states, severe CNS depression',
                interactions: 'Alcohol (↑ sedation), carbamazepine (↓ olanzapine levels), smoking (↓ levels)',
                monitoring: 'Weight, glucose, lipids, prolactin, FBC, LFTs, movement disorders',
                pregnancy: 'Use only if essential - risk of extrapyramidal symptoms in neonate',
                sideEffects: 'Weight gain, diabetes, dyslipidaemia, sedation, extrapyramidal effects (less than typical)',
                pharmacokinetics: 'Half-life: 30h, hepatic metabolism, smoking increases clearance',
                clinicalPearls: 'Lower EPS risk than haloperidol but significant metabolic effects. Regular monitoring essential',
                indication: 'Schizophrenia, bipolar disorder (acute mania), treatment-resistant depression'
            },
            'omeprazole': {
                name: 'Omeprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Irreversibly inhibits gastric H+/K+-ATPase (proton pump)',
                dosing: 'GORD: 20mg daily. Peptic ulcer: 20-40mg daily. H.pylori: 20mg BD with antibiotics',
                contraindications: 'Hypersensitivity to PPIs',
                interactions: 'Clopidogrel (↓ efficacy), warfarin (↑ INR), digoxin (↑ levels)',
                monitoring: 'Vitamin B12, magnesium with long-term use. Review need regularly',
                pregnancy: 'Generally safe - limited human data',
                sideEffects: 'Headache, GI upset, increased infection risk, hypomagnesaemia (long-term)',
                pharmacokinetics: 'Onset: 1h, Peak: 2h, Duration: 72h, CYP2C19 metabolism',
                clinicalPearls: 'First PPI available OTC in UK. Take 30min before food',
                indication: 'GORD, peptic ulcer disease, H.pylori eradication'
            },
            'ondansetron': {
                name: 'Ondansetron',
                class: 'Antiemetic (Selective 5-HT₃ receptor antagonist)',
                mechanism: 'Blocks serotonin 5-HT₃ receptors in the chemoreceptor trigger zone and GI tract',
                dosing: 'Post-operative or chemo-induced N/V: 4–8 mg IV or PO up to TDS (max single IV dose 16 mg due to QT risk)',
                contraindications: 'Congenital long QT syndrome, severe hepatic impairment',
                interactions: 'Other QT-prolonging drugs (macrolides, antipsychotics), serotonergic agents (risk of serotonin syndrome)',
                monitoring: 'ECG if risk factors for QT prolongation, constipation, LFTs if prolonged use',
                pregnancy: 'Can be used if clinically indicated for hyperemesis gravidarum (RCOG GTG 69)',
                sideEffects: 'Constipation, headache, flushing, QT prolongation (dose-related), rare arrhythmias',
                pharmacokinetics: 't½ ≈ 4 h, hepatic metabolism (CYP3A4/2D6)',
                clinicalPearls: 'Avoid single IV doses > 16 mg; monitor QT; good alternative to dopamine-blocking antiemetics in Parkinson’s disease',
                indication: 'Chemotherapy, radiotherapy, or post-operative nausea and vomiting; pregnancy sickness (second-line)'
            },
            'pantoprazole': {
                name: 'Pantoprazole',
                class: 'Proton Pump Inhibitor',
                mechanism: 'Irreversibly inhibits gastric H+/K+-ATPase (proton pump)',
                dosing: 'Adult: 40mg daily PO/IV. Severe GORD: 40mg BD. Zollinger-Ellison: up to 240mg daily',
                contraindications: 'Hypersensitivity to PPIs, severe liver disease',
                interactions: 'Clopidogrel (↓ efficacy), digoxin (↑ levels), ketoconazole (↓ absorption)',
                monitoring: 'Magnesium levels (long-term), B12 levels, bone density, C.diff risk',
                pregnancy: 'Generally considered compatible where clinically necessary; consult UKTIS',
                sideEffects: 'Headache, diarrhea, hypomagnesemia, increased fracture risk, C.diff',
                pharmacokinetics: 'Onset 2-3 days for full effect. t½ 1h. Hepatic metabolism (CYP2C19)',
                clinicalPearls: 'IV formulation available. Less drug interactions than omeprazole',
                indication: 'GORD, peptic ulcer disease, H.pylori eradication, stress ulcer prophylaxis'
            },
            'paracetamol': {
                name: 'Paracetamol',
                class: 'Paracetamol',
                mechanism: 'Inhibits COX enzymes centrally, affects prostaglandin synthesis in hypothalamus',
                dosing: 'Adults: 500mg-1g every 4-6 hours (max 4g/24h). Children: 15mg/kg every 4-6 hours (max 60mg/kg/24h)',
                contraindications: 'Severe hepatic impairment, hypersensitivity to paracetamol',
                interactions: 'Warfarin (↑ INR with regular use), carbamazepine (↑ hepatotoxicity risk), chronic alcohol (↑ hepatotoxicity)',
                monitoring: 'Liver function with prolonged use, paracetamol levels in overdose',
                pregnancy: 'Safe - preferred analgesic and antipyretic in pregnancy',
                sideEffects: 'Hepatotoxicity (overdose), very rarely serious skin reactions (SJS/TEN)',
                pharmacokinetics: 'Onset: 30min, Peak: 1h, Half-life: 2h, Metabolism: hepatic conjugation',
                clinicalPearls: 'First-line analgesic in UK. No anti-inflammatory effect. Overdose antidote: N-acetylcysteine. Safe in asthma',
                indication: 'Pain relief, fever reduction. Safe alternative to NSAIDs'
            },
            'phenytoin': {
                name: 'Phenytoin',
                class: 'Antiepileptic drug',
                mechanism: 'Blocks voltage-gated sodium channels, stabilizing neuronal membranes',
                dosing: 'Loading: 15-20mg/kg IV slowly. Maintenance: 300-400mg daily (adjust to levels)',
                contraindications: 'Heart block, sinus bradycardia, porphyria',
                interactions: 'Warfarin (variable), carbamazepine (↓ levels), numerous others',
                monitoring: 'Phenytoin levels (10-20mg/L), LFTs, FBC, folate, gum hyperplasia',
                pregnancy: 'Teratogenic - folate supplementation essential',
                sideEffects: 'Gum hyperplasia, hirsutism, acne, ataxia, nystagmus, confusion',
                pharmacokinetics: 'Zero-order kinetics at therapeutic doses, highly protein-bound',
                clinicalPearls: 'Narrow therapeutic window. Many drug interactions. IV administration requires cardiac monitoring',
                indication: 'Epilepsy, status epilepticus, trigeminal neuralgia'
            },
            'piperacillin-tazobactam': {
                name: 'Piperacillin–tazobactam',
                class: 'Penicillin/β-lactamase inhibitor combination (broad-spectrum)',
                mechanism: 'Piperacillin inhibits cell wall synthesis; tazobactam inhibits many β-lactamases',
                dosing: 'Typical adult IV dosing: 4.5 g every 6–8 h (consider extended/continuous infusion strategies in severe infections per local policy); adjust for renal impairment and indication. Follow local microbiology guidance for dosing in ICU/renal replacement therapy.',
                contraindications: 'Penicillin allergy, previous severe β-lactam hypersensitivity',
                interactions: 'May potentiate anticoagulants (↑ bleeding), methotrexate toxicity, high sodium load to consider in HF',
                monitoring: 'Renal function, electrolytes (sodium load), LFTs for prolonged therapy, clinical response',
                pregnancy: 'Generally acceptable if clinically indicated',
                sideEffects: 'Allergic reactions, diarrhoea, C. difficile infection, electrolyte disturbances (Na+)',
                pharmacokinetics: 'Renal elimination; time-dependent killing; short half-life',
                clinicalPearls: 'Broad-spectrum including Pseudomonas; stewardship important—use per local protocols. Consider extended or continuous infusion for severe/critically ill patients to optimise time > MIC.',
                indication: 'Severe healthcare-associated infections, intra-abdominal sepsis, neutropenic sepsis and other indications per local policy'
            },
            'prednisolone': {
                name: 'Prednisolone',
                class: 'Corticosteroid (glucocorticoid)',
                mechanism: 'Synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects',
                dosing: 'Acute: 30-60mg daily, then taper. Maintenance: 5-15mg daily. Always taper gradually',
                contraindications: 'Systemic infection (unless life-threatening), live vaccines',
                interactions: 'Warfarin (variable effect), NSAIDs (↑ GI bleeding), vaccines (↓ response)',
                monitoring: 'Blood glucose, blood pressure, bone density, growth (children)',
                pregnancy: 'Use if essential - may cause cleft palate (first trimester)',
                sideEffects: 'Weight gain, mood changes, osteoporosis, diabetes, increased infection risk',
                pharmacokinetics: 'Half-life: 12-36h, oral bioavailability: 70%',
                clinicalPearls: 'Never stop abruptly. Take with food. Consider bone protection',
                indication: 'Asthma, COPD exacerbation, inflammatory conditions'
            },
            'pregabalin': {
                name: 'Pregabalin',
                class: 'Gabapentinoids',
                mechanism: 'Binds to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release',
                dosing: 'Neuropathic pain: Start 75 mg twice daily, may increase to 150 mg twice daily after 1 week; typical range 150–300 mg twice daily. Epilepsy: 150–600 mg daily in divided doses. Renal dose adjustment required—use eGFR-based dosing (consult SmPC).',
                contraindications: 'Hypersensitivity to pregabalin',
                interactions: 'Additive CNS depression with opioids, benzodiazepines and alcohol; may increase dizziness/sedation when co-prescribed with other sedating agents',
                monitoring: 'Renal function (baseline and periodically), weight, signs of misuse or dependence, mood/behaviour (suicidal ideation), respiratory drive when used with opioids',
                pregnancy: 'Limited data—use in pregnancy only if clearly needed; discuss with specialist and consult UKTIS for detailed advice',
                sideEffects: 'Dizziness, somnolence, peripheral oedema, weight gain, blurred vision, ataxia, mood changes',
                pharmacokinetics: 'Oral bioavailability >90%, predominantly renally excreted unchanged; half-life ~6 hours',
                clinicalPearls: 'Class C controlled drug in the UK (special prescribing considerations). Warn patients about driving and alcohol. Taper gradually when discontinuing to reduce withdrawal symptoms. Use lowest effective dose in the elderly and those with renal impairment.',
                indication: 'Neuropathic pain (diabetic neuropathy, postherpetic neuralgia), adjunctive therapy for partial seizures, generalized anxiety disorder (licensed in some countries)'
            },
            'prochlorperazine': {
                name: 'Prochlorperazine',
                class: 'Phenothiazine antiemetic/antipsychotic',
                mechanism: 'Dopamine D2 receptor antagonist in the chemoreceptor trigger zone with additional anticholinergic effects',
                dosing: 'Adults: Oral 5–10 mg TDS; IM 12.5 mg single dose for acute nausea; PR 25 mg for severe nausea/vomiting. Avoid prolonged high-dose therapy; use the lowest effective dose and review regularly.',
                contraindications: 'Severe CNS depression, bone marrow suppression, known hypersensitivity, coma, Parkinson\'s disease (relative contraindication)',
                interactions: 'Additive CNS depression with opioids, benzodiazepines, anticholinergics; increased risk of extrapyramidal effects with other dopamine antagonists and lithium',
                monitoring: 'Watch for extrapyramidal symptoms (acute dystonia, parkinsonism, akathisia) and tardive dyskinesia with long-term use. Monitor ECG if other QT-prolonging drugs are co-prescribed and in at-risk patients.',
                pregnancy: 'Use only if benefit outweighs risk. Newborn extrapyramidal or withdrawal symptoms may occur after third-trimester exposure; consult UKTIS for detailed advice',
                sideEffects: 'Extrapyramidal reactions, sedation, anticholinergic effects, hypotension, tardive dyskinesia (long-term)',
                pharmacokinetics: 'Well absorbed orally; extensive hepatic metabolism, elimination in urine and bile',
                clinicalPearls: 'Avoid in elderly patients with dementia due to increased mortality and stroke risk. Acute dystonic reactions respond to anticholinergics (e.g. procyclidine). Reserve for severe nausea when other agents are unsuitable; consider alternatives in young children and in Parkinson\'s disease.',
                indication: 'Severe nausea and vomiting, vertigo-associated nausea, migraine-related nausea (short courses)'
            },
            'propofol': {
                name: 'Propofol',
                class: 'General Anaesthetic (Phenolic compound)',
                mechanism: 'GABA-A receptor agonist causing rapid onset anaesthesia',
                dosing: 'Induction: 1.5-2.5mg/kg IV. Maintenance: 4-12mg/kg/h IV. ICU sedation: 0.3-4mg/kg/h',
                contraindications: 'Egg/soy allergy, children <16 years (prolonged use), severe cardiac failure',
                interactions: 'CNS depressants (↑ effect), NO drug interactions metabolically',
                monitoring: 'Blood pressure, respiratory rate, depth of anaesthesia, lipid levels (prolonged use)',
                pregnancy: 'Use in pregnancy only if essential and after considering maternal and fetal risks; consult obstetric/anesthetic guidance',
                sideEffects: 'Hypotension, respiratory depression, injection pain, propofol infusion syndrome',
                pharmacokinetics: 'Rapid onset 40s, offset 5-10min. t½ 1-3h. Hepatic and extrahepatic metabolism',
                clinicalPearls: 'Painful injection - use lidocaine. Quick recovery. Risk of PRIS with prolonged use',
                indication: 'General anaesthesia induction/maintenance, ICU sedation, procedural sedation'
            },
            'quinine': {
                name: 'Quinine',
                class: 'Quinine',
                mechanism: 'Interferes with parasitic DNA replication, affects calcium distribution in muscle',
                dosing: 'Malaria: 600mg TDS for 7 days. Cramps: 200-300mg at bedtime (unlicensed)',
                contraindications: 'Optic neuritis, tinnitus, myasthenia gravis, G6PD deficiency',
                interactions: 'Warfarin (↑ INR), digoxin (↑ levels), mefloquine (↑ seizure risk)',
                monitoring: 'Hearing, vision, blood glucose, cardiac rhythm, signs of cinchonism',
                pregnancy: 'Use with caution - may cause thrombocytopenia in neonate',
                sideEffects: 'Cinchonism (tinnitus, headache, nausea), hypoglycaemia, arrhythmias',
                pharmacokinetics: 'Half-life: 18h in malaria (shorter in healthy), hepatic metabolism',
                clinicalPearls: 'Unlicensed use for nocturnal cramps. Monitor for cinchonism. Resistance common',
                indication: 'Complicated malaria, nocturnal leg cramps (second-line)'
            },
            'ramipril': {
                name: 'Ramipril',
                class: 'Angiotensin-converting enzyme (ACE) inhibitors',
                mechanism: 'Inhibits ACE, preventing conversion of angiotensin I to II, reducing aldosterone secretion',
                dosing: 'Hypertension: Start 1.25-2.5mg daily, usual 2.5-5mg daily, max 10mg daily. Heart failure: Start 1.25mg daily, target 10mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, angioedema history, hyperkalaemia >5.5mmol/L',
                interactions: 'NSAIDs (↓ antihypertensive effect, ↑ nephrotoxicity), potassium supplements (hyperkalaemia), lithium (↑ levels)',
                monitoring: 'eGFR and potassium baseline, 1-2 weeks after starting/dose change, then annually',
                pregnancy: 'Contraindicated - teratogenic (oligohydramnios, IUGR, renal dysgenesis)',
                sideEffects: 'Dry cough (10-15%), hyperkalaemia, acute kidney injury, angioedema (rare), hypotension',
                pharmacokinetics: 'Prodrug activated hepatically, Half-life: 13-17h, Excretion: renal and biliary',
                clinicalPearls: 'Most commonly prescribed ACE inhibitor in UK. Renoprotective in diabetes. Stop immediately if pregnant',
                indication: 'Hypertension, heart failure, post-MI, diabetic nephropathy, primary prevention in high CV risk'
            },
            'ranitidine': {
                name: 'Ranitidine',
                class: 'H2-receptor antagonist',
                mechanism: 'Competitive antagonist of histamine H2-receptors in gastric parietal cells',
                dosing: 'GORD: 150mg BD or 300mg at night. Peptic ulcer: 300mg at night. Acute: 50mg IV TDS',
                contraindications: 'Hypersensitivity, porphyria',
                interactions: 'Warfarin (may ↑ INR), ketoconazole (↓ absorption), atazanavir',
                monitoring: 'Symptom relief, signs of gastric malignancy (prolonged use)',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'Generally well tolerated, headache, dizziness, GI upset, confusion (elderly)',
                pharmacokinetics: 'Well absorbed, half-life: 2-3h, renal and hepatic elimination',
                clinicalPearls: 'Less effective than PPIs. Withdrawn in many countries due to NDMA contamination concerns',
                indication: 'GORD, peptic ulcer disease, stress ulcer prophylaxis'
            },
            'rivaroxaban': {
                name: 'Rivaroxaban',
                class: 'Direct oral anticoagulant (Factor Xa inhibitor)',
                mechanism: 'Direct, selective inhibition of factor Xa, interrupting thrombin generation and clot formation',
                dosing: 'AF (stroke prevention): 20 mg once daily with food (15 mg OD if eGFR 15–49 mL/min). VTE treatment: 15 mg BD for 21 days, then 20 mg OD with food. VTE prophylaxis post-orthopaedics: 10 mg OD.',
                contraindications: 'Active bleeding, hepatic disease with coagulopathy, pregnancy/breastfeeding, mechanical heart valves',
                interactions: 'Strong CYP3A4/P-gp inhibitors (e.g., azoles, HIV protease inhibitors ↑ levels), inducers (e.g., rifampicin ↓ effect)',
                monitoring: 'Renal & hepatic function at baseline and periodically; clinical signs of bleeding; no routine coagulation testing',
                pregnancy: 'Contraindicated',
                sideEffects: 'Bleeding, anaemia, GI upset, transaminitis',
                pharmacokinetics: 'Peak 2–4 h; t½ 5–13 h; dual hepatic/renal elimination',
                clinicalPearls: 'Take doses ≥15 mg with food. Hold ≥24 h pre-low bleed-risk procedures (longer if renal impairment). Reversal: andexanet alfa (where available) or PCC for life-threatening bleed.',
                indication: 'Non-valvular AF stroke prevention; treatment and secondary prevention of DVT/PE; VTE prophylaxis after hip/knee replacement'
            },
            'salbutamol': {
                name: 'Salbutamol',
                class: 'Short-acting β2-agonist (SABA)',
                mechanism: 'Selective β2-adrenoreceptor agonist causing bronchodilation',
                dosing: 'Inhaler: 100-200mcg PRN, max 800mcg daily. Nebuliser: 2.5-5mg QDS',
                contraindications: 'Hypersensitivity. Caution in cardiovascular disease',
                interactions: 'β-blockers (antagonistic), digoxin (hypokalaemia), diuretics',
                monitoring: 'Peak flow, symptoms, heart rate, potassium (high doses)',
                pregnancy: 'Safe - drug of choice in pregnancy',
                sideEffects: 'Tremor, palpitations, headache, hypokalaemia (high doses)',
                pharmacokinetics: 'Inhaled onset: 5min, Duration: 3-5h',
                clinicalPearls: 'Blue inhaler. If using >3x/week, need preventer. Use spacer',
                indication: 'Asthma, COPD, hyperkalaemia (nebulised)'
            },
            'salmeterol': {
                name: 'Salmeterol',
                class: 'Long-acting β2-agonist (LABA)',
                mechanism: 'Selective β2-adrenoreceptor agonist with 12-hour duration of action',
                dosing: 'Adults: 25-50mcg BD via inhaler. Always used with inhaled corticosteroid',
                contraindications: 'Hypersensitivity. Never use as monotherapy in asthma',
                interactions: 'β-blockers (antagonism), diuretics (hypokalaemia), theophylline',
                monitoring: 'Peak flow, asthma control, signs of paradoxical bronchospasm',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'Tremor, palpitations, headache, paradoxical bronchospasm',
                pharmacokinetics: 'Onset: 10-20min, Peak: 3-4h, Duration: 12h',
                clinicalPearls: 'Always combined with ICS. Not for acute relief. Green accuhaler common in UK',
                indication: 'Asthma (step 3+ therapy with ICS), COPD (combination inhalers)'
            },
            'senna': {
                name: 'Senna',
                class: 'Stimulant laxative',
                mechanism: 'Anthraquinone glycosides stimulate colonic peristalsis and inhibit water/electrolyte absorption',
                dosing: 'Adults: 7.5-15mg at bedtime (sennosides). Children >6 years: 3.75-7.5mg at bedtime',
                contraindications: 'Intestinal obstruction, inflammatory bowel disease, severe dehydration, appendicitis',
                interactions: 'Cardiac glycosides (hypokalaemia ↑ toxicity), thiazide diuretics',
                monitoring: 'Bowel movements, electrolyte balance with prolonged use, dependency',
                pregnancy: 'Generally considered compatible in pregnancy; consult UKTIS if exposure occurs',
                sideEffects: 'Abdominal cramps, hypokalaemia, melanosis coli (prolonged use), dependency',
                pharmacokinetics: 'Prodrug activated by colonic bacteria, onset 8-12h',
                clinicalPearls: 'Most widely used stimulant laxative in UK. Avoid prolonged use >1 week',
                indication: 'Constipation, bowel preparation, opioid-induced constipation'
            },
            'sertraline': {
                name: 'Sertraline',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Potent and selective inhibition of serotonin reuptake',
                dosing: 'Adults: Start 50mg daily, can increase by 50mg increments weekly, max 200mg daily. Take with food',
                contraindications: 'MAOIs, unstable epilepsy, mania',
                interactions: 'MAOIs, warfarin (↑ bleeding risk), NSAIDs, tramadol',
                monitoring: 'Mood, suicide risk (especially <25 years), bleeding if on anticoagulants',
                pregnancy: 'Preferred SSRI in pregnancy - lowest risk profile',
                sideEffects: 'Nausea, diarrhoea, insomnia, sexual dysfunction, tremor, dry mouth',
                pharmacokinetics: 'Half-life: 26h, extensive first-pass metabolism',
                clinicalPearls: 'NICE first-line SSRI choice. Take with food to ↓ GI upset. Lower drug interaction potential',
                indication: 'Depression, panic disorder, OCD, PTSD, social anxiety disorder'
            },
            'sildenafil': {
                name: 'Sildenafil',
                class: 'Phosphodiesterase type 5 inhibitor',
                mechanism: 'Inhibits PDE5, increasing cGMP levels and causing smooth muscle relaxation',
                dosing: 'Erectile dysfunction: 50mg 1h before sexual activity. Pulmonary hypertension: 20mg TDS',
                contraindications: 'Nitrates, recent MI/stroke, severe hypotension, hereditary retinal disorders',
                interactions: 'Nitrates (severe hypotension), alpha-blockers (hypotension), CYP3A4 inhibitors',
                monitoring: 'Blood pressure, vision changes, priapism, cardiovascular status',
                pregnancy: 'Not applicable for ED indication. Limited data for pulmonary hypertension',
                sideEffects: 'Headache, flushing, dyspepsia, visual disturbances, priapism (rare)',
                pharmacokinetics: 'Rapid absorption, peak: 1h, half-life: 4h, hepatic metabolism',
                clinicalPearls: 'Never with nitrates. High-fat meals delay absorption. Seek help if erection >4h',
                indication: 'Erectile dysfunction, pulmonary arterial hypertension'
            },
            'simvastatin': {
                name: 'Simvastatin',
                class: 'Statins',
                mechanism: 'Competitively inhibits HMG-CoA reductase, rate-limiting enzyme in cholesterol synthesis',
                dosing: 'Start 20mg at night, max 80mg daily. Usual maintenance: 20-40mg daily',
                contraindications: 'Active liver disease, pregnancy, breastfeeding',
                interactions: 'Amlodipine (max simvastatin 20mg), clarithromycin (rhabdomyolysis risk), grapefruit juice',
                monitoring: 'LFTs at baseline and 3 months, CK if muscle symptoms, lipid profile',
                pregnancy: 'Contraindicated - cholesterol essential for fetal development',
                sideEffects: 'Myalgia, rhabdomyolysis (rare), hepatotoxicity, diabetes risk',
                pharmacokinetics: 'Extensive first-pass metabolism, active metabolites, CYP3A4 substrate',
                clinicalPearls: 'Take at night (cholesterol synthesis peaks). Many drug interactions. Generic statin',
                indication: 'Hypercholesterolaemia, cardiovascular disease prevention'
            },
            'spironolactone': {
                name: 'Spironolactone',
                class: 'Aldosterone antagonists',
                mechanism: 'Competitive antagonist of aldosterone at mineralocorticoid receptors',
                dosing: 'Heart failure: Start 25mg daily, max 50mg daily. Ascites: 100-400mg daily. Monitor K+ closely',
                contraindications: 'Hyperkalaemia (>5.0mmol/L), severe renal impairment, Addison\'s disease',
                interactions: 'ACE inhibitors/ARBs (↑ hyperkalaemia), potassium supplements, trimethoprim',
                monitoring: 'U&Es within 1 week, then monthly for 3 months, then 3-monthly. Gynaecomastia',
                pregnancy: 'Avoid - feminisation of male fetus',
                sideEffects: 'Hyperkalaemia, gynaecomastia, menstrual irregularities, GI upset',
                pharmacokinetics: 'Half-life: 1-2 days (active metabolites), onset of action: 2-3 days',
                clinicalPearls: 'K+-sparing effect. Check K+ before starting and monitor closely. Mortality benefit in heart failure',
                indication: 'Heart failure (with ACE-I + β-blocker), primary hyperaldosteronism, ascites'
            },
            'sumatriptan': {
                name: 'Sumatriptan',
                class: 'Serotonin 5-HT1-receptor agonists (triptans)',
                mechanism: 'Selective 5-HT1B/1D receptor agonist causing vasoconstriction and neuronal inhibition',
                dosing: 'Subcutaneous: 6mg, may repeat after 1h. Oral: 50-100mg, may repeat after 2h. Max 300mg/24h',
                contraindications: 'Ischaemic heart disease, cerebrovascular disease, uncontrolled hypertension',
                interactions: 'MAOIs (avoid), SSRIs (serotonin syndrome risk), ergot alkaloids',
                monitoring: 'Cardiovascular status, blood pressure, frequency of use (medication overuse headache)',
                pregnancy: 'Avoid - limited safety data',
                sideEffects: 'Injection site reactions, chest tightness, dizziness, fatigue, medication overuse headache',
                pharmacokinetics: 'Rapid onset SC: 10-15min, Oral: 30min, half-life: 2h',
                clinicalPearls: 'Most effective when taken early in attack. Limit to 2 days/week to avoid medication overuse',
                indication: 'Acute migraine treatment, cluster headache (subcutaneous)'
            },
            'theophylline': {
                name: 'Theophylline',
                class: 'Methylxanthine bronchodilator',
                mechanism: 'Phosphodiesterase inhibition and adenosine receptor antagonism',
                dosing: 'MR preparation: 200-300mg BD. Adjust to therapeutic levels (10-20mg/L)',
                contraindications: 'Hypersensitivity, porphyria. Caution in cardiovascular disease',
                interactions: 'Ciprofloxacin (↑ levels), carbamazepine (↓ levels), smoking (↓ levels)',
                monitoring: 'Theophylline levels, signs of toxicity, heart rate, seizures',
                pregnancy: 'Use with caution - crosses placenta but appears safe',
                sideEffects: 'Nausea, headache, insomnia, arrhythmias, seizures (toxicity)',
                pharmacokinetics: 'Narrow therapeutic window, hepatic metabolism, wide individual variation',
                clinicalPearls: 'Narrow therapeutic window. Many factors affect levels (smoking, infections, drugs)',
                indication: 'Asthma/COPD (when other treatments inadequate), acute severe asthma'
            },
            'tramadol': {
                name: 'Tramadol',
                class: 'Opioids',
                mechanism: 'Weak mu-opioid agonist + inhibits serotonin/noradrenaline reuptake',
                dosing: 'Immediate release: 50-100mg QDS PRN (max 400mg daily). MR: 100-400mg daily',
                contraindications: 'Epilepsy, head injury, concurrent MAOIs, severe respiratory depression',
                interactions: 'MAOIs (serotonin syndrome), SSRIs (↑ seizure risk), carbamazepine (↓ efficacy)',
                monitoring: 'Seizure risk, respiratory depression, signs of dependence',
                pregnancy: 'Avoid - risk of neonatal withdrawal syndrome',
                sideEffects: 'Nausea, dizziness, seizures, constipation, serotonin syndrome, dependence',
                pharmacokinetics: 'Active metabolite via CYP2D6, half-life: 5-7h',
                clinicalPearls: 'Lower respiratory depression than other opioids. Seizure risk especially with SSRIs',
                indication: 'Moderate pain when paracetamol/NSAIDs insufficient'
            },
            'tranexamic-acid': {
                name: 'Tranexamic Acid',
                class: 'Antifibrinolytic',
                mechanism: 'Lysine analog that inhibits plasminogen activation and plasmin activity',
                dosing: 'Major bleeding: 1g IV over 10min, then 1g over 8h. Trauma: 1g IV then 1g over 8h within 3h',
                contraindications: 'Active thromboembolic disease, history of seizures, subarachnoid hemorrhage',
                interactions: 'Hormonal contraceptives (↑ thrombosis risk), factor IX complex concentrates',
                monitoring: 'Signs of thrombosis, renal function, visual disturbances',
                pregnancy: 'Generally considered compatible and widely used in postpartum haemorrhage; follow local guidance',
                sideEffects: 'Nausea, diarrhea, thrombosis (rare), seizures (high dose), visual disturbances',
                pharmacokinetics: 'Peak 3h PO, 1h IV. 90% excreted unchanged in urine. t½ 2-3h',
                clinicalPearls: 'Most effective within 3h of trauma. Reduces mortality in major bleeding',
                indication: 'Major bleeding, trauma, menorrhagia, hereditary angioedema'
            },
            'trimethoprim': {
                name: 'Trimethoprim',
                class: 'Folate synthesis inhibitor antibiotic',
                mechanism: 'Inhibits bacterial dihydrofolate reductase, preventing folate synthesis',
                dosing: 'UTI: 200mg BD for 3 days (uncomplicated) or 7 days (men/complicated). Prophylaxis: 100mg at night',
                contraindications: 'Folate deficiency, severe renal impairment, blood dyscrasias',
                interactions: 'Warfarin (↑ INR), methotrexate (↑ toxicity), ACE inhibitors (hyperkalaemia)',
                monitoring: 'FBC if prolonged use, U&Es (can cause hyperkalaemia), signs of folate deficiency',
                pregnancy: 'Avoid in first trimester (folate antagonist). Folate supplementation if essential',
                sideEffects: 'GI upset, skin rashes, hyperkalaemia, blood dyscrasias (rare)',
                pharmacokinetics: 'Well absorbed, Half-life: 10h, mainly renal excretion',
                clinicalPearls: 'First-line for uncomplicated UTI in women. Can cause hyperkalaemia especially with ACE-I',
                indication: 'UTI treatment and prophylaxis, pneumocystis pneumonia prophylaxis'
            },
            'vancomycin': {
                name: 'Vancomycin',
                class: 'Glycopeptide antibiotic',
                mechanism: 'Inhibits cell-wall synthesis by binding D-Ala-D-Ala termini of peptidoglycan precursors',
                dosing: 'IV: 15–20 mg/kg every 8–12 h (use local protocol for loading/maintenance based on weight/renal function). Oral: 125 mg QDS for C. difficile (dose varies with severity).',
                contraindications: 'Hypersensitivity',
                interactions: 'Other nephrotoxins (aminoglycosides, amphotericin), loop diuretics (↑ ototoxicity risk)',
                monitoring: 'Renal function; therapeutic levels per local protocol (AUC-guided or troughs); infusion reactions',
                pregnancy: 'Generally acceptable if indicated (IV); oral not systemically absorbed',
                sideEffects: 'Nephrotoxicity, ototoxicity (rare), “red man” syndrome with rapid infusion',
                pharmacokinetics: 'IV distributes widely; renal elimination; negligible oral absorption for systemic effect',
                clinicalPearls: 'Infuse over ≥60 min to minimise infusion reactions. Adjust dose to renal function and target levels.',
                indication: 'Serious Gram-positive infections (incl. MRSA); oral therapy for C. difficile infection'
            },
            'warfarin': {
                name: 'Warfarin',
                class: 'Vitamin K antagonist (oral anticoagulant)',
                mechanism: 'Inhibits vitamin K epoxide reductase (VKORC1), reducing synthesis of clotting factors II, VII, IX and X and proteins C and S',
                dosing: 'Highly individualised using INR-guided dosing; typical initiation regimens vary (e.g., 1–5 mg OD titrated against INR). Usual maintenance targets: INR 2.0–3.0 for AF/VTE (target 2.5); higher targets (e.g., 2.5–3.5) for some mechanical valves — follow local guidance.',
                contraindications: 'Pregnancy (teratogenic, especially early gestation and near term), active bleeding, severe hepatic impairment, inability to adhere to monitoring',
                interactions: 'Very many: antibiotics (macrolides, metronidazole), azoles, amiodarone (↑ INR); enzyme inducers (carbamazepine, rifampicin) ↓ INR; dietary vitamin K (green leafy veg) affects control. Check interactions prior to changes.',
                monitoring: 'INR frequently until stable (often several times weekly initially), then spacing to every 4–12 weeks depending on stability; check LFTs, full medication review and adherence. Monitor for bleeding signs.',
                pregnancy: 'Generally avoid; if anticoagulation essential in pregnancy use LMWH under specialist care. Warfarin contraindicated around delivery.',
                sideEffects: 'Bleeding (minor to major), skin necrosis (rare), purple toe syndrome (rare)',
                pharmacokinetics: 'Delayed onset/offset due to existing clotting factor half-lives (effect usually seen 48–72 h); hepatic metabolism (CYP2C9 and others)',
                clinicalPearls: 'Stop ~5 days before elective procedures; consider bridging with LMWH only for high thrombotic risk patients. Reversal: oral/IV vitamin K for elevated INR without major bleeding; prothrombin complex concentrate (PCC) ± IV vitamin K for major bleeding or urgent reversal. Liaise with haematology/anticoagulation service for complex cases.',
                indication: 'Stroke prevention in AF (where DOACs unsuitable), VTE treatment and secondary prevention, mechanical prosthetic valves (depending on type)',
            },
            'zopiclone': {
                name: 'Zopiclone',
                class: 'Z-drug (non-benzodiazepine hypnotic)',
                mechanism: 'Selective GABA-A receptor modulator at benzodiazepine binding site',
                dosing: 'Adults: 7.5mg at bedtime. Elderly: 3.75mg. Max 4 weeks treatment',
                contraindications: 'Severe respiratory insufficiency, myasthenia gravis, severe hepatic impairment',
                interactions: 'Alcohol (↑ sedation), opioids (respiratory depression), CYP3A4 inhibitors',
                monitoring: 'Sleep quality, daytime drowsiness, signs of dependence, memory problems',
                pregnancy: 'Avoid - risk of withdrawal symptoms in neonate',
                sideEffects: 'Metallic taste, daytime drowsiness, dependence, rebound insomnia, amnesia',
                pharmacokinetics: 'Rapid absorption, half-life: 5h, hepatic metabolism',
                clinicalPearls: 'Shorter course than benzodiazepines but still dependence risk. Distinctive metallic taste',
                indication: 'Short-term insomnia (max 4 weeks). Second-line to sleep hygiene measures'
            },
            'sitagliptin': {
                name: 'Sitagliptin',
                class: 'Dipeptidylpeptidase-4 inhibitors',
                mechanism: 'Inhibits DPP-4 enzyme, increasing incretin hormone levels (GLP-1 and GIP)',
                dosing: 'Type 2 diabetes: 100mg daily. Renal impairment: 50mg daily (eGFR 30-50), 25mg daily (eGFR <30)',
                contraindications: 'Type 1 diabetes, diabetic ketoacidosis, hypersensitivity',
                interactions: 'Minimal drug interactions. Digoxin (↑ levels slightly)',
                monitoring: 'HbA1c, renal function, signs of pancreatitis, hypoglycaemia (with other drugs)',
                pregnancy: 'Avoid - limited safety data, insulin preferred',
                sideEffects: 'Headache, URTI, pancreatitis (rare), hypoglycaemia (with insulin/sulfonylureas)',
                pharmacokinetics: 'Good oral absorption, half-life: 12h, mainly renal excretion',
                clinicalPearls: 'Weight neutral. Low hypoglycaemia risk as monotherapy. Good add-on to metformin',
                indication: 'Type 2 diabetes as monotherapy or combination therapy'
            },
            'venlafaxine': {
                name: 'Venlafaxine',
                class: 'Antidepressants, tetracyclic and serotonin-noradrenaline reuptake inhibitors',
                mechanism: 'Inhibits reuptake of serotonin and noradrenaline (SNRI)',
                dosing: 'Depression: Start 75mg daily, usual 150mg daily, max 375mg daily. XL formulation preferred',
                contraindications: 'MAOIs, uncontrolled hypertension, severe hepatic/renal impairment',
                interactions: 'MAOIs (serotonin syndrome), warfarin (↑ bleeding), tramadol (↑ seizure risk)',
                monitoring: 'Blood pressure (dose-related ↑), mood, suicide risk, withdrawal symptoms',
                pregnancy: 'Use if benefit outweighs risk - neonatal complications possible',
                sideEffects: 'Nausea, headache, hypertension (dose-related), withdrawal syndrome, sexual dysfunction',
                pharmacokinetics: 'Half-life: 5h (active metabolite 11h), hepatic metabolism',
                clinicalPearls: 'Monitor BP regularly. Severe withdrawal syndrome - taper slowly. Effective for anxiety',
                indication: 'Depression, generalized anxiety disorder, social anxiety disorder, panic disorder'
            },
            'quetiapine': {
                name: 'Quetiapine',
                class: 'Antipsychotics, second-generation (atypical)',
                mechanism: 'Dopamine D2 and serotonin 5-HT2A receptor antagonist',
                dosing: 'Schizophrenia: Start 25mg BD, increase to 300-450mg daily. Bipolar: 300-800mg daily',
                contraindications: 'Comatose states, severe CNS depression',
                interactions: 'Alcohol (↑ sedation), CYP3A4 inhibitors (↑ levels), phenytoin (↓ levels)',
                monitoring: 'Blood glucose, lipids, weight, prolactin, ECG, movement disorders',
                pregnancy: 'Use only if essential - extrapyramidal symptoms in neonate possible',
                sideEffects: 'Sedation, weight gain, diabetes, postural hypotension, dry mouth, constipation',
                pharmacokinetics: 'Half-life: 6h (XR: 7h), extensive hepatic metabolism',
                clinicalPearls: 'Lower EPS risk than typical antipsychotics. Significant metabolic effects. Take with food',
                indication: 'Schizophrenia, bipolar disorder, adjunctive treatment in depression'
            },
            'glucagon': {
                name: 'Glucagon',
                class: 'Emergency drugs',
                mechanism: 'Hormone that stimulates hepatic glucose production and glycogenolysis',
                dosing: 'Severe hypoglycaemia: 1mg IM/SC/IV. Children <25kg: 0.5mg. May repeat after 10min',
                contraindications: 'Phaeochromocytoma (may cause hypertensive crisis)',
                interactions: 'Warfarin (may ↑ anticoagulant effect)',
                monitoring: 'Blood glucose, consciousness level, blood pressure',
                pregnancy: 'Safe when clinically indicated',
                sideEffects: 'Nausea, vomiting, hypokalaemia, hypotension, allergic reactions',
                pharmacokinetics: 'Onset: 8-10min IM, Duration: 1-2h, hepatic metabolism',
                clinicalPearls: 'Give glucose orally when conscious. Ineffective if glycogen stores depleted. Train family/carers',
                indication: 'Severe hypoglycaemia when IV glucose not possible, diagnostic use'
            },
            'diltiazem': {
                name: 'Diltiazem',
                class: 'Calcium channel blockers',
                mechanism: 'Non-dihydropyridine CCB - blocks L-type calcium channels in heart and vessels',
                dosing: 'Hypertension: 60mg BD or 120mg XL daily. Angina: 60mg TDS or 120-300mg XL daily',
                contraindications: 'Heart block, sick sinus syndrome, severe bradycardia, severe heart failure',
                interactions: 'Beta-blockers (↑ bradycardia), digoxin (↑ levels), simvastatin (↑ levels)',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, liver function',
                pregnancy: 'Avoid unless essential - limited safety data',
                sideEffects: 'Bradycardia, heart block, ankle oedema, constipation, gingival hyperplasia',
                pharmacokinetics: 'Half-life: 3-4h (XL: 6-8h), extensive hepatic metabolism',
                clinicalPearls: 'Rate-limiting CCB. Good for AF rate control. Avoid with beta-blockers',
                indication: 'Hypertension, angina, atrial fibrillation (rate control)'
            },
            'glimepiride': {
                name: 'Glimepiride',
                class: 'Sulfonylureas',
                mechanism: 'Stimulates insulin release from pancreatic β-cells by blocking K-ATP channels',
                dosing: 'Start 1mg daily with breakfast, usual 1-4mg daily, max 6mg daily',
                contraindications: 'Type 1 diabetes, ketoacidosis, severe renal/hepatic impairment',
                interactions: 'Alcohol (↑ hypoglycaemia), β-blockers (mask hypoglycaemia), steroids (↑ glucose)',
                monitoring: 'Blood glucose, HbA1c, weight, signs of hypoglycaemia',
                pregnancy: 'Switch to insulin - crosses placenta',
                sideEffects: 'Hypoglycaemia, weight gain, GI upset, skin reactions, hyponatraemia',
                pharmacokinetics: 'Half-life: 5-8h, hepatic metabolism, renal excretion',
                clinicalPearls: 'Longer acting than gliclazide. Take with breakfast. Lower hypoglycaemia risk than glibenclamide',
                indication: 'Type 2 diabetes (when metformin contraindicated/not tolerated or as add-on)'
            },
            'pioglitazone': {
                name: 'Pioglitazone',
                class: 'Thiazolidinediones',
                mechanism: 'PPAR-γ agonist, improves insulin sensitivity in muscle and adipose tissue',
                dosing: 'Start 15-30mg daily, max 45mg daily. Take with or without food',
                contraindications: 'Heart failure, bladder cancer history, severe hepatic impairment',
                interactions: 'Insulin (↑ hypoglycaemia, fluid retention), gemfibrozil (↑ levels)',
                monitoring: 'Weight, signs of heart failure, liver function, bone density, bladder symptoms',
                pregnancy: 'Avoid - limited safety data, insulin preferred',
                sideEffects: 'Weight gain, fluid retention, heart failure, bone fractures, bladder cancer risk',
                pharmacokinetics: 'Half-life: 3-7h (active metabolites 16-24h), hepatic metabolism',
                clinicalPearls: 'May take 2-3 months for full effect. Monitor for heart failure. Avoid in osteoporosis',
                indication: 'Type 2 diabetes as monotherapy or combination therapy'
            },
            'escitalopram': {
                name: 'Escitalopram',
                class: 'Antidepressants, selective serotonin reuptake inhibitors',
                mechanism: 'Selective inhibition of serotonin reuptake with high selectivity',
                dosing: 'Adults: Start 10mg daily, usual dose 10-20mg daily. Elderly: max 10mg daily',
                contraindications: 'MAOIs, QT prolongation, recent MI',
                interactions: 'MAOIs (serotonin syndrome), drugs prolonging QT interval, warfarin',
                monitoring: 'ECG if cardiac risk factors, mood, suicide risk, sexual function',
                pregnancy: 'Use if benefit outweighs risk - potential neonatal complications',
                sideEffects: 'Nausea, headache, sexual dysfunction, insomnia, QT prolongation',
                pharmacokinetics: 'Half-life: 27-32h, hepatic metabolism via CYP2C19',
                clinicalPearls: 'S-enantiomer of citalopram. Often better tolerated than citalopram. Take any time of day',
                indication: 'Depression, generalized anxiety disorder, panic disorder, social anxiety'
            },
            'tiotropium': {
                name: 'Tiotropium',
                class: 'Antimuscarinics, bronchodilators',
                mechanism: 'Long-acting muscarinic antagonist (LAMA) - blocks M3 receptors in airways',
                dosing: 'COPD: 18mcg daily via HandiHaler or 5mcg daily via Respimat. Take same time each day',
                contraindications: 'Hypersensitivity to atropine derivatives',
                interactions: 'Other anticholinergics (↑ anticholinergic effects)',
                monitoring: 'Lung function, symptoms, anticholinergic side effects, narrow-angle glaucoma',
                pregnancy: 'Use only if benefit outweighs risk - limited safety data',
                sideEffects: 'Dry mouth, constipation, urinary retention, narrow-angle glaucoma, paradoxical bronchospasm',
                pharmacokinetics: 'Long duration of action (24h), minimal systemic absorption',
                clinicalPearls: 'Once daily LAMA for COPD. Different devices deliver different doses. Avoid contact with eyes',
                indication: 'COPD maintenance therapy, add-on to bronchodilators'
            },
            'mesalazine': {
                name: 'Mesalazine',
                class: 'Aminosalicylates',
                mechanism: 'Anti-inflammatory action in gut mucosa, exact mechanism unknown',
                dosing: 'Ulcerative colitis: 1.2-2.4g daily in divided doses. Maintenance: 1.2-1.6g daily',
                contraindications: 'Severe renal impairment, salicylate hypersensitivity',
                interactions: 'Lactulose (↓ release), azathioprine (theoretical ↑ leucopenia)',
                monitoring: 'FBC, U&Es, LFTs before and during treatment. Annual monitoring',
                pregnancy: 'Safe - continue treatment. Folic acid supplementation recommended',
                sideEffects: 'Headache, nausea, rash, blood dyscrasias, nephrotoxicity (rare)',
                pharmacokinetics: 'Topical action in gut, minimal systemic absorption',
                clinicalPearls: 'Take with food. Multiple formulations with different release characteristics',
                indication: 'Ulcerative colitis treatment and maintenance, Crohn\'s disease (limited efficacy)'
            },
            'loperamide': {
                name: 'Loperamide',
                class: 'Antidiarrhoeal drugs',
                mechanism: 'Mu-opioid receptor agonist in GI tract, slows intestinal motility',
                dosing: 'Adults: 4mg initially, then 2mg after each loose stool (max 16mg daily). Children >4 years: weight-based',
                contraindications: 'Acute dysentery, acute ulcerative colitis, bacterial enterocolitis, children <4 years',
                interactions: 'P-glycoprotein inhibitors (↑ CNS effects), quinidine, ritonavir',
                monitoring: 'Stool frequency, abdominal pain, signs of toxic megacolon',
                pregnancy: 'Safe - limited systemic absorption, no increased malformation risk',
                sideEffects: 'Constipation, abdominal cramps, drowsiness, dry mouth, nausea',
                pharmacokinetics: 'Poor oral absorption, minimal CNS penetration, Half-life: 10-14h',
                clinicalPearls: 'Available OTC (max 2 days). Does not cross blood-brain barrier at therapeutic doses',
                indication: 'Acute diarrhoea, chronic diarrhoea, IBS with diarrhoea'
            },
            'topiramate': {
                name: 'Topiramate',
                class: 'Antiepileptic drugs',
                mechanism: 'Multiple mechanisms: blocks sodium channels, enhances GABA, blocks glutamate receptors',
                dosing: 'Epilepsy: Start 25mg BD, increase weekly to 200-400mg daily. Migraine: 25mg daily, increase to 100mg daily',
                contraindications: 'Hypersensitivity, acute narrow-angle glaucoma',
                interactions: 'Carbamazepine (↓ topiramate), oral contraceptives (↓ efficacy), lithium (↑ levels)',
                monitoring: 'Weight, kidney stones, mood changes, cognitive function, visual disturbances',
                pregnancy: 'Avoid - teratogenic risk including cleft palate. Effective contraception essential',
                sideEffects: 'Weight loss, cognitive impairment, kidney stones, acute glaucoma, metabolic acidosis',
                pharmacokinetics: 'Half-life: 20-30h, 80% renal excretion unchanged',
                clinicalPearls: 'Weight loss common (beneficial in some). Cognitive effects dose-related. Slow titration essential',
                indication: 'Epilepsy, migraine prophylaxis, bipolar disorder (unlicensed)'
            },
            'candesartan': {
                name: 'Candesartan',
                class: 'Angiotensin receptor blockers',
                mechanism: 'Selective antagonist of angiotensin II at AT1 receptors',
                dosing: 'Hypertension: Start 8mg daily, usual 8-16mg daily, max 32mg daily. Heart failure: Start 4mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, severe renal/hepatic impairment',
                interactions: 'NSAIDs (↓ efficacy), potassium supplements (hyperkalemia), lithium (↑ levels)',
                monitoring: 'eGFR, potassium, blood pressure. Check 1-2 weeks after starting',
                pregnancy: 'Contraindicated - teratogenic in 2nd/3rd trimester',
                sideEffects: 'Dizziness, hyperkalemia, acute kidney injury, angioedema (rare)',
                pharmacokinetics: 'Prodrug, active metabolite half-life: 9h, renal and biliary excretion',
                clinicalPearls: 'Alternative to ACE inhibitor if cough. Often better tolerated than other ARBs',
                indication: 'Hypertension, heart failure, diabetic nephropathy, post-MI'
            },
            'formoterol': {
                name: 'Formoterol',
                class: 'Beta2-agonists',
                mechanism: 'Selective β2-adrenoreceptor agonist with rapid onset and long duration',
                dosing: 'Adults: 12mcg BD via dry powder inhaler. Max 48mcg daily. Always with ICS in asthma',
                contraindications: 'Hypersensitivity. Never use as monotherapy in asthma',
                interactions: 'β-blockers (antagonism), diuretics (hypokalemia), theophylline',
                monitoring: 'Peak flow, asthma control, heart rate, potassium (high doses)',
                pregnancy: 'Safe - no evidence of harm',
                sideEffects: 'Tremor, palpitations, headache, muscle cramps, hypokalemia',
                pharmacokinetics: 'Onset: 1-3min, Duration: 12h, hepatic metabolism',
                clinicalPearls: 'Rapid onset unlike salmeterol. Always combined with ICS. Available in combination inhalers',
                indication: 'Asthma (step 3+ with ICS), COPD (combination inhalers)'
            },
            'budesonide': {
                name: 'Budesonide',
                class: 'Corticosteroids, inhaled',
                mechanism: 'Synthetic glucocorticoid with potent anti-inflammatory effects in airways',
                dosing: 'Adults: 200-800mcg BD inhaled. Children: 100-400mcg BD. Use spacer device',
                contraindications: 'Hypersensitivity. Caution in active pulmonary TB',
                interactions: 'CYP3A4 inhibitors (↑ systemic exposure), minimal with inhaled use',
                monitoring: 'Growth in children, oral candidiasis, signs of systemic effects',
                pregnancy: 'Safe - preferred ICS in pregnancy',
                sideEffects: 'Oral candidiasis, hoarse voice, growth suppression (children, high doses)',
                pharmacokinetics: 'High first-pass metabolism, low systemic bioavailability',
                clinicalPearls: 'High potency ICS. Good safety profile. Rinse mouth after use',
                indication: 'Asthma prophylaxis, COPD (in combination inhalers), Crohn\'s disease (oral)'
            },
            'norethisterone': {
                name: 'Norethisterone',
                class: 'Oestrogens and progestogens',
                mechanism: 'Synthetic progestogen with weak androgenic and estrogenic activity',
                dosing: 'Menorrhagia: 5mg TDS for 10 days. Contraception: 350mcg daily. Endometriosis: 10-15mg daily',
                contraindications: 'Pregnancy, severe liver disease, thromboembolism, breast cancer',
                interactions: 'Enzyme inducers (↓ efficacy), lamotrigine (may ↓ levels)',
                monitoring: 'Breakthrough bleeding, weight, mood, thrombotic risk factors',
                pregnancy: 'Contraindicated - may masculinize female fetus',
                sideEffects: 'Weight gain, mood changes, breakthrough bleeding, acne, androgenic effects',
                pharmacokinetics: 'Well absorbed, hepatic metabolism, half-life: 5-13h',
                clinicalPearls: 'Multiple indications and doses. Weak androgenic effects. Can delay menstruation',
                indication: 'Menorrhagia, endometriosis, contraception (POP), HRT, delayed menstruation'
            },
            'hydroxychloroquine': {
                name: 'Hydroxychloroquine',
                class: 'Disease-modifying antirheumatic drugs',
                mechanism: 'Antimalarial with immunomodulatory effects, exact mechanism in rheumatic disease unknown',
                dosing: 'Rheumatoid arthritis: 200-400mg daily with food. Max 5mg/kg/day based on ideal body weight',
                contraindications: 'Retinal/visual field changes, severe liver disease, porphyria',
                interactions: 'Digoxin (↑ levels), antiepileptics (↓ seizure threshold), QT-prolonging drugs',
                monitoring: 'Annual ophthalmology screening, FBC, liver function, symptoms',
                pregnancy: 'Safe in established rheumatic disease - continue treatment',
                sideEffects: 'Retinopathy (dose/time related), GI upset, skin reactions, cardiomyopathy (rare)',
                pharmacokinetics: 'Long half-life: 1-2 months, extensive tissue distribution',
                clinicalPearls: 'Takes 2-3 months for effect. Retinopathy related to cumulative dose. Generally well tolerated',
                indication: 'Rheumatoid arthritis, SLE, malaria prophylaxis and treatment'
            },
            'phenoxymethylpenicillin': {
                name: 'Phenoxymethylpenicillin (Penicillin V)',
                class: 'Penicillins, narrow-spectrum',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'Adults: 500mg QDS on empty stomach. Children: 62.5-125mg QDS (<1yr), 125-250mg QDS (1-5yrs), 250mg QDS (6-12yrs)',
                contraindications: 'Penicillin allergy, severe renal impairment',
                interactions: 'Methotrexate (↑ toxicity), probenecid (↑ levels), oral contraceptives (↓ efficacy)',
                monitoring: 'Signs of allergic reaction, C. difficile-associated diarrhoea',
                pregnancy: 'Safe - suitable for use in pregnancy',
                sideEffects: 'GI upset, diarrhoea, allergic reactions, CDAD, oral thrush',
                pharmacokinetics: 'Variable oral absorption, best on empty stomach, half-life: 0.5-1h',
                clinicalPearls: 'Oral alternative to benzylpenicillin. Take 1h before or 2h after food. First-line for streptococcal infections',
                coverage: 'Gram-positive: Streptococci, pneumococci. Limited gram-negative cover. No staphylococcal cover',
                indication: 'Streptococcal pharyngitis, pneumococcal infections, rheumatic fever prophylaxis, endocarditis prophylaxis'
            },
            'dihydrocodeine': {
                name: 'Dihydrocodeine',
                class: 'Opioid analgesic',
                mechanism: 'Mu-opioid receptor agonist, weaker than morphine but stronger than codeine',
                dosing: 'Adults: 30mg every 4-6 hours PRN (max 240mg daily). Modified release: 60-120mg BD',
                contraindications: 'Respiratory depression, acute abdomen, severe asthma, paralytic ileus',
                interactions: 'CNS depressants (↑ sedation), MAOIs (avoid), rifampicin (↓ efficacy)',
                monitoring: 'Respiratory rate, sedation level, bowel function, pain scores, signs of dependence',
                pregnancy: 'Use with caution - neonatal withdrawal syndrome possible',
                sideEffects: 'Sedation, constipation, nausea, respiratory depression, dependence, tolerance',
                pharmacokinetics: 'Good oral bioavailability, half-life: 3-4h, hepatic metabolism',
                clinicalPearls: 'Step 2 analgesic (WHO ladder). Always prescribe laxatives. Less euphoric than morphine',
                indication: 'Moderate to severe pain, persistent cough (unlicensed)'
            },
            'flumazenil': {
                name: 'Flumazenil',
                class: 'Benzodiazepine antagonist',
                mechanism: 'Competitive antagonist at benzodiazepine binding site on GABA-A receptor',
                dosing: 'IV: 200mcg over 15 seconds, then 100mcg at 60-second intervals (max 1mg). Infusion: 100-400mcg/h',
                contraindications: 'Mixed overdose with tricyclics, epilepsy on benzodiazepines, chronic benzodiazepine use',
                interactions: 'Can precipitate withdrawal seizures in chronic benzodiazepine users',
                monitoring: 'Consciousness level, respiratory rate, blood pressure, seizure activity, re-sedation',
                pregnancy: 'Use only if clearly indicated - limited safety data',
                sideEffects: 'Anxiety, agitation, seizures (especially in mixed overdose), re-sedation, withdrawal syndrome',
                pharmacokinetics: 'Rapid onset: 1-2min, short duration: 20-50min, hepatic metabolism',
                clinicalPearls: 'Short half-life - may need repeated doses. Risk of seizures in mixed overdose. Monitor for re-sedation',
                indication: 'Benzodiazepine overdose reversal, procedural sedation reversal, hepatic encephalopathy (unlicensed)'
            },
            'atenolol': {
                name: 'Atenolol',
                class: 'Beta-blockers',
                mechanism: 'Selective beta-1 adrenergic receptor antagonist',
                dosing: 'Hypertension: 25-50mg daily. Angina: 50-100mg daily. Post-MI: 50mg BD. Elderly: start 25mg daily',
                contraindications: 'Asthma, severe COPD, cardiogenic shock, severe bradycardia, heart block',
                interactions: 'Calcium channel blockers (↑ bradycardia), insulin (masks hypoglycaemia), NSAIDs (↓ antihypertensive effect)',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, renal function, glucose (diabetics)',
                pregnancy: 'Use with caution; consult UKTIS for guidance',
                sideEffects: 'Bradycardia, hypotension, fatigue, cold extremities, bronchospasm, vivid dreams',
                pharmacokinetics: 'Low lipophilicity, mainly renal excretion, half-life: 6-7h',
                clinicalPearls: 'Less CNS side effects than lipophilic beta-blockers. Reduce dose in renal impairment. Water-soluble',
                indication: 'Hypertension, angina, post-MI, arrhythmias, anxiety (short-term)'
            },
            'carbimazole': {
                name: 'Carbimazole',
                class: 'Antithyroid drugs',
                mechanism: 'Inhibits thyroid peroxidase, blocking iodine organification and thyroid hormone synthesis',
                dosing: 'Initial: 15-40mg daily in divided doses. Maintenance: 5-15mg daily. Titrate according to TFTs',
                contraindications: 'Severe blood disorders, severe liver disease, breast-feeding',
                interactions: 'Warfarin (↓ anticoagulation as thyroid status normalises), digoxin (↓ levels)',
                monitoring: 'TFTs every 4-6 weeks initially, then 2-3 monthly. FBC (especially first 3 months), LFTs',
                pregnancy: 'Use propylthiouracil in first trimester - carbimazole teratogenic',
                sideEffects: 'Rash, arthralgia, agranulocytosis (rare but serious), hepatitis, vasculitis',
                pharmacokinetics: 'Prodrug converted to methimazole, half-life: 4-6h, crosses placenta',
                clinicalPearls: 'Monitor for sore throat/fever (agranulocytosis). Switch to propylthiouracil in pregnancy. Block-and-replace regimen option',
                indication: 'Hyperthyroidism (Graves disease, toxic multinodular goitre), pre-operative preparation'
            },
            'paroxetine': {
                name: 'Paroxetine',
                class: 'Selective serotonin reuptake inhibitors',
                mechanism: 'Selective inhibition of serotonin reuptake, minimal effect on noradrenaline and dopamine',
                dosing: 'Depression: 20mg daily, max 50mg daily. Panic disorder: 10mg daily initially, usual 40mg daily',
                contraindications: 'MAOIs (within 14 days), pregnancy/breastfeeding, unstable epilepsy',
                interactions: 'MAOIs (serotonin syndrome), warfarin (↑ bleeding), tramadol (serotonin syndrome), tamoxifen (↓ efficacy)',
                monitoring: 'Mood, suicidal ideation (especially <25yrs), weight, sexual function, withdrawal symptoms',
                pregnancy: 'Avoid - increased malformation risk, especially cardiac defects',
                sideEffects: 'Nausea, sexual dysfunction, weight gain, withdrawal syndrome, sweating, tremor',
                pharmacokinetics: 'Short half-life: 24h, extensive hepatic metabolism, highly protein-bound',
                clinicalPearls: 'Most sedating SSRI. Worst withdrawal syndrome - taper slowly. Strong CYP2D6 inhibitor',
                indication: 'Depression, panic disorder, OCD, social anxiety disorder, PTSD'
            },
            'risperidone': {
                name: 'Risperidone',
                class: 'Atypical antipsychotics',
                mechanism: 'Dopamine D2 and serotonin 5-HT2A receptor antagonist',
                dosing: 'Schizophrenia: 2mg daily initially, usual 4-6mg daily. Elderly: 0.5mg BD initially',
                contraindications: 'Coma, CNS depression, phaeochromocytoma, prolactinoma',
                interactions: 'CNS depressants (↑ sedation), carbamazepine (↓ levels), fluoxetine (↑ levels)',
                monitoring: 'Weight, glucose, lipids, prolactin, movement disorders, LFTs, FBC, ECG',
                pregnancy: 'Use only if benefit outweighs risk - risk of extrapyramidal symptoms in neonate',
                sideEffects: 'Extrapyramidal symptoms, hyperprolactinaemia, weight gain, sedation, postural hypotension',
                pharmacokinetics: 'Good oral bioavailability, half-life: 3h (parent), 24h (active metabolite)',
                clinicalPearls: 'Lower risk of metabolic effects than olanzapine. Monitor for tardive dyskinesia. Depot formulation available',
                indication: 'Schizophrenia, bipolar mania, behavioural disturbance in dementia (short-term)'
            },
            'nifedipine': {
                name: 'Nifedipine',
                class: 'Calcium channel blockers',
                mechanism: 'Blocks L-type calcium channels, causing vasodilation and reduced peripheral resistance',
                dosing: 'Hypertension: Modified release 10mg BD or 30mg daily. Max 90mg daily. Angina: 5-20mg TDS (immediate release)',
                contraindications: 'Cardiogenic shock, unstable angina, acute MI, aortic stenosis',
                interactions: 'Beta-blockers (↑ hypotension), digoxin (↑ levels), grapefruit juice (↑ levels)',
                monitoring: 'Blood pressure, heart rate, ankle oedema, signs of heart failure',
                pregnancy: 'Use with caution - may inhibit labour',
                sideEffects: 'Flushing, headache, ankle oedema, gingival hyperplasia, palpitations',
                pharmacokinetics: 'Rapid absorption, extensive first-pass metabolism, half-life: 2-5h (immediate), 7-12h (modified release)',
                clinicalPearls: 'Use modified-release preparations only. Sublingual immediate-release can cause stroke. Peripheral oedema dose-related',
                indication: 'Hypertension, angina, Raynaud phenomenon'
            },
            'sulfasalazine': {
                name: 'Sulfasalazine',
                class: 'Disease-modifying antirheumatic drugs',
                mechanism: 'Cleaved in colon to 5-aminosalicylic acid and sulfapyridine, anti-inflammatory action',
                dosing: 'Rheumatoid arthritis: 500mg daily initially, increase weekly to 2-3g daily in divided doses',
                contraindications: 'Sulfonamide allergy, severe renal/hepatic impairment, porphyria',
                interactions: 'Folate antagonists (↑ toxicity), digoxin (↓ absorption), warfarin (↑ anticoagulation)',
                monitoring: 'FBC (especially first 3 months), LFTs, U&Es, folate levels',
                pregnancy: 'Generally safe - supplement with folate 5mg daily',
                sideEffects: 'GI upset, rash, blood disorders, male infertility (reversible), orange discoloration of urine',
                pharmacokinetics: 'Prodrug, cleaved by colonic bacteria, active metabolites have different kinetics',
                clinicalPearls: 'DMARD with dual action (RA and IBD). Take with food. Supplement folate. Check G6PD deficiency',
                indication: 'Rheumatoid arthritis, ulcerative colitis, Crohn disease'
            },
            'bisacodyl': {
                name: 'Bisacodyl',
                class: 'Stimulant laxatives',
                mechanism: 'Stimulates colonic nerve plexus, increasing peristalsis and secretion',
                dosing: 'Oral: 5-10mg at night. Rectal: 10mg suppository. Max 3 consecutive days',
                contraindications: 'Intestinal obstruction, acute abdomen, severe dehydration, ileus',
                interactions: 'Milk/antacids (enteric coating dissolution), diuretics (↑ electrolyte loss)',
                monitoring: 'Bowel movements, electrolytes (with prolonged use), signs of dependency',
                pregnancy: 'Safe for short-term use',
                sideEffects: 'Abdominal cramps, diarrhoea, electrolyte imbalance, dependency with long-term use',
                pharmacokinetics: 'Enteric-coated tablets, activated in alkaline environment of small intestine',
                clinicalPearls: 'Take tablets whole, avoid milk within 1h. Suppositories work within 30min. Short-term use only',
                indication: 'Constipation, bowel preparation for procedures'
            }
            ,
            'enalapril': {
                name: 'Enalapril',
                class: 'ACE inhibitor',
                mechanism: 'Inhibits angiotensin-converting enzyme, lowering angiotensin II production',
                dosing: 'Start 2.5-5mg once daily in elderly; usual maintenance 5-20mg once daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, history of ACE inhibitor–induced angioedema',
                interactions: 'Potassium supplements/ACEi/ARBs (↑ hyperkalaemia), NSAIDs (↓ effect), lithium (↑ toxicity)',
                monitoring: 'BP, renal function and K+ 1-2 weeks after starting or dose changes',
                pregnancy: 'Contraindicated - fetal toxicity',
                sideEffects: 'Cough, hyperkalaemia, hypotension, dizziness, renal impairment, angioedema',
                pharmacokinetics: 'Prodrug converted to enalaprilat; excreted renally; half-life variable',
                clinicalPearls: 'Start low and titrate, check renal function after initiation. Substitute with ARB if cough occurs',
                indication: 'Hypertension, heart failure, post-MI'
            },
            'levetiracetam': {
                name: 'Levetiracetam',
                class: 'Antiepileptic',
                mechanism: 'Binds to synaptic vesicle protein SV2A, modulating neurotransmitter release',
                dosing: 'Adults: 500-1000mg BD (may increase to 3000mg/day). IV formulations available for acute seizures',
                contraindications: 'Hypersensitivity to levetiracetam',
                interactions: 'Minimal drug interactions (advantageous in polypharmacy)',
                monitoring: 'Renal dose adjustments (check CrCl), mood/behaviour for irritability',
                pregnancy: 'Use with caution; folate recommended pre-conception',
                sideEffects: 'Somnolence, dizziness, behavioural changes, irritability, rarely psychosis',
                pharmacokinetics: 'Renal excretion primarily unchanged; half-life ~6-8h (longer in elderly)',
                clinicalPearls: 'Favourable interaction profile; widely used for acute and chronic seizure control',
                indication: 'Focal and generalized seizures, status epilepticus adjunct'
            },
            'nitroglycerin': {
                name: 'Nitroglycerin (GTN)',
                class: 'Nitrate vasodilator',
                mechanism: 'Releases nitric oxide causing venodilation and coronary artery dilation',
                dosing: 'Sublingual: 400-600mcg (1-2 sprays or tablets) every 5 minutes up to 3 doses. IV infusion titrated in acute coronary syndromes/heart failure',
                contraindications: 'Hypotension, use with PDE5 inhibitors (sildenafil) within 24-48h, severe aortic stenosis',
                interactions: 'PDE5 inhibitors (severe hypotension), antihypertensives (additive hypotension)',
                monitoring: 'BP, heart rate, relief of chest pain, signs of headache or flushing',
                pregnancy: 'Use if clearly indicated; consult obstetrics',
                sideEffects: 'Headache, hypotension, flushing, reflex tachycardia',
                pharmacokinetics: 'Rapid onset sublingual; short half-life; hepatic metabolism for oral/IV forms',
                clinicalPearls: 'Sublingual GTN for acute angina; remove patch at night to reduce tolerance. Avoid with PDE5 inhibitors',
                indication: 'Acute angina, acute pulmonary oedema (IV), myocardial ischaemia'
            },
            'potassium-chloride': {
                name: 'Potassium Chloride (KCl)',
                class: 'Electrolyte replacement',
                mechanism: 'Provides potassium ions to correct hypokalaemia',
                dosing: 'Oral: 600mg (8mmol) BD-TDS or as prescribed. IV: individualised replacement guided by serum K+ (use diluted IV KCl not bolus) ',
                contraindications: 'Hyperkalaemia, severe renal impairment without monitoring, untreated Addison’s disease',
                interactions: 'ACE inhibitors/ARBs/spironolactone (↑ hyperkalaemia risk), trimethoprim, NSAIDs',
                monitoring: 'Serum potassium, renal function, ECG during IV replacement',
                pregnancy: 'Use if required with monitoring',
                sideEffects: 'GI upset, local pain at infusion site, hyperkalaemia if over-replaced',
                pharmacokinetics: 'Rapidly distributed in extracellular fluid; excreted renally',
                clinicalPearls: 'Never give concentrated IV KCl as bolus. Dilute and infuse slowly with cardiac monitoring for significant deficits',
                indication: 'Hypokalaemia replacement and prevention'
            },
            'clindamycin': {
                name: 'Clindamycin',
                class: 'Lincosamide antibiotic',
                mechanism: 'Inhibits 50S ribosomal subunit, preventing bacterial protein synthesis',
                dosing: 'Adults: 300-450mg TDS PO or 600-900mg IV in divided doses depending on infection severity',
                contraindications: 'History of C. difficile colitis associated with prior clindamycin use',
                interactions: 'Neuromuscular blockers (may potentiate blockade), erythromycin (antagonism)',
                monitoring: 'GI symptoms, signs of C. difficile infection, LFTs for prolonged therapy',
                pregnancy: 'Generally considered safe in pregnancy when needed',
                sideEffects: 'Diarrhoea, risk of C. difficile, rash, metallic taste',
                pharmacokinetics: 'Good tissue penetration including bone; hepatic metabolism',
                clinicalPearls: 'Good for skin/soft tissue infections and anaerobic coverage when beta-lactams cannot be used',
                indication: 'Skin/soft tissue infections, anaerobic infections, aspiration pneumonia (in combination)'
            }
            ,
            'cefuroxime': {
                name: 'Cefuroxime',
                class: 'Second-generation cephalosporin',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: 'IV: 750mg-1.5g BD depending on infection severity. PO (axetil): 250-500mg BD',
                contraindications: 'Severe β-lactam allergy',
                interactions: 'May affect warfarin (monitor INR), probenecid (↑ levels)',
                monitoring: 'Renal function for dose adjustment, signs of hypersensitivity',
                pregnancy: 'Generally considered safe in pregnancy when indicated',
                sideEffects: 'GI upset, rash, allergic reactions, C. difficile-associated diarrhoea',
                pharmacokinetics: 'Good oral absorption (axetil prodrug), renal excretion',
                clinicalPearls: 'Good for respiratory tract infections and some soft tissue infections; check local susceptibility',
                indication: 'Respiratory tract infections, pyelonephritis (IV), skin/soft tissue infections'
            },
            'dalteparin': {
                name: 'Dalteparin',
                class: 'Low molecular weight heparin (LMWH)',
                mechanism: 'Enhances antithrombin-mediated inhibition of factor Xa',
                dosing: 'Prophylaxis: 2500-5000 units SC once daily. Treatment dosing weight-based (e.g., 200 units/kg daily or 100 units/kg BD)',
                contraindications: 'Active bleeding, severe thrombocytopenia, history of heparin-induced thrombocytopenia (HIT)',
                interactions: 'Antiplatelet agents (↑ bleeding), other anticoagulants',
                monitoring: 'Platelet count (for HIT), renal function, signs of bleeding',
                pregnancy: 'Preferred anticoagulant in pregnancy when anticoagulation needed',
                sideEffects: 'Bleeding, injection site reactions, thrombocytopenia (rare), hyperkalaemia',
                pharmacokinetics: 'SC absorption with predictable dose-response; renal excretion',
                clinicalPearls: 'Use dose adjustment for renal impairment and obesity. Monitor anti-Xa in special populations',
                indication: 'VTE prophylaxis and treatment, bridging for high-risk patients'
            },
            'celecoxib': {
                name: 'Celecoxib',
                class: 'COX-2 selective NSAID',
                mechanism: 'Selective inhibition of cyclooxygenase-2 enzyme, reducing prostaglandin synthesis',
                dosing: '200mg once daily or 100mg BD depending on indication',
                contraindications: 'Established cardiovascular disease (caution), active peptic ulcer disease, severe renal impairment',
                interactions: 'Warfarin (↑ bleeding), ACEi/ARBs (↓ efficacy), lithium (↑ levels)',
                monitoring: 'Renal function, BP, signs of GI bleeding',
                pregnancy: 'Avoid in late pregnancy (risk of premature closure of ductus arteriosus)',
                sideEffects: 'GI upset, increased cardiovascular risk, renal impairment, hypertension',
                pharmacokinetics: 'Oral absorption, hepatic metabolism CYP2C9, half-life ~11h',
                clinicalPearls: 'Lower GI risk than non-selective NSAIDs but may increase CV risk. Use lowest effective dose for the shortest duration',
                indication: 'Osteoarthritis, acute pain where NSAID indicated and GI risk a concern'
            },
            'ketorolac': {
                name: 'Ketorolac',
                class: 'Non-selective NSAID',
                mechanism: 'Inhibits COX-1 and COX-2, reducing prostaglandin synthesis',
                dosing: 'IV/IM: 10-30mg single doses as required. PO: 10mg then 10mg every 4-6h (max 40mg/day) for short-term use',
                contraindications: 'Active peptic ulcer, significant renal impairment, bleeding diathesis, recent major surgery (esp. CABG)',
                interactions: 'Anticoagulants/antiplatelets (↑ bleeding), ACEi/ARBs (↓ efficacy)',
                monitoring: 'Renal function, signs of bleeding, pain relief',
                pregnancy: 'Avoid in late pregnancy; use caution earlier',
                sideEffects: 'GI bleeding, renal impairment, increased bleeding risk, bronchospasm in aspirin-sensitive asthma',
                pharmacokinetics: 'Good analgesic potency; short-term use only to limit adverse effects',
                clinicalPearls: 'Powerful analgesic for short-term use (≤5 days). Avoid with other NSAIDs and in renal impairment',
                indication: 'Moderate to severe acute pain (short-term postoperative pain)'
            },
            'moxifloxacin': {
                name: 'Moxifloxacin',
                class: 'Fluoroquinolone antibiotic',
                mechanism: 'Inhibits bacterial DNA gyrase and topoisomerase IV',
                dosing: '400mg once daily PO/IV',
                contraindications: 'Tendon disorders related to fluoroquinolones, pregnancy (avoid unless necessary), prolonged QT',
                interactions: 'Drugs that prolong QT (macrolides, some antipsychotics), antacids (↓ absorption)',
                monitoring: 'QT interval for at-risk patients, hepatic function in prolonged use',
                pregnancy: 'Generally avoided unless benefit outweighs risk',
                sideEffects: 'Tendonitis/tendon rupture, QT prolongation, nausea, CNS effects (confusion, hallucinations)',
                pharmacokinetics: 'Good tissue penetration, hepatic metabolism and renal excretion',
                clinicalPearls: 'Reserve for specific indications due to safety concerns and rising resistance',
                indication: 'Certain respiratory and intra-abdominal infections where indicated'
            },
            'oxytocin': {
                name: 'Oxytocin',
                class: 'Uterotonic',
                mechanism: 'Stimulates uterine smooth muscle contraction via oxytocin receptors',
                dosing: 'IV infusion titrated for labour induction/augmentation; IM 10 units for postpartum haemorrhage',
                contraindications: 'Uterine rupture risk, foetal distress when vaginal birth not advisable',
                interactions: 'Vasoconstrictors and ergometrine (use caution), tocolytics (antagonistic)',
                monitoring: 'Continuous CTG during labour, uterine tone, maternal vital signs',
                pregnancy: 'Used during labour and postpartum under obstetric supervision',
                sideEffects: 'Uterine hyperstimulation, hypotension, water retention with prolonged high-dose infusion',
                pharmacokinetics: 'Rapid onset; short half-life',
                clinicalPearls: 'Use with careful monitoring in labour wards and for PPH management',
                indication: 'Labour induction/augmentation, postpartum haemorrhage'
            },
            'clotrimazole': {
                name: 'Clotrimazole',
                class: 'Azole antifungal (topical)',
                mechanism: 'Inhibits ergosterol synthesis by blocking fungal CYP450 enzymes',
                dosing: 'Topical cream/ointment/vaginal pessary dosing varies by preparation; follow product instructions',
                contraindications: 'Hypersensitivity to imidazoles',
                interactions: 'Minimal for topical use; systemic formulations have more interactions (CYP450)',
                monitoring: 'Local skin reactions',
                pregnancy: 'Topical use generally considered safe in pregnancy for vulvovaginal candidiasis',
                sideEffects: 'Local irritation, burning, rash',
                pharmacokinetics: 'Poor systemic absorption when used topically',
                clinicalPearls: 'Useful topical antifungal; choose formulation based on site of infection',
                indication: 'Vaginal thrush, cutaneous fungal infections'
            }
            ,
            'linezolid': {
                name: 'Linezolid',
                class: 'Oxazolidinone antibiotic',
                mechanism: 'Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit and preventing formation of the initiation complex',
                dosing: 'Adults: 600mg IV/PO every 12 hours (usual duration depends on infection)',
                contraindications: 'Concurrent or recent (within 2 weeks) MAOI use, uncontrolled hypertension, untreated peripheral neuropathy',
                interactions: 'SSRIs/SNRIs/TCAs (risk of serotonin syndrome), tyramine-rich foods (hypertensive reactions), MAOIs',
                monitoring: 'Full blood count (weekly if >2 weeks), signs of neuropathy, blood pressure if hypertensive',
                pregnancy: 'Use only if clearly needed - limited data',
                sideEffects: 'Myelosuppression (thrombocytopenia, anaemia), peripheral and optic neuropathy with prolonged use, lactic acidosis (rare)',
                pharmacokinetics: 'Good oral bioavailability (~100%), wide tissue distribution, hepatic metabolism to inactive metabolites',
                clinicalPearls: 'Reserve for resistant Gram-positive infections including MRSA and VRE where appropriate. Limit duration where possible and monitor blood counts',
                indication: 'Serious Gram-positive infections including MRSA, VRE, complicated skin and soft tissue infections, some pneumonia'
            },
            'colistin': {
                name: 'Colistin (polymyxin E)',
                class: 'Polymyxin antibiotic',
                mechanism: 'Cationic detergent that disrupts bacterial cell membrane integrity (Gram-negative bacteria)',
                dosing: 'Dosing complex - use local guidance and consult pharmacy; typical IV dosing based on colistin base activity and renal function',
                contraindications: 'Hypersensitivity to polymyxins',
                interactions: 'Other nephrotoxic or neurotoxic agents (aminoglycosides, vancomycin, amphotericin)',
                monitoring: 'Renal function, respiratory status, neuromuscular blockade signs',
                pregnancy: 'Use only if no safer alternatives - limited data',
                sideEffects: 'Nephrotoxicity, neurotoxicity (paresthesia, dizziness, neuromuscular blockade), bronchospasm with inhaled forms',
                pharmacokinetics: 'Poor oral absorption; IV or inhaled administration. Renal clearance; dosing adjusted for renal impairment',
                clinicalPearls: 'Often used as a last-resort agent for multidrug-resistant Gram-negative infections; dosing regimens vary—consult infectious diseases/pharmacy',
                indication: 'Severe infections due to MDR Pseudomonas, Acinetobacter, Klebsiella species when other options exhausted'
            },
            'amikacin': {
                name: 'Amikacin',
                class: 'Aminoglycoside antibiotic',
                mechanism: 'Binds 30S ribosomal subunit inhibiting protein synthesis and causing bacterial cell death (concentration-dependent)',
                dosing: 'Typically 15mg/kg once daily IV/IM (adjust for renal function and therapeutic drug monitoring)',
                contraindications: 'Myasthenia gravis or other neuromuscular disorders (risk of paralysis), known hypersensitivity',
                interactions: 'Other nephrotoxic or ototoxic drugs (vancomycin, loop diuretics), neuromuscular blockers',
                monitoring: 'Renal function, trough/peak levels (TDM), audiology if prolonged therapy',
                pregnancy: 'Avoid unless benefit outweighs risk - risk of fetal ototoxicity',
                sideEffects: 'Nephrotoxicity, ototoxicity (vestibular and cochlear), neuromuscular blockade (rare)',
                pharmacokinetics: 'Poor oral absorption; IV/IM dosing. Renal excretion; half-life prolonged in renal impairment',
                clinicalPearls: 'Use TDM and once-daily dosing where possible. Adjust dose interval in renal impairment',
                indication: 'Serious Gram-negative infections, synergy for some Gram-positive infections in combination therapy'
            },
            'ertapenem': {
                name: 'Ertapenem',
                class: 'Carbapenem antibiotic',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins',
                dosing: '1g IV/IM once daily',
                contraindications: 'Known hypersensitivity to carbapenems, history of seizures (use caution)',
                interactions: 'Valproate (↓ levels), probenecid (↓ clearance), other β-lactams (additive effects)',
                monitoring: 'Renal function, signs of C. difficile infection, seizure activity',
                pregnancy: 'Use if clearly needed - limited data',
                sideEffects: 'GI upset, rash, seizures (rare, especially with renal impairment), C. difficile colitis',
                pharmacokinetics: 'Once-daily dosing due to longer half-life than some carbapenems; primarily renal excretion',
                clinicalPearls: 'Does NOT reliably cover Pseudomonas or Acinetobacter (unlike meropenem). Useful for community severe infections and intra-abdominal sepsis in some protocols',
                indication: 'Intra-abdominal infections, complicated skin/soft tissue infections, community-acquired severe infections, some UTIs'
            },
            'cefepime': {
                name: 'Cefepime',
                class: 'Fourth-generation cephalosporin',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to PBPs; increased Gram-negative and Pseudomonas coverage',
                dosing: '1-2g IV every 8-12 hours (adjust for renal function)',
                contraindications: 'Cephalosporin hypersensitivity',
                interactions: 'Aminoglycosides (↑ nephrotoxicity risk), antacids (↓ absorption for oral forms - not applicable to IV)',
                monitoring: 'Renal function, signs of encephalopathy (rare with renal impairment)',
                pregnancy: 'Use if needed - limited data but often used in pregnancy when indicated',
                sideEffects: 'GI upset, allergic reactions, neurotoxicity (encephalopathy/seizures in renal impairment), C. difficile',
                pharmacokinetics: 'Good distribution including CSF in inflamed meninges; renal elimination',
                clinicalPearls: 'Strong anti-pseudomonal activity; dose adjust in renal impairment; watch for neurotoxicity in elderly/renal failure',
                indication: 'Serious Gram-negative infections including Pseudomonas, hospital-acquired pneumonia, febrile neutropenia'
            },
            'tigecycline': {
                name: 'Tigecycline',
                class: 'Glycylcycline antibiotic',
                mechanism: 'Binds 30S ribosomal subunit inhibiting protein synthesis',
                dosing: 'Loading 100mg IV, then 50mg IV every 12 hours (adjust per product guidance)',
                contraindications: 'Severe hepatic impairment (dose adjustment), hypersensitivity to tetracyclines/glycylcyclines',
                interactions: 'May reduce effectiveness of oral contraceptives; interactions similar to tetracyclines',
                monitoring: 'LFTs, clinical response, signs of pancreatitis (rare)',
                pregnancy: 'Contraindicated (tetracycline class effects on teeth/bone)',
                sideEffects: 'Nausea/vomiting (common), increased mortality signal in some studies when used for severe infections, photosensitivity',
                pharmacokinetics: 'Large volume of distribution (poor serum concentrations), hepatic metabolism',
                clinicalPearls: 'Not ideal for bloodstream infections due to low serum levels. Use for complicated intra-abdominal and skin infections where organisms resistant to other agents',
                indication: 'Complicated intra-abdominal infections, complicated skin/soft tissue infections, some MDR organisms when options limited'
            },
            'daptomycin': {
                name: 'Daptomycin',
                class: 'Lipopeptide antibiotic',
                mechanism: 'Causes rapid depolarization of bacterial cell membrane leading to cell death (concentration-dependent)',
                dosing: '4-8mg/kg IV once daily (higher doses for bacteraemia/endocarditis); adjust for renal function',
                contraindications: 'Pneumonia (inactivated by surfactant), hypersensitivity',
                interactions: 'Statins (↑ risk of myopathy/rhabdomyolysis), concurrent muscle-toxic drugs',
                monitoring: 'CK at baseline and weekly during therapy, renal function, signs of myopathy',
                pregnancy: 'Use only if clearly needed - limited data',
                sideEffects: 'Myopathy, elevated CK, peripheral neuropathy (rare), eosinophilic pneumonia (rare)',
                pharmacokinetics: 'IV only; renal excretion; poor lung penetration (not for pneumonia)',
                clinicalPearls: 'Excellent for Gram-positive bacteraemia and endocarditis including MRSA and VRE; monitor CK and avoid concurrent statin use if possible',
                indication: 'Serious Gram-positive infections including MRSA bacteraemia, right-sided endocarditis, complicated skin/soft tissue infections'
            },
            'teicoplanin': {
                name: 'Teicoplanin',
                class: 'Glycopeptide antibiotic',
                mechanism: 'Inhibits bacterial cell wall synthesis by binding to D-ala-D-ala termini',
                dosing: 'Loading: 6-12mg/kg IV every 12 hours for 3 doses then 6-12mg/kg once daily; adjust for renal function and product guidance',
                contraindications: 'Hypersensitivity to glycopeptides',
                interactions: 'Other nephrotoxic agents (↑ nephrotoxicity risk)',
                monitoring: 'Renal function, trough levels where available, signs of ototoxicity/nephrotoxicity',
                pregnancy: 'Use if clearly needed - limited data',
                sideEffects: 'Infusion-related reactions, rash, nephrotoxicity (less than vancomycin in some studies)',
                pharmacokinetics: 'Long half-life allowing once-daily dosing after loading; mainly renal excretion',
                clinicalPearls: 'Used similarly to vancomycin in some settings; local dosing/monitoring protocols vary',
                indication: 'Gram-positive infections including MRSA and serious staphylococcal infections'
            },
            'ticagrelor': {
                name: 'Ticagrelor',
                class: 'Antiplatelet - P2Y12 receptor antagonist (reversible)',
                mechanism: 'Direct-acting reversible P2Y12 ADP receptor antagonist, prevents platelet aggregation',
                dosing: 'Loading 180mg PO, then 90mg BD for maintenance (duration per ACS/PCI protocol)',
                contraindications: 'Active bleeding, history of intracranial haemorrhage, severe hepatic impairment',
                interactions: 'Strong CYP3A4 inhibitors/inducers, concomitant anticoagulants/antiplatelets (↑ bleeding)',
                monitoring: 'Signs of bleeding, haemoglobin, platelets',
                pregnancy: 'Use only if clearly needed',
                sideEffects: 'Dyspnoea (commonly reported), bleeding, bradyarrhythmias (rare)',
                pharmacokinetics: 'Rapid onset; hepatic metabolism via CYP3A4',
                clinicalPearls: 'Used in acute coronary syndromes and after PCI; do not give with ticlopidine/clopidogrel concurrently',
                indication: 'Acute coronary syndrome (with or without PCI) and secondary prevention when indicated'
            },
            /* --- High-yield omitted drugs (added) --- */
            'fentanyl': {
                name: 'Fentanyl',
                class: 'Opioid analgesic (synthetic)',
                mechanism: 'Potent μ-opioid receptor agonist',
                dosing: 'Analgesia: 25-100mcg IV bolus titrated to effect; intranasal 100-200mcg (device dependent) for prehospital/ED use. Reduce dose in elderly and renal impairment',
                contraindications: 'Respiratory depression, acute severe asthma, hypersensitivity',
                interactions: 'CNS depressants, MAOIs, CYP3A4 inhibitors',
                monitoring: 'Respiratory rate, oxygen saturation, sedation score, BP',
                pregnancy: 'Use with caution; neonatal respiratory depression possible with prolonged maternal use',
                sideEffects: 'Respiratory depression, bradycardia, nausea, constipation, chest wall rigidity with large rapid boluses',
                clinicalPearls: 'Short-acting and potent — useful for ED analgesia and procedural analgesia. Titrate slowly and monitor closely',
                indication: 'Severe acute pain, procedural sedation/analgesia, peri-intubation analgesia'
            },
            'buprenorphine': {
                name: 'Buprenorphine',
                class: 'Partial opioid agonist',
                mechanism: 'Partial μ-opioid receptor agonist, κ-antagonist',
                dosing: 'Analgesic patches: variable; OST (sublingual) doses per specialist protocol. Avoid giving full opioid agonists shortly after buprenorphine in opioid-dependent patients (precipitated withdrawal)',
                contraindications: 'Severe respiratory depression without monitoring',
                interactions: 'CNS depressants, CYP3A4 modulators',
                monitoring: 'Respiratory monitoring, signs of withdrawal in dependent patients',
                pregnancy: 'Use in pregnancy for opioid dependence only under specialist antenatal care',
                sideEffects: 'Sedation, constipation, nausea, precipitated withdrawal risk',
                clinicalPearls: 'Partial agonist: risk of precipitated withdrawal in opioid-tolerant patients. Used for opioid substitution and some pain formulations',
                indication: 'Opioid dependence (OST), chronic pain management under specialist guidance'
            },
            'methadone': {
                name: 'Methadone',
                class: 'Long-acting opioid agonist',
                mechanism: 'Full μ-opioid agonist; NMDA receptor antagonist properties',
                dosing: 'Specialist supervised dosing for OST; analgesic regimens individualised. Risk of accumulation — start low and titrate slowly',
                contraindications: 'Respiratory depression, severe asthma, uncontrolled QT prolongation',
                interactions: 'Many CYP interactions, QT-prolonging drugs',
                monitoring: 'ECG (QT), respiratory status, signs of accumulation',
                pregnancy: 'Used in pregnancy for OST under specialist care',
                sideEffects: 'Respiratory depression, sedation, QT prolongation, constipation',
                clinicalPearls: 'Long half-life and accumulation risk; specialist prescribing and community OST pathways apply',
                indication: 'Opioid substitution therapy, severe chronic pain under specialist supervision'
            },
            'thiamine': {
                name: 'Thiamine (B1) / Pabrinex',
                class: 'Vitamin / metabolic therapy',
                mechanism: 'Cofactor in carbohydrate metabolism (pyruvate dehydrogenase, transketolase)',
                dosing: 'Prevention: IV thiamine 200mg daily in at-risk alcohol-dependent patients; Treatment (suspected Wernicke): high-dose parenteral thiamine (e.g., Pabrinex or 500mg IV thiamine 3x daily) per local protocol',
                contraindications: 'None significant for thiamine itself; follow product guidance for Pabrinex components',
                interactions: 'None clinically important',
                monitoring: 'Clinical neurological signs, magnesium status (replete Mg if low)',
                pregnancy: 'Safe and indicated when required',
                sideEffects: 'Rare hypersensitivity (parenteral formulations)',
                clinicalPearls: 'Give thiamine prior to/during glucose administration in malnourished or alcohol-dependent patients to avoid precipitating Wernicke',
                indication: 'Prevention/treatment of Wernicke encephalopathy; thiamine deficiency'
            },
            'prasugrel': {
                name: 'Prasugrel',
                class: 'Antiplatelet - irreversible P2Y12 inhibitor',
                mechanism: 'Irreversible P2Y12 receptor antagonist',
                dosing: 'Loading 60mg, then 10mg daily (consider 5mg daily in elderly/low body weight per guidance); used per ACS/PCI protocols',
                contraindications: 'History of stroke/TIA, active pathological bleeding',
                interactions: 'Other antiplatelet/anticoagulant drugs (↑ bleeding)',
                monitoring: 'Signs of bleeding, Hb and platelets',
                pregnancy: 'Use only if benefit outweighs risk',
                sideEffects: 'Bleeding, bruising',
                clinicalPearls: 'Preferentially used in PCI populations; avoid in prior stroke/TIA',
                indication: 'ACS patients undergoing PCI (per cardiology guidance)'
            },
            'edoxaban': {
                name: 'Edoxaban',
                class: 'Direct oral anticoagulant (DOAC) – factor Xa inhibitor',
                mechanism: 'Selective inhibition of factor Xa, reducing thrombin generation',
                dosing: 'Atrial fibrillation (stroke prevention): 60 mg once daily; reduce to 30 mg once daily if CrCl 15–50 mL/min, body weight ≤60 kg, or concomitant P-gp inhibitors (e.g. verapamil, dronedarone). VTE treatment: start with parenteral anticoagulation for 5–10 days then edoxaban 60 mg once daily (30 mg if dose reduction criteria met). Always check SmPC/local guidelines for indication-specific dosing.',
                contraindications: 'Active clinically significant bleeding, severe hepatic impairment associated with coagulopathy, mechanical prosthetic heart valves, pregnancy',
                interactions: 'P-gp inhibitors (↑ edoxaban levels) and inducers (↓ levels), other anticoagulants and antiplatelets (↑ bleeding risk); check for P-gp inhibitors such as amiodarone, verapamil, dronedarone',
                monitoring: 'Renal function at baseline and periodically (dose adjustments for changes); clinical monitoring for bleeding, Hb and platelets as indicated',
                pregnancy: 'Contraindicated – use specialist advice',
                sideEffects: 'Bleeding, anaemia, bruising',
                reversal: 'No routine specific oral reversal widely available; in life‑threatening bleeding consider idarucizumab only for dabigatran; for factor Xa inhibitors consider prothrombin complex concentrate (PCC) and urgent haematology advice. Local major haemorrhage guidelines apply (urgent PCC ± tranexamic acid, local protocols).',
                clinicalPearls: 'Assess renal function and body weight before initiating. Missed doses should be taken as soon as remembered on the same day but do not double doses. Use caution with concomitant antiplatelet therapy.',
                indication: 'Stroke prevention in non-valvular AF, treatment and secondary prevention of VTE'
            },
            'dabigatran': {
                name: 'Dabigatran etexilate (dabigatran)',
                class: 'Direct oral anticoagulant (direct thrombin inhibitor)',
                mechanism: 'Prodrug converted to dabigatran which directly and reversibly inhibits thrombin (factor IIa), preventing fibrin formation',
                dosing: 'AF: 150 mg BD (consider 110 mg BD if ≥80 years, low body weight, or high bleeding risk). VTE treatment: after 5 days parenteral anticoagulation → 150 mg BD (dose reduce per local guidance). Adjust or avoid in significant renal impairment (CrCl <30 mL/min).',
                contraindications: 'Active pathological bleeding, mechanical prosthetic heart valves, clinically significant bleeding risk, severe renal impairment (CrCl <30 mL/min for many indications), pregnancy/breastfeeding',
                interactions: 'P-gp inhibitors (e.g., amiodarone, verapamil) ↑ levels; P-gp inducers ↓ levels. Concomitant anticoagulants/antiplatelets ↑ bleeding risk',
                monitoring: 'Renal function at baseline and periodically (frequency depends on renal function); clinical monitoring for bleeding',
                pregnancy: 'Contraindicated',
                sideEffects: 'Bleeding (including GI), dyspepsia, anaemia',
                pharmacokinetics: 'Peak 1–2 h; half-life ~12–17 h (renal-dependent); ~80% renal elimination',
                clinicalPearls: 'Capsules must be swallowed whole (acidic core). For life‑threatening bleeding or urgent reversal: idarucizumab 5 g IV (two 2.5 g boluses) as per SmPC and local major haemorrhage protocols. Stop 24–48 h pre-procedure depending on renal function and bleeding risk; involve haematology/local major haemorrhage team for complex cases.',
                indication: 'Stroke prevention in non-valvular AF; treatment and secondary prevention of VTE'
            },
            'fondaparinux': {
                name: 'Fondaparinux',
                class: 'Synthetic pentasaccharide (indirect anti‑Xa)',
                mechanism: 'Antithrombin-mediated selective factor Xa inhibition',
                dosing: 'Weight-based dosing for VTE prophylaxis/treatment; see local guideline. Used in some ACS pathways per local protocol',
                contraindications: 'Severe renal impairment (CrCl <30 mL/min), active bleeding, bacterial endocarditis',
                interactions: 'Other anticoagulants (↑ bleeding risk)',
                monitoring: 'Renal function, platelet count',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Bleeding',
                clinicalPearls: 'Once-daily subcutaneous injection; check weight-based dose and renal function',
                indication: 'VTE prophylaxis/treatment, used in certain ACS pathways per protocol'
            },
            'valsartan': {
                name: 'Valsartan',
                class: 'Angiotensin receptor blocker (ARB)',
                mechanism: 'Selective AT1 receptor antagonist',
                dosing: 'Hypertension: 80-160mg daily; titrate per response',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements, lithium',
                monitoring: 'eGFR and potassium baseline and 1–2 weeks after initiation',
                pregnancy: 'Contraindicated',
                sideEffects: 'Dizziness, hyperkalaemia, renal impairment',
                clinicalPearls: 'Alternative to ACE inhibitors when cough/intolerance occurs',
                indication: 'Hypertension, heart failure (where indicated)'
            },
            'irbesartan': {
                name: 'Irbesartan',
                class: 'Angiotensin receptor blocker (ARB)',
                mechanism: 'Selective AT1 receptor antagonist',
                dosing: 'Hypertension: 150-300mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements, lithium',
                monitoring: 'eGFR and potassium baseline and 1–2 weeks after initiation',
                pregnancy: 'Contraindicated',
                sideEffects: 'Dizziness, hyperkalaemia',
                clinicalPearls: 'Common ARB for hypertension and nephropathy',
                indication: 'Hypertension, proteinuric CKD'
            },
            'perindopril': {
                name: 'Perindopril',
                class: 'ACE inhibitor',
                mechanism: 'ACE inhibition reducing angiotensin II and aldosterone',
                dosing: 'Hypertension: start 2-4mg daily and titrate as tolerated',
                contraindications: 'Pregnancy, bilateral renal artery stenosis, history of ACEi-induced angioedema',
                interactions: 'NSAIDs, potassium-sparing diuretics, lithium',
                monitoring: 'eGFR and potassium baseline and 1–2 weeks after initiation',
                pregnancy: 'Contraindicated',
                sideEffects: 'Cough, hyperkalaemia, hypotension, angioedema',
                clinicalPearls: 'Used widely in UK cardiology/HTN pathways',
                indication: 'Hypertension, heart failure, post-MI'
            },
            'eplerenone': {
                name: 'Eplerenone',
                class: 'Mineralocorticoid receptor antagonist (MRA)',
                mechanism: 'Selective aldosterone receptor antagonist',
                dosing: 'Heart failure: 25mg daily, up-titrate to 50mg daily as tolerated',
                contraindications: 'Hyperkalaemia, severe renal impairment, pregnancy',
                interactions: 'Potassium supplements, ACEi/ARBs (↑ hyperkalaemia risk), CYP3A4 inhibitors',
                monitoring: 'U&Es frequently after initiation and dose changes (K+ monitoring)',
                pregnancy: 'Avoid',
                sideEffects: 'Hyperkalaemia, dizziness',
                clinicalPearls: 'Less anti-androgenic effects than spironolactone; used in heart failure with reduced ejection fraction',
                indication: 'Heart failure (HFrEF) as per guideline; alternative MRA'
            },
            'isosorbide-mononitrate': {
                name: 'Isosorbide mononitrate',
                class: 'Nitrate (long-acting)',
                mechanism: 'NO donor causing venodilation and reduced preload',
                dosing: 'Immediate/modified-release preparations vary; commonly 20-60mg daily for chronic angina; follow product guidance',
                contraindications: 'Concurrent PDE5 inhibitor use, hypotension, severe anemia',
                interactions: 'PDE5 inhibitors (profound hypotension)',
                monitoring: 'BP, symptomatic response',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension, reflex tachycardia',
                clinicalPearls: 'Use nitrate-free interval to avoid tolerance',
                indication: 'Chronic stable angina, heart failure symptom control in some patients'
            },
            'isosorbide-dinitrate': {
                name: 'Isosorbide dinitrate',
                class: 'Nitrate (shorter-acting)',
                mechanism: 'NO donor — venodilation and preload reduction',
                dosing: 'Typical dosing varies by formulation and indication; follow product guidance',
                contraindications: 'Concurrent PDE5 inhibitors, hypotension',
                interactions: 'PDE5 inhibitors',
                monitoring: 'BP',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension',
                clinicalPearls: 'Used less commonly than ISMN for chronic management',
                indication: 'Angina, acute heart failure symptom relief in some settings'
            },
            /* --- Additional high-yield drugs (respiratory, diabetes, antimicrobials, obstetrics, vitamin K) --- */
            'salbutamol': {
                name: 'Salbutamol (albuterol)',
                class: 'Short-acting β2-agonist (SABA)',
                mechanism: 'β2-adrenoceptor agonist causing bronchodilation',
                dosing: 'Inhaler 100mcg per puff (usual 1-2 puffs as needed); nebuliser 2.5–5mg for severe bronchospasm',
                contraindications: 'Tachyarrhythmia (relative)',
                interactions: 'β-blockers may antagonise effect; hypokalaemia risk with diuretics',
                monitoring: 'Respiratory status, HR, potassium in high-dose therapy',
                pregnancy: 'Considered safe for use in pregnancy when indicated',
                sideEffects: 'Tachycardia, tremor, hypokalaemia',
                clinicalPearls: 'First-line reliever inhaler for asthma and COPD exacerbations',
                indication: 'Relief of bronchospasm in asthma/COPD'
            },
            'ipratropium': {
                name: 'Ipratropium',
                class: 'Short-acting muscarinic antagonist (SAMA)',
                mechanism: 'Antagonises M3 receptors causing bronchodilation',
                dosing: 'Inhaler/nebuliser formulations — commonly added to salbutamol in severe exacerbations',
                contraindications: 'Hypersensitivity to atropine derivatives',
                interactions: 'Additive anticholinergic effects with other antimuscarinics',
                monitoring: 'Symptom response',
                pregnancy: 'Use if clinically needed',
                sideEffects: 'Dry mouth, blurred vision (if sprayed into eyes)',
                clinicalPearls: 'Useful adjunct in severe COPD/asthma exacerbations',
                indication: 'Bronchodilation in exacerbations, particularly COPD'
            },
            'salmeterol': {
                name: 'Salmeterol',
                class: 'Long-acting β2-agonist (LABA)',
                mechanism: 'Long-acting β2 agonist for maintenance bronchodilation',
                dosing: 'Inhaled via DPI/Breath-actuated; usually 50mcg BD (product-specific)',
                contraindications: 'Use without inhaled corticosteroid in asthma (increases risk of severe exacerbations)',
                interactions: 'β-blockers, CYP3A4 inhibitors may increase levels',
                monitoring: 'Asthma control and exacerbation frequency',
                pregnancy: 'Use with inhaled steroid as indicated',
                sideEffects: 'Tremor, palpitations',
                clinicalPearls: 'Always ensure concomitant inhaled corticosteroid for asthma',
                indication: 'Maintenance therapy for asthma/COPD'
            },
            'formoterol': {
                name: 'Formoterol',
                class: 'Long-acting β2-agonist (LABA)',
                mechanism: 'Rapid-onset LABA used for maintenance and sometimes as part of SMART regimens with budesonide',
                dosing: 'Typical dosing via inhaler; follow product labelling',
                contraindications: 'As for other LABAs — not monotherapy in asthma',
                interactions: 'β-blockers, CYP3A4 inhibitors',
                monitoring: 'Asthma control',
                pregnancy: 'Use with ICS when indicated',
                sideEffects: 'Tremor, palpitations',
                clinicalPearls: 'Used in combination inhalers and as reliever in some SMART strategies',
                indication: 'Maintenance therapy in asthma and COPD'
            },
            'budesonide-inhaled': {
                name: 'Budesonide (inhaled)',
                class: 'Inhaled corticosteroid (ICS)',
                mechanism: 'Anti-inflammatory glucocorticoid receptor agonist',
                dosing: 'Dose varies by device and indication; low-medium-high dosing tiers for asthma',
                contraindications: 'Acute severe asthma as sole therapy',
                interactions: 'Systemic corticosteroids interactions',
                monitoring: 'Clinical response, inhaler technique; consider oral candidiasis prevention',
                pregnancy: 'Preferred ICS in pregnancy when inhaled steroid is needed',
                sideEffects: 'Oral thrush (use spacer/rinse mouth), dysphonia',
                clinicalPearls: 'Mainstay of maintenance asthma therapy',
                indication: 'Maintenance anti-inflammatory therapy for asthma'
            },
            'fluticasone-inhaled': {
                name: 'Fluticasone (inhaled)',
                class: 'Inhaled corticosteroid (ICS)',
                mechanism: 'Anti-inflammatory corticosteroid',
                dosing: 'Device-specific dosing; used BD typically',
                contraindications: 'None specific',
                interactions: 'Systemic CYP3A4 inhibitors may increase systemic exposure',
                monitoring: 'Inhaler technique, thrush prevention',
                pregnancy: 'Use if indicated; discuss with obstetric team',
                sideEffects: 'Oral candidiasis, dysphonia',
                clinicalPearls: 'Often used in combination inhalers with LABA',
                indication: 'Maintenance asthma/COPD (as appropriate)'
            },
            'tiotropium': {
                name: 'Tiotropium',
                class: 'Long-acting muscarinic antagonist (LAMA)',
                mechanism: 'M3 receptor antagonist producing long-acting bronchodilation',
                dosing: 'Once-daily inhaler (18mcg via HandiHaler or 5mcg Respimat per product)',
                contraindications: 'Hypersensitivity to atropine derivatives',
                interactions: 'Additive anticholinergic effects',
                monitoring: 'Symptom response, anticholinergic side-effects',
                pregnancy: 'Use if necessary',
                sideEffects: 'Dry mouth, urinary retention, constipation',
                clinicalPearls: 'Mainstay maintenance bronchodilator in COPD and add-on in asthma',
                indication: 'COPD maintenance; some asthma indications as add-on'
            },
            'montelukast': {
                name: 'Montelukast',
                class: 'Leukotriene receptor antagonist',
                mechanism: 'Blocks CysLT1 receptors reducing leukotriene-mediated bronchoconstriction',
                dosing: '10mg daily (adults); paediatric dosing variable',
                contraindications: 'Hypersensitivity',
                interactions: 'Minimal',
                monitoring: 'Mood/behaviour changes (rare neuropsychiatric effects)',
                pregnancy: 'Use if clinically indicated',
                sideEffects: 'Rare neuropsychiatric effects, headache',
                clinicalPearls: 'Useful in aspirin-exacerbated respiratory disease and as adjunct in allergic asthma',
                indication: 'Adjunct asthma therapy, allergic rhinitis in some cases'
            },
            'empagliflozin': {
                name: 'Empagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2 in proximal renal tubule to promote glucosuria',
                dosing: '10-25mg once daily (depending on indication)',
                contraindications: 'Type 1 diabetes, active bladder cancer (caution), severe renal impairment',
                interactions: 'Diuretics (volume depletion), insulin/secretagogues (hypoglycaemia risk)',
                monitoring: 'Renal function, ketones if unwell, BP, genital infections',
                pregnancy: 'Avoid',
                sideEffects: 'Genital mycotic infections, volume depletion, rare euglycaemic DKA',
                clinicalPearls: 'Shown to reduce HF hospitalisations and renal outcomes in specific populations',
                indication: 'Type 2 diabetes; cardio-renal protective indications per guidance'
            },
            'dapagliflozin': {
                name: 'Dapagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Promotes glucosuria by inhibiting renal SGLT2',
                dosing: '10mg once daily (typical)',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                interactions: 'Diuretics (caution), insulin/secretagogues',
                monitoring: 'Renal function, signs of volume depletion and genital infections',
                pregnancy: 'Avoid',
                sideEffects: 'Genital infections, volume depletion, rare DKA',
                clinicalPearls: 'Cardiorenal benefit in selected patients',
                indication: 'Type 2 diabetes; heart failure/CKD indications per guidance'
            },
            'liraglutide': {
                name: 'Liraglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue increasing insulin secretion and reducing appetite',
                dosing: 'Titrated subcutaneously per product regimen; doses vary by indication',
                contraindications: 'Personal/family history of medullary thyroid carcinoma (MTC), MEN2',
                interactions: 'May delay gastric emptying affecting absorption of oral meds',
                monitoring: 'GI tolerance, weight, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea, vomiting, pancreatitis (rare)',
                clinicalPearls: 'Useful for weight loss and glycaemic control; specialist initiation often',
                indication: 'Type 2 diabetes; weight management in some licensed indications'
            },
            'semaglutide': {
                name: 'Semaglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue with potent glycaemic and weight loss effects',
                dosing: 'Subcutaneous or oral formulations per product; titration required',
                contraindications: 'MTC/MEN2 history',
                interactions: 'May delay absorption of oral drugs',
                monitoring: 'GI symptoms, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea, pancreatitis risk (rare)',
                clinicalPearls: 'Increasingly used for weight and glucose control; cost and access vary',
                indication: 'Type 2 diabetes; weight management in select settings'
            },
            'sitagliptin': {
                name: 'Sitagliptin',
                class: 'DPP-4 inhibitor',
                mechanism: 'Inhibits DPP-4 to increase endogenous incretins',
                dosing: '100mg once daily (adjust for renal impairment)',
                contraindications: 'Hypersensitivity',
                interactions: 'Minimal',
                monitoring: 'Renal function, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Rare pancreatitis, joint pain',
                clinicalPearls: 'Generally weight neutral and well tolerated',
                indication: 'Type 2 diabetes adjunct therapy'
            },
            'insulin-aspart': {
                name: 'Insulin aspart',
                class: 'Rapid-acting insulin analogue',
                mechanism: 'Rapid-onset insulin for prandial glucose control',
                dosing: 'Doses individualized; given at mealtimes or by pump',
                contraindications: 'Hypoglycaemia',
                interactions: 'Drugs affecting glucose levels (steroids, beta-blockers)',
                monitoring: 'Blood glucose, signs of hypoglycaemia',
                pregnancy: 'Used in pregnancy when required (insulin of choice per obstetric guidance)',
                sideEffects: 'Hypoglycaemia, weight gain',
                clinicalPearls: 'Short-acting prandial insulin used in multiple regimens',
                indication: 'Prandial insulin therapy in type 1 and type 2 diabetes as required'
            },
            'insulin-glargine': {
                name: 'Insulin glargine (long-acting analogue)',
                class: 'Basal insulin analogue',
                mechanism: 'Long-acting basal insulin providing relatively flat 24-hour coverage',
                dosing: 'Once-daily dosing at the same time each day; individualize dose (typical starting doses vary by prior therapy and weight)',
                contraindications: 'Hypoglycaemia',
                interactions: 'Drugs affecting glucose control (steroids ↑ requirements, beta-blockers may mask hypoglycaemia)',
                monitoring: 'Capillary blood glucose, HbA1c, injection sites; monitor for hypoglycaemia during dose titration',
                pregnancy: 'Use with specialist/obstetric guidance; insulin remains treatment of choice in pregnancy when required',
                sideEffects: 'Hypoglycaemia, weight gain, injection-site reactions',
                clinicalPearls: 'Common basal insulin; counsel patients on hypoglycaemia recognition and dose adjustment during intercurrent illness',
                indication: 'Basal insulin therapy in type 1 and type 2 diabetes'
            },
            'gentamicin': {
                name: 'Gentamicin',
                class: 'Aminoglycoside antibiotic',
                mechanism: 'Binds 30S ribosomal subunit causing misreading and inhibition of protein synthesis',
                dosing: 'IV dosing weight-based and indication-specific; use once-daily regimens where appropriate and monitor levels',
                contraindications: 'Myasthenia gravis (relative), hypersensitivity',
                interactions: 'Nephrotoxins (vancomycin, loop diuretics), neuromuscular blockers',
                monitoring: 'Renal function, gentamicin trough/peak levels per local protocol, hearing/vestibular symptoms',
                pregnancy: 'Use if essential with caution',
                sideEffects: 'Nephrotoxicity, ototoxicity (esp. high doses/rapid IV or coadministration with other ototoxins)',
                clinicalPearls: 'Dose and monitor levels closely; adjust for renal impairment',
                indication: 'Severe Gram-negative infections, synergistic therapy in endocarditis'
            },
            'vancomycin': {
                name: 'Vancomycin',
                class: 'Glycopeptide antibiotic',
                mechanism: 'Inhibits cell wall synthesis by binding D-Ala-D-Ala termini of peptidoglycan precursors',
                dosing: 'IV: loading and maintenance weight-based regimens per local protocol (commonly 15–20 mg/kg IV loading then 15–20 mg/kg q8–12h adjusted for renal function). Use local nomograms. Oral: 125–500 mg PO QDS for C. difficile depending on severity and guidance.',
                contraindications: 'Hypersensitivity to glycopeptides',
                interactions: 'Other nephrotoxins and ototoxins (aminoglycosides, amphotericin, loop diuretics) — increased nephro/ototoxicity risk',
                monitoring: 'Renal function and fluid balance closely; therapeutic drug monitoring (AUC-guided preferred where available; trough-based monitoring per local policy). Monitor for infusion reactions and hearing when prolonged therapy',
                pregnancy: 'Use if essential; seek specialist/obstetric advice',
                sideEffects: 'Nephrotoxicity, ototoxicity (rare), infusion-related reactions including "Red man" syndrome if infused too rapidly',
                clinicalPearls: 'Prefer AUC-guided TDM when available (reduces nephrotoxicity risk). Infuse over ≥60 minutes (longer for higher doses) to reduce infusion reactions; premedicate/slow infusion if prior reactions. Adjust dose for renal impairment and use local microbiology/ID guidance for target exposures.',
                indication: 'Serious Gram-positive infections including MRSA, endocarditis, bone and joint infections; oral vancomycin for C. difficile colitis'
            },
            /* duplicate piperacillin-tazobactam removed (consolidated earlier) */
            'co-amoxiclav': {
                name: 'Co-amoxiclav (amoxicillin + clavulanic acid)',
                class: 'Aminopenicillin + β-lactamase inhibitor',
                mechanism: 'Inhibits cell wall synthesis with β-lactamase protection',
                dosing: 'Oral/IV formulations; adjust for severity and renal impairment',
                contraindications: 'History of cholestatic jaundice/hepatic dysfunction with prior co-amoxiclav',
                interactions: 'May affect oral contraceptives efficacy (rare)',
                monitoring: 'LFTs if prolonged therapy',
                pregnancy: 'Generally considered safe',
                sideEffects: 'Diarrhoea, hypersensitivity, cholestatic hepatitis (rare)',
                clinicalPearls: 'Common community/hospital antibiotic for mixed infections',
                indication: 'Respiratory, ENT, skin/soft tissue, intra-abdominal infections as indicated'
            },
            'ceftriaxone': {
                name: 'Ceftriaxone',
                class: 'Third-generation cephalosporin',
                mechanism: 'Inhibits bacterial cell wall synthesis',
                dosing: 'IV dosing once daily commonly; adjust in severe hepatic dysfunction',
                contraindications: 'Neonates with hyperbilirubinaemia (risk), calcium-containing IV products concurrently in neonates',
                interactions: 'May displace bilirubin in neonates',
                monitoring: 'LFTs if prolonged therapy',
                pregnancy: 'Use if necessary',
                sideEffects: 'Allergic reactions, diarrhoea',
                clinicalPearls: 'Useful for many severe community-acquired infections including meningitis (higher doses)',
                indication: 'Severe community infections, meningitis, gonorrhoea (depending on guidance)'
            },
            'ciprofloxacin': {
                name: 'Ciprofloxacin',
                class: 'Fluoroquinolone antibiotic',
                mechanism: 'Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication',
                dosing: 'Typical: 500 mg BD (UTI 250–500 mg BD 3 days; pyelonephritis 500 mg BD 7 days). Adjust in renal impairment.',
                contraindications: 'Pregnancy, breastfeeding, children (<18 years – arthropathy risk), previous quinolone tendon injury',
                interactions: 'Warfarin (↑ INR), theophylline (↑ toxicity), antacids / iron (↓ absorption), QT-prolonging agents',
                monitoring: 'Tendon pain, CNS effects, QT interval, renal function',
                pregnancy: 'Contraindicated',
                sideEffects: 'Tendon rupture, neuropathy, QT prolongation, hypoglycaemia, CNS effects, aortic aneurysm risk (MHRA 2024)',
                pharmacokinetics: 'Oral ≈ 70 % bioavailable; renal ± hepatic excretion; t½ ≈ 4 h',
                clinicalPearls: 'Reserve for resistant infections; avoid in patients with history of tendon disorders or aortic aneurysm. Discontinue immediately if tendon pain, neuropathy, or mental disturbance.',
                indication: 'Complicated UTI, severe GI/respiratory infections, Pseudomonal infections (per microbiology advice)'
            },
            'oxytocin': {
                name: 'Oxytocin',
                class: 'Uterotonic (peptide hormone)',
                mechanism: 'Stimulates uterine smooth muscle contraction',
                dosing: 'IV infusion or IM bolus as per obstetric protocols for labour augmentation or postpartum haemorrhage',
                contraindications: 'Active genital herpes, previous classical caesarean section (relative for induction)',
                interactions: 'Other uterotonics (additive effect)',
                monitoring: 'Maternal vitals, uterine tone, fetal monitoring in labour',
                pregnancy: 'Used in labour and postpartum as indicated',
                sideEffects: 'Tachysystole, hypotension with rapid IV bolus, water retention',
                clinicalPearls: 'Primary uterotonic for prevention and treatment of postpartum haemorrhage',
                indication: 'Induction/augmentation of labour; prevention/treatment of postpartum haemorrhage'
            },
            'ergometrine': {
                name: 'Ergometrine (ergonovine)',
                class: 'Ergot alkaloid uterotonic',
                mechanism: 'Stimulates uterine smooth muscle causing sustained contraction',
                dosing: 'IM/IV bolus for postpartum haemorrhage as per protocol; IV should be given slowly with monitoring',
                contraindications: 'Hypertension, pre-eclampsia, cardiac disease, sepsis, pregnancy for labour augmentation',
                interactions: 'Other vasoconstrictors, macrolides (may increase levels)',
                monitoring: 'BP, uterine tone, signs of ischemia',
                pregnancy: 'Used postpartum for PPH; contraindicated for induction of labour in hypertensive disease',
                sideEffects: 'Hypertension, coronary vasospasm (rare), nausea',
                clinicalPearls: 'Use with caution in cardiac disease; often second-line or adjunct to oxytocin',
                indication: 'Management of postpartum haemorrhage'
            },
            'misoprostol': {
                name: 'Misoprostol',
                class: 'Prostaglandin E1 analogue (uterotonic)',
                mechanism: 'Causes uterine contractions and cervical ripening',
                dosing: 'Vaginal/oral/rectal/PO forms used in obstetrics per protocol; doses depend on indication',
                contraindications: 'Previous uterine surgery with caution, hypersensitivity',
                interactions: 'Other uterotonics (additive)',
                monitoring: 'Uterine activity, maternal vitals',
                pregnancy: 'Used in obstetrics as indicated (often for PPH or induction depending on protocol)',
                sideEffects: 'Fever, diarrhoea, uterine hyperstimulation',
                clinicalPearls: 'Widely used in global obstetric protocols; dosing and route vary by setting',
                indication: 'Prevention/treatment of PPH, induction of labour in select contexts'
            },
            'vitamin-k': {
                name: 'Vitamin K (phytonadione)',
                class: 'Fat-soluble vitamin / antidote',
                mechanism: 'Required for γ-carboxylation of clotting factors II, VII, IX and X',
                dosing: 'IV/IM/SC/PO dosing varies by indication; IV should be given slowly to reduce anaphylactoid risk',
                contraindications: 'Hypersensitivity to phytonadione or excipients',
                interactions: 'Warfarin (antagonises effect)',
                monitoring: 'INR for reversal of warfarin anticoagulation',
                pregnancy: 'Use when indicated (neonatal prophylaxis given IM at birth in many systems)',
                sideEffects: 'Rare hypersensitivity with IV administration',
                clinicalPearls: 'Essential antidote for warfarin over-anticoagulation; route/dose depend on urgency',
                indication: 'Reversal of vitamin K antagonist (warfarin) effects, neonatal prophylaxis'
            },
            /* --- More high-yield drugs (reversal agents, antifungals, PPIs, laxatives, psychotropics, etc.) --- */
            'naloxone': {
                name: 'Naloxone',
                class: 'Opioid antagonist',
                mechanism: 'Competitive opioid receptor antagonist (μ-opioid receptors)',
                dosing: 'IV/IM/SC 0.4-2 mg bolus (titrate to effect) or intranasal 400mcg-2mg depending on formulation; may require infusion for long-acting opioids',
                contraindications: 'None absolute in opioid overdose',
                interactions: 'Precipitates withdrawal in opioid-dependent patients',
                monitoring: 'Respiratory rate, consciousness, recurrence of respiratory depression',
                pregnancy: 'Use when maternal respiratory depression due to opioids occurs',
                sideEffects: 'Acute withdrawal, agitation, vomiting',
                clinicalPearls: 'Short-acting—monitor for re-sedation after effect wears off',
                indication: 'Opioid overdose reversal'
            },
            'flumazenil': {
                name: 'Flumazenil',
                class: 'Benzodiazepine antagonist',
                mechanism: 'Competitive antagonist at benzodiazepine binding site on GABA-A receptor',
                dosing: 'IV bolus 0.2mg, repeat to max 1-3mg per local protocol',
                contraindications: 'Chronic benzodiazepine dependence, mixed overdose with proconvulsant agents or TCA overdose',
                interactions: 'May precipitate seizures in chronic benzodiazepine users',
                monitoring: 'Conscious level, seizure activity',
                pregnancy: 'Use only if benefits outweigh risks',
                sideEffects: 'Seizures (rare), agitation',
                clinicalPearls: 'Use cautiously; only where benzo reversal indicated and risk of seizures low',
                indication: 'Reversal of benzodiazepine sedation/overdose in selected patients'
            },
            'idarucizumab': {
                name: 'Idarucizumab',
                class: 'Dabigatran reversal agent (monoclonal antibody fragment)',
                mechanism: 'Binds dabigatran and neutralises its anticoagulant effect',
                dosing: '5 g IV (administer as two consecutive 2.5 g boluses) as per SmPC for urgent reversal of dabigatran',
                contraindications: 'Hypersensitivity to idarucizumab or excipients',
                interactions: 'No clinically significant drug interactions documented',
                monitoring: 'Clinical haemostasis and bleeding; coagulation tests may include thrombin time (TT) or diluted thrombin time to document effect where available; monitor renal function',
                pregnancy: 'Use only if clearly indicated and after specialist assessment',
                sideEffects: 'Headache, hypokalaemia, fever, constipation (generally well tolerated)',
                clinicalPearls: 'Reserved for emergency reversal of dabigatran in life‑threatening bleeding or urgent procedures. Contact haematology and follow local major haemorrhage protocols. Re-dosing is rarely required; consider dabigatran plasma level testing if available.',
                indication: 'Rapid reversal of dabigatran anticoagulation'
            },
            'prothrombin-concentrate': {
                name: 'Prothrombin complex concentrate (PCC)',
                class: 'Coagulation factor concentrate',
                mechanism: 'Contains factors II, VII, IX, X (and variable protein C/S) to rapidly reverse vitamin K antagonists',
                dosing: 'Dose based on INR and weight per local guideline',
                contraindications: 'Known allergy to product components',
                interactions: 'None specific',
                monitoring: 'INR, haemostasis',
                pregnancy: 'Specialist use only',
                sideEffects: 'Thrombosis risk',
                clinicalPearls: 'Used for rapid reversal of warfarin in major bleeding or emergency surgery',
                indication: 'Rapid warfarin reversal'
            },
            'n-acetylcysteine': {
                name: 'N-acetylcysteine (NAC)',
                class: 'Antidote / mucolytic',
                mechanism: 'Replenishes glutathione to detoxify NAPQI in paracetamol overdose',
                dosing: 'IV protocols vary (e.g., 150mg/kg over 1h, then 50mg/kg over 4h, then 100mg/kg over 16h) or oral 72h regimen',
                contraindications: 'Hypersensitivity to components',
                interactions: 'None significant',
                monitoring: 'LFTs, clinical status, anaphylactoid reactions during IV infusion',
                pregnancy: 'Use when indicated',
                sideEffects: 'Anaphylactoid reactions with rapid IV infusion',
                clinicalPearls: 'Start empirically if uncertain timing for paracetamol overdose and NAC is available',
                indication: 'Paracetamol overdose'
            },
            'fluconazole': {
                // Note: fluconazole was updated earlier; include another antifungal entry for broader coverage
                name: 'Fluconazole (antifungal)',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal ergosterol synthesis via 14α-demethylase inhibition',
                dosing: 'Oral/IV dosing varies by indication (e.g., single 150mg dose for vaginal candidiasis)',
                contraindications: 'Known QT prolongation, significant hepatic impairment',
                interactions: 'Many CYP-mediated interactions (CYP3A4, CYP2C9)',
                monitoring: 'LFTs for prolonged therapy',
                pregnancy: 'Avoid high/prolonged doses in pregnancy; single 150mg dose for thrush is unlikely to increase risk',
                sideEffects: 'Nausea, headache, hepatotoxicity (rare)',
                clinicalPearls: 'Consider local guidance for systemic vs topical therapy',
                indication: 'Candidiasis and other systemic fungal infections as indicated'
            },
            'amphotericin-b': {
                name: 'Amphotericin B',
                class: 'Polyenes (antifungal)',
                mechanism: 'Binds ergosterol and disrupts fungal cell membranes',
                dosing: 'IV formulations vary; lipid formulations reduce nephrotoxicity',
                contraindications: 'Hypersensitivity to amphotericin',
                interactions: 'Nephrotoxins increase toxicity risk',
                monitoring: 'Renal function, electrolytes (K+, Mg2+), infusion reactions',
                pregnancy: 'Use if necessary',
                sideEffects: 'Nephrotoxicity, infusion-related fevers, electrolyte disturbances',
                clinicalPearls: 'Reserved for serious systemic fungal infections',
                indication: 'Serious systemic fungal infections'
            },
            'omeprazole': {
                name: 'Omeprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Inhibits H+/K+ ATPase in gastric parietal cells',
                dosing: '20-40mg once daily depending on indication',
                contraindications: 'Hypersensitivity',
                interactions: 'Clopidogrel activation may be reduced (CYP2C19 interaction for some PPIs)',
                monitoring: 'Symptom response, magnesium with long-term use',
                pregnancy: 'Use if clinically indicated',
                sideEffects: 'Headache, GI upset, long-term risk: B12 deficiency, hypomagnesaemia',
                clinicalPearls: 'Use for stress ulcer prophylaxis in selected critically ill patients',
                indication: 'GORD, peptic ulcer disease, PPI prophylaxis'
            },
            'lansoprazole': {
                name: 'Lansoprazole',
                class: 'Proton pump inhibitor (PPI)',
                mechanism: 'Inhibits gastric H+/K+ ATPase',
                dosing: '15-30mg once daily',
                contraindications: 'Hypersensitivity',
                interactions: 'Potential CYP interactions',
                monitoring: 'Symptom response',
                pregnancy: 'Use if necessary',
                sideEffects: 'GI upset, headache',
                clinicalPearls: 'Alternative PPI option',
                indication: 'GORD, ulcer disease'
            },
            'senna': {
                name: 'Senna',
                class: 'Stimulant laxative',
                mechanism: 'Increases colonic motility via mucosal irritation and fluid secretion',
                dosing: '7.5-15mg at night (adults), follow local dosing',
                contraindications: 'Obstructive bowel disease, acute surgical abdomen',
                interactions: 'None significant',
                monitoring: 'Electrolytes with prolonged use',
                pregnancy: 'Use with caution',
                sideEffects: 'Abdominal cramp, diarrhoea',
                clinicalPearls: 'Useful for opioid-induced constipation when combined with laxative regimens',
                indication: 'Constipation'
            },
            'lactulose': {
                name: 'Lactulose',
                class: 'Osmotic laxative',
                mechanism: 'Increases colonic osmotic load and softens stool',
                dosing: '15-30ml daily titrated to effect',
                contraindications: 'Galactosaemia (some formulations)',
                interactions: 'None clinically significant',
                monitoring: 'Electrolytes if used long-term',
                pregnancy: 'Considered safe when needed',
                sideEffects: 'Flatulence, bloating',
                clinicalPearls: 'Also used to reduce ammonia absorption in hepatic encephalopathy',
                indication: 'Constipation, hepatic encephalopathy'
            },
            'sertraline': {
                name: 'Sertraline',
                class: 'Selective serotonin reuptake inhibitor (SSRI)',
                mechanism: 'Inhibits serotonin reuptake increasing synaptic serotonin',
                dosing: '50mg daily (start low and titrate)',
                contraindications: 'Concomitant MAOI use, acute mania',
                interactions: 'Other serotonergic drugs (risk serotonin syndrome), anticoagulants (↑ bleeding)',
                monitoring: 'Mood, suicidality (esp. initiation), hyponatraemia in elderly',
                pregnancy: 'Assess risks/benefits with obstetrics',
                sideEffects: 'Nausea, sexual dysfunction, insomnia',
                clinicalPearls: 'Common first-line antidepressant',
                indication: 'Depression, anxiety disorders, OCD'
            },
            'mirtazapine': {
                name: 'Mirtazapine',
                class: 'Noradrenergic and specific serotonergic antidepressant (NaSSA)',
                mechanism: 'Antagonises central α2-adrenergic and certain 5-HT receptors',
                dosing: '15-45mg at night',
                contraindications: 'Concurrent MAOI use',
                interactions: 'Other serotonergic agents',
                monitoring: 'Mood and weight (appetite increases)',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Sedation, increased appetite, weight gain',
                clinicalPearls: 'Useful when insomnia and poor appetite are comorbid',
                indication: 'Depression (second-line/alternative)'
            },
            'haloperidol': {
                name: 'Haloperidol',
                class: 'Typical antipsychotic',
                mechanism: 'D2 receptor antagonist',
                dosing: 'Oral/IM formulations; acute agitation IM dosing varies (e.g., 2.5-10mg)',
                contraindications: 'Parkinson disease, severe CNS depression',
                interactions: 'QT-prolonging drugs, other sedatives',
                monitoring: 'EPS, QT interval if IV/rapid dosing, sedation',
                pregnancy: 'Use only if necessary',
                sideEffects: 'Extrapyramidal symptoms, QT prolongation, sedation',
                clinicalPearls: 'Effective for acute psychosis and agitation; use lowest effective dose',
                indication: 'Acute psychosis, agitation'
            },
            /* --- Batch added: Cardiovascular, Endocrine, Respiratory, ID, GI, Neuro/Psych, Analgesia, Obstetrics, Haem/Onc --- */
            /* Cardiovascular */
            'prasugrel': {
                name: 'Prasugrel',
                class: 'P2Y12 inhibitor (antiplatelet)',
                mechanism: 'Irreversible P2Y12 receptor blockade',
                dosing: 'Loading 60mg then 10mg daily (consider 5mg for elderly/low body weight per local guidance)',
                contraindications: 'History of stroke/TIA, active bleeding',
                interactions: 'Other antithrombotics (↑ bleeding)',
                monitoring: 'Signs of bleeding, FBC',
                pregnancy: 'Specialist decision',
                sideEffects: 'Bleeding, bruising',
                clinicalPearls: 'Avoid in prior stroke/TIA; used in ACS/PCI per cardiology guidance',
                indication: 'ACS with PCI'
            },
            'fondaparinux': {
                name: 'Fondaparinux',
                class: 'Indirect factor Xa inhibitor (synthetic pentasaccharide)',
                mechanism: 'Enhances antithrombin action against factor Xa',
                dosing: 'Weight-dependent dosing for VTE prophylaxis/treatment; see local guideline',
                contraindications: 'Severe renal impairment (CrCl <30 mL/min), active bleeding',
                interactions: 'Other anticoagulants (↑ bleeding risk)',
                monitoring: 'Renal function, bleeding signs',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Bleeding',
                clinicalPearls: 'Once-daily subcutaneous injection; check weight-based dosing',
                indication: 'VTE prophylaxis/treatment'
            },
            'edoxaban': {
                name: 'Edoxaban',
                class: 'DOAC - factor Xa inhibitor',
                mechanism: 'Direct inhibition of factor Xa',
                dosing: 'AF: 60mg once daily (reduce to 30mg with renal impairment, low body weight or P-gp inhibitors)',
                contraindications: 'Active bleeding, mechanical heart valves',
                interactions: 'P-gp inhibitors/inducers, other anticoagulants',
                monitoring: 'Renal function, bleeding',
                pregnancy: 'Avoid',
                sideEffects: 'Bleeding, anaemia',
                clinicalPearls: 'Dose adjustments required per SmPC',
                indication: 'AF stroke prevention, VTE'
            },
            'dabigatran': {
                name: 'Dabigatran',
                class: 'DOAC - direct thrombin inhibitor',
                mechanism: 'Direct inhibition of thrombin (factor IIa)',
                dosing: 'AF: 150mg BD (110mg BD for selected patients/renal impairment); VTE dosing per guideline',
                contraindications: 'Active bleeding, mechanical heart valves, severe renal impairment',
                interactions: 'P-gp modulators',
                monitoring: 'Renal function; idarucizumab is specific antidote',
                pregnancy: 'Avoid',
                sideEffects: 'Bleeding, dyspepsia',
                clinicalPearls: 'Observe renal dosing and adherence',
                indication: 'AF, VTE'
            },
            'eplerenone': {
                name: 'Eplerenone',
                class: 'Mineralocorticoid receptor antagonist (MRA)',
                mechanism: 'Selective aldosterone receptor antagonist',
                dosing: '25mg daily, titrate to 50mg as tolerated in heart failure',
                contraindications: 'Hyperkalaemia, severe renal impairment',
                interactions: 'ACEi/ARBs, potassium supplements (↑ hyperkalaemia risk), CYP3A4 inhibitors',
                monitoring: 'U&Es after initiation and dose changes',
                pregnancy: 'Avoid',
                sideEffects: 'Hyperkalaemia',
                clinicalPearls: 'Alternative to spironolactone with fewer endocrine side effects',
                indication: 'Heart failure with reduced EF'
            },
            'valsartan': {
                name: 'Valsartan',
                class: 'ARB',
                mechanism: 'Selective antagonist at AT1 receptor',
                dosing: '80-160mg daily',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements',
                monitoring: 'eGFR and potassium',
                pregnancy: 'Contraindicated',
                sideEffects: 'Dizziness, hyperkalaemia',
                clinicalPearls: 'Alternative to ACEi for cough intolerance',
                indication: 'Hypertension, HF'
            },
            'irbesartan': {
                name: 'Irbesartan',
                class: 'ARB',
                mechanism: 'AT1 receptor antagonist',
                dosing: '150-300mg daily',
                contraindications: 'Pregnancy',
                interactions: 'NSAIDs, lithium',
                monitoring: 'eGFR, K+',
                pregnancy: 'Contraindicated',
                sideEffects: 'Hyperkalaemia, hypotension',
                clinicalPearls: 'Used in HTN and diabetic nephropathy',
                indication: 'Hypertension, CKD'
            },
            'perindopril': {
                name: 'Perindopril',
                class: 'ACE inhibitor',
                mechanism: 'Inhibits ACE',
                dosing: 'Start 2-4mg daily and titrate',
                contraindications: 'Pregnancy, bilateral renal artery stenosis',
                interactions: 'NSAIDs, potassium supplements',
                monitoring: 'Renal function, potassium',
                pregnancy: 'Contraindicated',
                sideEffects: 'Cough, hyperkalaemia',
                clinicalPearls: 'Commonly used ACE inhibitor',
                indication: 'HTN, HF'
            },
            'isosorbide-mononitrate': {
                name: 'Isosorbide mononitrate',
                class: 'Nitrate',
                mechanism: 'NO donor causing venodilation',
                dosing: '20-60mg daily depending on formulation',
                contraindications: 'Concurrent PDE5 inhibitors, hypotension',
                interactions: 'PDE5 inhibitors',
                monitoring: 'BP',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension',
                clinicalPearls: 'Avoid tolerance with nitrate-free interval',
                indication: 'Angina'
            },
            'isosorbide-dinitrate': {
                name: 'Isosorbide dinitrate',
                class: 'Nitrate',
                mechanism: 'NO donor',
                dosing: 'Variable by formulation',
                contraindications: 'PDE5 inhibitors',
                interactions: 'PDE5 inhibitors',
                monitoring: 'BP',
                pregnancy: 'Use if essential',
                sideEffects: 'Headache, hypotension',
                clinicalPearls: 'Shorter acting than ISMN',
                indication: 'Angina'
            },
            /* End cardiovascular */

            /* Endocrine / Diabetes */
            'dapagliflozin': {
                name: 'Dapagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2 causing glucosuria',
                dosing: '10mg once daily',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                interactions: 'Diuretics (volume depletion), insulin (hypoglycaemia risk)',
                monitoring: 'Renal function, ketones if unwell',
                pregnancy: 'Avoid',
                sideEffects: 'Genital mycotic infections, volume depletion, DKA (rare)',
                clinicalPearls: 'Cardio-renal benefit in selected patients',
                indication: 'T2DM, HF/CKD indications per guidance'
            },
            'canagliflozin': {
                name: 'Canagliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2',
                dosing: '100-300mg daily',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                interactions: 'Diuretics',
                monitoring: 'Renal function, foot checks (amputation signal in some studies)',
                pregnancy: 'Avoid',
                sideEffects: 'Genital infections, volume depletion, rare DKA',
                clinicalPearls: 'Watch for foot infections/amputation signal in older studies',
                indication: 'T2DM'
            },
            'ertugliflozin': {
                name: 'Ertugliflozin',
                class: 'SGLT2 inhibitor',
                mechanism: 'Inhibits SGLT2',
                dosing: '5-15mg once daily',
                contraindications: 'Type 1 diabetes, severe renal impairment',
                monitoring: 'Renal function',
                pregnancy: 'Avoid',
                sideEffects: 'Genital infections',
                clinicalPearls: 'One of the SGLT2 class; follow SmPC for indications',
                indication: 'T2DM'
            },
            'semaglutide': {
                name: 'Semaglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue',
                dosing: 'Subcutaneous or oral titration per product',
                contraindications: 'MTC/MEN2 history',
                monitoring: 'GI tolerance, glycaemic control',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea, pancreatitis (rare)',
                clinicalPearls: 'Powerful weight and glycaemic effects; specialist initiation often',
                indication: 'T2DM, weight management in specific settings'
            },
            'liraglutide': {
                name: 'Liraglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue',
                dosing: 'Titrated SC per product',
                contraindications: 'MTC/MEN2',
                monitoring: 'GI tolerance',
                pregnancy: 'Avoid',
                sideEffects: 'Nausea',
                clinicalPearls: 'Used for glycaemic control and weight management',
                indication: 'T2DM'
            },
            'dulaglutide': {
                name: 'Dulaglutide',
                class: 'GLP-1 receptor agonist',
                mechanism: 'GLP-1 analogue',
                dosing: 'Once-weekly SC per product',
                contraindications: 'MTC/MEN2',
                monitoring: 'GI tolerance',
                sideEffects: 'Nausea',
                clinicalPearls: 'Once-weekly option',
                indication: 'T2DM'
            },
            'linagliptin': {
                name: 'Linagliptin',
                class: 'DPP-4 inhibitor',
                mechanism: 'Inhibits DPP-4 increasing incretins',
                dosing: '5mg once daily',
                contraindications: 'Hypersensitivity',
                monitoring: 'Renal function (dose adjustment not required for many patients)',
                pregnancy: 'Avoid',
                sideEffects: 'Pancreatitis (rare)',
                clinicalPearls: 'No dose adjustment usually required in renal impairment',
                indication: 'T2DM'
            },
            'saxagliptin': {
                name: 'Saxagliptin',
                class: 'DPP-4 inhibitor',
                mechanism: 'Inhibits DPP-4',
                dosing: '5mg once daily (adjust for renal impairment)',
                contraindications: 'Hypersensitivity',
                monitoring: 'Renal function',
                pregnancy: 'Avoid',
                sideEffects: 'Pancreatitis (rare)',
                clinicalPearls: 'Well-tolerated, weight neutral',
                indication: 'T2DM'
            },
            'insulin-degludec': {
                name: 'Insulin degludec',
                class: 'Ultra-long acting insulin analogue',
                mechanism: 'Basal insulin replacement with very long duration',
                dosing: 'Once daily individualized dosing',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG, HbA1c',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Very long-acting basal insulin',
                indication: 'Basal insulin therapy'
            },
            'insulin-detemir': {
                name: 'Insulin detemir',
                class: 'Long-acting insulin analogue',
                mechanism: 'Basal insulin',
                dosing: 'Once or twice daily individualized dosing',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Basal insulin option',
                indication: 'Basal insulin therapy'
            },
            /* duplicate insulin-glargine removed - consolidated to canonical entry earlier */
            'insulin-aspart': {
                name: 'Insulin aspart',
                class: 'Rapid-acting insulin analogue',
                mechanism: 'Prandial insulin',
                dosing: 'Individualized at mealtimes',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG',
                pregnancy: 'Used in pregnancy when required',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Prandial insulin option',
                indication: 'Prandial insulin'
            },
            'insulin-lispro': {
                name: 'Insulin lispro',
                class: 'Rapid-acting insulin analogue',
                mechanism: 'Prandial insulin',
                dosing: 'Individualized',
                contraindications: 'Hypoglycaemia',
                monitoring: 'BG',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Hypoglycaemia',
                clinicalPearls: 'Rapid onset prandial insulin',
                indication: 'Prandial insulin'
            },
            'propylthiouracil': {
                name: 'Propylthiouracil (PTU)',
                class: 'Antithyroid drug',
                mechanism: 'Inhibits thyroid peroxidase and peripheral conversion of T4 to T3',
                dosing: 'Thyroid storm: high-dose per endocrinology guidance; regular dosing individualized',
                contraindications: 'Severe liver disease',
                interactions: 'Other hepatotoxic drugs',
                monitoring: 'LFTs, FBC',
                pregnancy: 'Preferred in first trimester as alternative to carbimazole in some cases; specialist advice',
                sideEffects: 'Hepatotoxicity, agranulocytosis (rare)',
                clinicalPearls: 'Use specialist guidance for thyroid storm and pregnancy',
                indication: 'Hyperthyroidism, thyroid storm'
            },
            /* End endocrine */

            /* Respiratory */
            'fluticasone': {
                name: 'Fluticasone (inhaled)',
                class: 'Inhaled corticosteroid',
                mechanism: 'Anti-inflammatory corticosteroid',
                dosing: 'Device-specific dosing; typically BD',
                contraindications: 'Hypersensitivity',
                monitoring: 'Inhaler technique, oral thrush',
                pregnancy: 'Use with ICS as indicated',
                sideEffects: 'Oral candidiasis, dysphonia',
                clinicalPearls: 'Often combined with LABA',
                indication: 'Asthma maintenance'
            },
            'mometasone': {
                name: 'Mometasone (inhaled)',
                class: 'Inhaled corticosteroid',
                mechanism: 'Anti-inflammatory',
                dosing: 'Device-specific',
                contraindications: 'Hypersensitivity',
                monitoring: 'Inhaler technique',
                pregnancy: 'Use if needed',
                sideEffects: 'Oral thrush',
                clinicalPearls: 'Once-daily options exist',
                indication: 'Asthma'
            },
            'budesonide-formoterol': {
                name: 'Budesonide/formoterol',
                class: 'ICS/LABA combination',
                mechanism: 'Anti-inflammatory + bronchodilator',
                dosing: 'Device-specific; follow product guidance',
                contraindications: 'See individual components',
                monitoring: 'Asthma control',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'As for components',
                clinicalPearls: 'Used in maintenance and SMART regimens',
                indication: 'Asthma maintenance; COPD in select cases'
            },
            'fluticasone-salmeterol': {
                name: 'Fluticasone/salmeterol',
                class: 'ICS/LABA combination',
                mechanism: 'Anti-inflammatory + bronchodilator',
                dosing: 'Device-specific',
                contraindications: 'See components',
                monitoring: 'Asthma control',
                pregnancy: 'Use if needed',
                sideEffects: 'As for components',
                clinicalPearls: 'Common combination inhaler',
                indication: 'Asthma, COPD (as appropriate)'
            },
            'montelukast': {
                name: 'Montelukast',
                class: 'Leukotriene receptor antagonist',
                mechanism: 'Blocks CysLT1 receptor',
                dosing: '10mg daily (adults)',
                contraindications: 'Hypersensitivity',
                monitoring: 'Mood/behaviour changes',
                pregnancy: 'Use if needed',
                sideEffects: 'Rare neuropsychiatric effects',
                clinicalPearls: 'Useful in aspirin-exacerbated respiratory disease',
                indication: 'Adjunct asthma therapy'
            },
            /* End respiratory */

            /* Infectious Diseases */
            'rifampicin': {
                name: 'Rifampicin',
                class: 'Rifamycin antibiotic',
                mechanism: 'Inhibits DNA-dependent RNA polymerase',
                dosing: '600mg daily in TB regimens (adult)',
                contraindications: 'Severe hepatic impairment',
                interactions: 'Potent CYP inducer (many drug interactions)',
                monitoring: 'LFTs, drug interactions',
                pregnancy: 'Use if benefits outweigh risks',
                sideEffects: 'Hepatotoxicity, orange discoloration of bodily fluids',
                clinicalPearls: 'Powerful CYP inducer — review all meds',
                indication: 'TB (part of multi-drug regimens)'
            },
            'isoniazid': {
                name: 'Isoniazid',
                class: 'Antitubercular',
                mechanism: 'Inhibits mycolic acid synthesis',
                dosing: '300mg daily (adult) in TB regimens',
                contraindications: 'Acute liver disease',
                interactions: 'Inhibits CYP enzymes (some interactions)',
                monitoring: 'LFTs, pyridoxine supplementation (B6) to reduce neuropathy',
                pregnancy: 'Use if indicated with pyridoxine',
                sideEffects: 'Hepatotoxicity, peripheral neuropathy',
                clinicalPearls: 'Give pyridoxine to prevent neuropathy',
                indication: 'TB'
            },
            'pyrazinamide': {
                name: 'Pyrazinamide',
                class: 'Antitubercular',
                mechanism: 'Prodrug active in acidic environments',
                dosing: 'Weight-based dosing per TB regimen',
                contraindications: 'Severe liver disease, acute gout',
                interactions: 'May ↑ uric acid',
                monitoring: 'LFTs, uric acid',
                pregnancy: 'Use per specialist guidance',
                sideEffects: 'Hepatotoxicity, hyperuricaemia',
                clinicalPearls: 'Part of standard TB regimen',
                indication: 'TB'
            },
            'ethambutol': {
                name: 'Ethambutol',
                class: 'Antitubercular',
                mechanism: 'Inhibits arabinosyl transferase (cell wall synthesis)',
                dosing: 'Weight-based dosing per TB regimen',
                contraindications: 'Children unable to report vision changes',
                interactions: 'None major',
                monitoring: 'Visual acuity and colour vision',
                pregnancy: 'Use if necessary',
                sideEffects: 'Optic neuropathy (dose-related)',
                clinicalPearls: 'Monitor vision regularly',
                indication: 'TB'
            },
            'oseltamivir': {
                name: 'Oseltamivir',
                class: 'Neuraminidase inhibitor',
                mechanism: 'Inhibits influenza neuraminidase',
                dosing: '75mg BD for 5 days (treatment) or 75mg once daily for prophylaxis',
                contraindications: 'Hypersensitivity',
                interactions: 'None major',
                monitoring: 'Clinical response',
                pregnancy: 'Use if clinical need',
                sideEffects: 'Nausea, vomiting',
                clinicalPearls: 'Start within 48h of symptom onset for greatest benefit',
                indication: 'Influenza treatment/prophylaxis'
            },
            'chloramphenicol': {
                name: 'Chloramphenicol',
                class: 'Broad-spectrum antibiotic',
                mechanism: 'Inhibits 50S ribosomal subunit',
                dosing: 'Topical ophthalmic or systemic dosing varies — systemic use limited by toxicity',
                contraindications: 'Aplastic anaemia history',
                interactions: 'Bone marrow suppressing drugs',
                monitoring: 'FBC for aplastic anaemia with systemic use',
                pregnancy: 'Use with caution; topical ophthalmic use common',
                sideEffects: 'Bone marrow suppression, aplastic anaemia (rare)',
                clinicalPearls: 'Topical ophthalmic use for conjunctivitis; systemic use limited due to toxicity',
                indication: 'Ophthalmic infections, selected systemic infections'
            },
            'fosfomycin': {
                name: 'Fosfomycin',
                class: 'Cell wall synthesis inhibitor (phosphonic acid derivative)',
                mechanism: 'Inhibits early stage peptidoglycan synthesis',
                dosing: 'Single-dose oral 3g sachet for uncomplicated UTI (women)',
                contraindications: 'Hypersensitivity',
                interactions: 'None major',
                monitoring: 'Clinical response',
                pregnancy: 'Use if needed',
                sideEffects: 'GI upset, headache',
                clinicalPearls: 'Useful for resistant UTI pathogens where appropriate',
                indication: 'Uncomplicated UTI'
            },
            'voriconazole': {
                name: 'Voriconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal 14α-demethylase',
                dosing: 'Weight and route dependent; IV/PO dosing per SmPC',
                contraindications: 'Concurrent terfenadine, astemizole, cisapride',
                interactions: 'Extensive CYP interactions',
                monitoring: 'LFTs, visual disturbances, drug levels in prolonged therapy',
                pregnancy: 'Avoid unless necessary',
                sideEffects: 'Visual disturbance, hepatotoxicity, photosensitivity',
                clinicalPearls: 'First-line for invasive aspergillosis in many settings',
                indication: 'Serious invasive fungal infections'
            },
            'posaconazole': {
                name: 'Posaconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits ergosterol synthesis',
                dosing: 'Oral/IV formulation dosing per product',
                contraindications: 'Contraindicated with certain medications',
                interactions: 'CYP3A4 interactions',
                monitoring: 'LFTs, drug levels',
                pregnancy: 'Avoid unless necessary',
                sideEffects: 'GI upset, hepatotoxicity',
                clinicalPearls: 'Used for prophylaxis in neutropenic patients and resistant infections',
                indication: 'Invasive fungal infections'
            },
            'caspofungin': {
                name: 'Caspofungin',
                class: 'Echinocandin antifungal',
                mechanism: 'Inhibits β-(1,3)-D-glucan synthesis in fungal cell wall',
                dosing: 'IV dosing per product',
                contraindications: 'Hypersensitivity',
                interactions: 'Cyclosporin may ↑ levels',
                monitoring: 'LFTs',
                pregnancy: 'Use if necessary',
                sideEffects: 'Infusion reactions, hepatotoxicity',
                clinicalPearls: 'Useful for invasive Candida and salvage therapy',
                indication: 'Invasive fungal infections'
            },
            'anidulafungin': {
                name: 'Anidulafungin',
                class: 'Echinocandin antifungal',
                mechanism: 'Inhibits β-(1,3)-D-glucan synthesis',
                dosing: 'IV per product',
                contraindications: 'Hypersensitivity',
                monitoring: 'LFTs',
                pregnancy: 'Use if necessary',
                sideEffects: 'Infusion reactions',
                clinicalPearls: 'Another echinocandin option for invasive fungal infections',
                indication: 'Invasive Candida'
            },
            'itraconazole': {
                name: 'Itraconazole',
                class: 'Triazole antifungal',
                mechanism: 'Inhibits fungal ergosterol synthesis',
                dosing: 'Oral dosing varies by indication',
                contraindications: 'Coadministration with certain CYP substrates',
                interactions: 'Extensive CYP interactions',
                monitoring: 'LFTs',
                pregnancy: 'Avoid',
                sideEffects: 'GI upset, hepatotoxicity',
                clinicalPearls: 'Used for certain systemic mycoses',
                indication: 'Systemic fungal infections'
            },
            /* GI / Hepatology */
            'macrogol': {
                name: 'Macrogol (polyethylene glycol)',
                class: 'Osmotic laxative',
                mechanism: 'Osmotic water retention in colon',
                dosing: 'Constipation: sachet daily; bowel prep doses higher per protocol',
                contraindications: 'Bowel obstruction',
                monitoring: 'Electrolytes if prolonged use',
                pregnancy: 'Use if necessary',
                sideEffects: 'Bloating, diarrhoea',
                clinicalPearls: 'First-line for chronic constipation',
                indication: 'Constipation'
            },
            'docusate': {
                name: 'Docusate (stool softener)',
                class: 'Stool softener',
                mechanism: 'Surfactant reducing stool surface tension',
                dosing: 'Per product directions',
                contraindications: 'Intestinal obstruction',
                monitoring: 'Clinical response',
                pregnancy: 'Use if needed',
                sideEffects: 'GI upset',
                clinicalPearls: 'Often combined with stimulant laxatives',
                indication: 'Constipation'
            },
            'sodium-picosulfate': {
                name: 'Sodium picosulfate',
                class: 'Stimulant laxative (prodrug)',
                mechanism: 'Converted by gut bacteria to active stimulant',
                dosing: 'Per bowel prep or constipation dosing',
                contraindications: 'Bowel obstruction',
                monitoring: 'Electrolytes if significant use',
                pregnancy: 'Use with caution',
                sideEffects: 'Abdominal cramp, diarrhoea',
                clinicalPearls: 'Common in bowel prep formulations',
                indication: 'Constipation, bowel prep'
            },
            'rabeprazole': {
                name: 'Rabeprazole',
                class: 'PPI',
                mechanism: 'Proton pump inhibitor',
                dosing: '20mg once daily',
                contraindications: 'Hypersensitivity',
                monitoring: 'Response, magnesium with long-term use',
                pregnancy: 'Use if necessary',
                sideEffects: 'GI upset, headache',
                clinicalPearls: 'Alternative PPI',
                indication: 'GORD, PUD'
            },
            'ursodeoxycholic-acid': {
                name: 'Ursodeoxycholic acid (UDCA)',
                class: 'Bile acid',
                mechanism: 'Decreases cholesterol absorption and bile toxicity',
                dosing: '10-15mg/kg daily divided',
                contraindications: 'Obstructive bile duct disease without decompression',
                monitoring: 'LFTs, response',
                pregnancy: 'Use if indicated',
                sideEffects: 'Diarrhoea',
                clinicalPearls: 'Used in cholestatic liver disease and gallstone dissolution in select cases',
                indication: 'Primary biliary cholangitis, cholestasis'
            },
            'misoprostol-gastro': {
                name: 'Misoprostol (GI use)',
                class: 'Prostaglandin E1 analogue',
                mechanism: 'Protects gastric mucosa and reduces acid secretion',
                dosing: 'Use per product indication',
                contraindications: 'Pregnancy for some indications (teratogenic/abortifacient risk)',
                monitoring: 'GI response',
                pregnancy: 'Avoid for non-obstetric indications',
                sideEffects: 'Diarrhoea, abdominal pain',
                clinicalPearls: 'Used for NSAID ulcer prevention in some contexts',
                indication: 'GI mucosal protection'
            },
            /* Neurology / Psychiatry */
            'sodium-valproate': {
                name: 'Sodium valproate',
                class: 'Antiepileptic',
                mechanism: 'Multiple mechanisms incl. GABAergic effects',
                dosing: 'Loading/maintenance dosing per indication',
                contraindications: 'Pregnancy (teratogenic), hepatic disease',
                interactions: 'Many CYP interactions, lamotrigine levels affected',
                monitoring: 'LFTs, FBC, plasma levels where indicated',
                pregnancy: 'Contraindicated in pregnancy for many indications (teratogenic risk) - specialist advice',
                sideEffects: 'Weight gain, tremor, hair loss, hepatotoxicity, teratogenicity',
                clinicalPearls: 'Avoid in women of childbearing potential if possible',
                indication: 'Epilepsy, bipolar disorder (some indications)'
            },
            'lamotrigine': {
                name: 'Lamotrigine',
                class: 'Antiepileptic',
                mechanism: 'Inhibits voltage-gated sodium channels, reduces glutamate release',
                dosing: 'Slow titration to reduce rash risk',
                contraindications: 'Hypersensitivity',
                interactions: 'Valproate increases lamotrigine levels',
                monitoring: 'Skin reactions, clinical efficacy',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Rash (SJS risk), dizziness, ataxia',
                clinicalPearls: 'Slow titration required',
                indication: 'Epilepsy, bipolar maintenance'
            },
            'levetiracetam': {
                name: 'Levetiracetam',
                class: 'Antiepileptic',
                mechanism: 'Binds synaptic vesicle protein SV2A',
                dosing: '500-1500mg BD; adjust in renal impairment',
                contraindications: 'Hypersensitivity',
                interactions: 'Few significant interactions',
                monitoring: 'Mood changes, renal function',
                pregnancy: 'Use with specialist advice',
                sideEffects: 'Irritability, mood changes, somnolence',
                clinicalPearls: 'Well tolerated and widely used',
                indication: 'Epilepsy'
            },
            'clozapine': {
                name: 'Clozapine',
                class: 'Atypical antipsychotic',
                mechanism: 'Multiple receptor actions incl. D2 partial, 5-HT2A antagonism',
                dosing: 'Specialist initiation only with monitoring',
                contraindications: 'Uncontrolled epilepsy, myocarditis',
                interactions: 'Many CYP interactions',
                monitoring: 'Mandatory blood monitoring for neutropenia (ANC), ECG, metabolic monitoring',
                pregnancy: 'Specialist decision',
                sideEffects: 'Agranulocytosis risk, weight gain, sedation, myocarditis',
                clinicalPearls: 'Reserved for treatment-resistant schizophrenia with strict monitoring',
                indication: 'Treatment-resistant schizophrenia'
            },
            'quetiapine': {
                name: 'Quetiapine',
                class: 'Atypical antipsychotic',
                mechanism: 'D2 and 5-HT2 receptor antagonism',
                dosing: 'Dose varies by indication',
                contraindications: 'Hypersensitivity',
                interactions: 'CYP3A4 inhibitors',
                monitoring: 'Metabolic parameters, sedation',
                pregnancy: 'Specialist advice',
                sideEffects: 'Sedation, weight gain, metabolic syndrome',
                clinicalPearls: 'Used for psychosis, bipolar disorder, adjunct in depression',
                indication: 'Schizophrenia, bipolar disorder'
            },
            'olanzapine': {
                name: 'Olanzapine',
                class: 'Atypical antipsychotic',
                mechanism: 'D2 and 5-HT2 receptor antagonism',
                dosing: 'Dose varies by indication',
                contraindications: 'Hypersensitivity',
                interactions: 'CYP1A2 inducers/inhibitors',
                monitoring: 'Metabolic parameters',
                pregnancy: 'Specialist advice',
                sideEffects: 'Weight gain, metabolic syndrome, sedation',
                clinicalPearls: 'High metabolic risk',
                indication: 'Schizophrenia, bipolar disorder'
            },
            'clonazepam': {
                name: 'Clonazepam',
                class: 'Benzodiazepine',
                mechanism: 'Enhances GABA-A receptor activity',
                dosing: '0.5-2mg daily in divided doses (depending on indication)',
                contraindications: 'Respiratory depression, severe hepatic impairment',
                interactions: 'CNS depressants',
                monitoring: 'Sedation, dependence',
                pregnancy: 'Use with caution',
                sideEffects: 'Sedation, dependence, withdrawal risk',
                clinicalPearls: 'Used for panic disorder, some seizure types',
                indication: 'Seizures, anxiety'
            },
            'sumatriptan': {
                name: 'Sumatriptan',
                class: 'Triptan (5-HT1 agonist)',
                mechanism: '5-HT1B/1D agonist causing cranial vasoconstriction and reduced trigeminal transmission',
                dosing: '50-100mg oral or 6mg SC; repeat per guidance',
                contraindications: 'IHD, uncontrolled hypertension, hemiplegic migraine',
                interactions: 'MAOIs, other triptans (avoid within 24h)',
                monitoring: 'Blood pressure in patients with CV risk',
                pregnancy: 'Use with caution',
                sideEffects: 'Chest tightness, paraesthesia, dizziness',
                clinicalPearls: 'Effective for acute migraine attack',
                indication: 'Acute migraine'
            },
            'topiramate': {
                name: 'Topiramate',
                class: 'Antiepileptic and migraine prophylactic',
                mechanism: 'Multiple mechanisms including sodium channel blockade and GABAergic effects',
                dosing: 'Titrate slowly up to typical prophylactic doses',
                contraindications: 'Pregnancy (cleft risk), severe hepatic impairment',
                interactions: 'CYP interactions',
                monitoring: 'Weight, mood, cognitive side effects',
                pregnancy: 'Avoid if possible',
                sideEffects: 'Cognitive impairment, weight loss, paresthesia',
                clinicalPearls: 'Useful for migraine prophylaxis and adjunct in epilepsy',
                indication: 'Migraine prophylaxis, epilepsy'
            },
            /* Analgesia / Anaesthesia */
            'fentanyl': {
                name: 'Fentanyl',
                class: 'Synthetic opioid agonist',
                mechanism: 'Potent μ-opioid receptor agonist',
                dosing: 'IV 25-100mcg titrated; intranasal and patch formulations per product',
                contraindications: 'Respiratory depression, severe asthma',
                interactions: 'CNS depressants, CYP3A4 inhibitors',
                monitoring: 'Respiratory rate, sedation',
                pregnancy: 'Use with caution',
                sideEffects: 'Respiratory depression, bradycardia, chest wall rigidity (rare)',
                clinicalPearls: 'Short-acting and potent; titrate carefully',
                indication: 'Severe pain, anaesthesia adjunct'
            },
            'buprenorphine': {
                name: 'Buprenorphine',
                class: 'Partial opioid agonist',
                mechanism: 'Partial μ-opioid receptor agonist',
                dosing: 'Sublingual or patch formulations per indication',
                contraindications: 'Acute severe respiratory depression',
                interactions: 'CNS depressants',
                monitoring: 'Respiratory rate',
                pregnancy: 'Use under specialist care for OST',
                sideEffects: 'Constipation, sedation',
                clinicalPearls: 'Risks of precipitated withdrawal in opioid-dependent patients',
                indication: 'OST, pain management'
            },
            'methadone': {
                name: 'Methadone',
                class: 'Long-acting opioid agonist',
                mechanism: 'Full μ-opioid receptor agonist',
                dosing: 'Specialist OST dosing; analgesic dosing individualized',
                contraindications: 'Respiratory depression, QT prolongation',
                interactions: 'Many CYP interactions',
                monitoring: 'ECG (QT), respiratory status',
                pregnancy: 'Used in pregnancy for OST',
                sideEffects: 'QT prolongation, sedation, dependence',
                clinicalPearls: 'Long half-life — risk of accumulation',
                indication: 'OST, chronic pain (specialist)'
            },
            'ketamine': {
                name: 'Ketamine',
                class: 'NMDA antagonist / dissociative anaesthetic',
                mechanism: 'NMDA receptor antagonist producing dissociative anaesthesia and analgesia',
                dosing: 'Analgesic/ED doses: 0.1-0.5mg/kg IV (subanaesthetic) or 0.25-0.5mg/kg IM for induction depending on use',
                contraindications: 'Severe hypertension, aneurysm, raised intracranial pressure (relative)',
                interactions: 'CNS stimulants/depressants',
                monitoring: 'BP, consciousness, psychotomimetic effects',
                pregnancy: 'Use with caution',
                sideEffects: 'Hypertension, tachycardia, emergence reactions',
                clinicalPearls: 'Useful for analgesia and procedural sedation; preserves airway reflexes',
                indication: 'Analgesia, induction of anaesthesia, procedural sedation'
            },
            'lidocaine-systemic': {
                name: 'Lidocaine (systemic)',
                class: 'Local anaesthetic / antiarrhythmic',
                mechanism: 'Blocks voltage-gated sodium channels',
                dosing: 'IV bolus for arrhythmia 1-1.5mg/kg; infusion per protocol. Toxic doses vary',
                contraindications: 'Severe heart block without pacemaker, severe SA node dysfunction',
                interactions: 'Other antiarrhythmics',
                monitoring: 'ECG, signs of local anaesthetic systemic toxicity (LAST)',
                pregnancy: 'Use if necessary',
                sideEffects: 'CNS toxicity (tremor, seizures), cardiac toxicity at high doses',
                clinicalPearls: 'Monitor levels with infusion; treat LAST with lipid emulsion therapy',
                indication: 'Arrhythmias (IV), analgesia (topical/infiltration)'
            },
            /* Antidotes */
            'naloxone': {
                name: 'Naloxone',
                class: 'Opioid antagonist',
                mechanism: 'Competitive opioid receptor antagonist',
                dosing: 'IV/IM 0.4-2mg titrated; intranasal options available',
                contraindications: 'None in overdose',
                interactions: 'Precipitates withdrawal',
                monitoring: 'Respiratory rate',
                pregnancy: 'Use if maternal opioid toxicity',
                sideEffects: 'Acute withdrawal symptoms',
                clinicalPearls: 'Short-acting — monitor for re-sedation',
                indication: 'Opioid overdose'
            },
            'flumazenil': {
                name: 'Flumazenil',
                class: 'Benzodiazepine antagonist',
                mechanism: 'GABA-A benzodiazepine site antagonist',
                dosing: 'IV bolus 0.2mg increments to effect',
                contraindications: 'Chronic benzodiazepine use, mixed overdose with proconvulsants',
                monitoring: 'Seizure activity',
                sideEffects: 'Seizures (rare)',
                clinicalPearls: 'Use cautiously',
                indication: 'Benzodiazepine reversal'
            },
            /* Obstetrics / Gynaecology */
            'carboprost': {
                name: 'Carboprost',
                class: 'Prostaglandin F2α analogue (uterotonic)',
                mechanism: 'Stimulates uterine contraction',
                dosing: 'IM 250mcg repeated per PPH protocols',
                contraindications: 'Asthma (relative), severe hypertension',
                interactions: 'Other uterotonics',
                monitoring: 'Uterine tone, BP, respiratory status in asthma',
                pregnancy: 'Used postpartum for PPH',
                sideEffects: 'Bronchospasm, fever, vomiting',
                clinicalPearls: 'Avoid in severe asthma',
                indication: 'PPH management'
            },
            'magnesium-sulfate': {
                name: 'Magnesium sulfate',
                class: 'Anticonvulsant / tocolytic adjunct',
                mechanism: 'Multiple mechanisms including NMDA antagonism and calcium channel modulation',
                dosing: 'Severe pre-eclampsia: 4g IV loading then 1g/hr infusion (local protocols vary)',
                contraindications: 'Myasthenia gravis',
                interactions: 'CNS depressants, neuromuscular blockers',
                monitoring: 'Reflexes, respiratory rate, urine output, magnesium levels',
                pregnancy: 'Indicated for eclampsia prophylaxis and treatment',
                sideEffects: 'Flushing, hypotension, respiratory depression at high levels',
                clinicalPearls: 'Monitor closely; calcium gluconate is antidote',
                indication: 'Eclampsia prophylaxis/treatment'
            },
            /* Haematology / Oncology */
            'hydroxycarbamide': {
                name: 'Hydroxycarbamide (hydroxyurea)',
                class: 'Antimetabolite / cytoreductive',
                mechanism: 'Inhibits ribonucleotide reductase',
                dosing: 'Dosing per indication (e.g., myeloproliferative disease)',
                contraindications: 'Pregnancy, severe bone marrow suppression',
                interactions: 'Cytotoxic drugs (additive marrow suppression)',
                monitoring: 'FBC, renal, hepatic function',
                pregnancy: 'Contraindicated',
                sideEffects: 'Myelosuppression, mucositis, teratogenicity',
                clinicalPearls: 'Used for myeloproliferative neoplasms and sickle cell to reduce crises',
                indication: 'Polycythaemia vera, essential thrombocythaemia, sickle cell disease'
            },
            'azathioprine': {
                name: 'Azathioprine',
                class: 'Immunosuppressant/antimetabolite',
                mechanism: 'Purine analogue inhibiting DNA synthesis',
                dosing: 'Dose per indication; TPMT testing recommended prior to use',
                contraindications: 'Pregnancy unless benefits outweigh risks (specialist advice)',
                interactions: 'Allopurinol (↑ azathioprine toxicity), other immunosuppressants',
                monitoring: 'FBC, LFTs, TPMT activity',
                pregnancy: 'Use only if necessary with specialist advice',
                sideEffects: 'Myelosuppression, hepatotoxicity',
                clinicalPearls: 'Check TPMT before prescribing',
                indication: 'Autoimmune diseases, transplant'
            },
            'methotrexate': {
                name: 'Methotrexate',
                class: 'Antimetabolite/antifolate',
                mechanism: 'Inhibits dihydrofolate reductase',
                dosing: 'Low-dose weekly regimens for rheumatologic use; higher doses in oncology',
                contraindications: 'Pregnancy, breastfeeding, severe hepatic/renal impairment',
                interactions: 'NSAIDs (may ↑ levels), folic acid supplementation recommended',
                monitoring: 'FBC, LFTs, renal function',
                pregnancy: 'Contraindicated',
                sideEffects: 'Myelosuppression, hepatotoxicity, mucositis',
                clinicalPearls: 'Weekly dosing for rheumatology; ensure folic acid cover',
                indication: 'Rheumatologic disease, oncology'
            },
            'filgrastim': {
                name: 'Filgrastim (G-CSF)',
                class: 'Hematopoietic growth factor',
                mechanism: 'Stimulates neutrophil production',
                dosing: 'Per protocol for chemotherapy-induced neutropenia or stem cell mobilisation',
                contraindications: 'Hypersensitivity',
                interactions: 'None major',
                monitoring: 'FBC',
                pregnancy: 'Use if necessary',
                sideEffects: 'Bone pain, leukocytosis',
                clinicalPearls: 'Used to reduce duration of neutropenia',
                indication: 'Chemotherapy-induced neutropenia'
            },
            'tamoxifen': {
                name: 'Tamoxifen',
                class: 'Selective oestrogen receptor modulator (SERM)',
                mechanism: 'Oestrogen receptor antagonist in breast tissue',
                dosing: '20mg once daily',
                contraindications: 'History of thromboembolism, pregnancy',
                interactions: 'CYP interactions',
                monitoring: 'LFTs, signs of VTE',
                pregnancy: 'Contraindicated',
                sideEffects: 'Hot flushes, VTE risk, endometrial changes',
                clinicalPearls: 'Used as adjuvant therapy in ER+ breast cancer',
                indication: 'Breast cancer'
            },
            'letrozole': {
                name: 'Letrozole',
                class: 'Aromatase inhibitor',
                mechanism: 'Inhibits peripheral conversion of androgens to oestrogens',
                dosing: '2.5mg once daily',
                contraindications: 'Pregnancy',
                interactions: 'CYP interactions',
                monitoring: 'Bone density, lipids',
                pregnancy: 'Contraindicated',
                sideEffects: 'Hot flushes, arthralgia, bone density loss',
                clinicalPearls: 'Used in postmenopausal ER+ breast cancer',
                indication: 'Breast cancer'
            },
            'anastrozole': {
                name: 'Anastrozole',
                class: 'Aromatase inhibitor',
                mechanism: 'Inhibits aromatase',
                dosing: '1mg once daily',
                contraindications: 'Pregnancy',
                monitoring: 'Bone density',
                pregnancy: 'Contraindicated',
                sideEffects: 'Arthralgia, osteoporosis risk',
                clinicalPearls: 'Postmenopausal breast cancer therapy',
                indication: 'Breast cancer'
            },
            /* Infectious prophylaxis / antidotes */
            'pabrinex': {
                name: 'Pabrinex (Multivitamin infusion)',
                class: 'Vitamin replacement',
                mechanism: 'High-dose parenteral vitamins including thiamine',
                dosing: 'Per local protocol (e.g., parenteral B vitamins in alcohol withdrawal/malnutrition)',
                contraindications: 'Hypersensitivity',
                monitoring: 'Allergic reactions, clinical response',
                pregnancy: 'Use if indicated',
                sideEffects: 'Rare hypersensitivity',
                clinicalPearls: 'Used in malnutrition and alcohol withdrawal; provides parenteral thiamine',
                indication: 'Vitamin replacement in deficiency'
            },
            'thiamine': {
                name: 'Thiamine (Vitamin B1)',
                class: 'Vitamin',
                mechanism: 'Cofactor for carbohydrate metabolism',
                dosing: 'Often 200mg IV daily or per local protocol for deficiency/Wernicke',
                contraindications: 'Hypersensitivity',
                monitoring: 'Clinical response, magnesium status',
                pregnancy: 'Safe when indicated',
                sideEffects: 'Rare hypersensitivity',
                clinicalPearls: 'Give prior to glucose in malnourished/alcohol-dependent patients',
                indication: 'Prevention/treatment of Wernicke encephalopathy'
            },
            'activated-charcoal': {
                name: 'Activated charcoal',
                class: 'Adsorbent (decontamination)',
                mechanism: 'Adsorbs many toxins in GI tract reducing absorption',
                dosing: '50-100g orally for adults (single dose) — follow toxicology guidance',
                contraindications: 'Unprotected airway, caustic ingestion',
                interactions: 'May adsorb orally administered antidotes/meds',
                monitoring: 'Airway protection, vomiting',
                pregnancy: 'Use if indicated',
                sideEffects: 'Vomiting, aspiration risk if airway not protected',
                clinicalPearls: 'Most effective when given early after ingestion',
                indication: 'Acute poisoning (selected cases)'
            },
            'metoprolol': {
                name: 'Metoprolol',
                class: 'Beta-blocker (β1 selective)',
                mechanism: 'Selective β1-adrenoceptor antagonist reducing heart rate and myocardial contractility',
                dosing: 'Hypertension/angina: 50-100mg daily (in divided doses or extended-release). IV for acute rate control per local protocol',
                contraindications: 'Uncompensated heart failure, severe bradycardia, cardiogenic shock, asthma with active bronchospasm (use cautiously)',
                interactions: 'Other rate-limiting drugs (CCBs, digoxin), insulin (masks hypoglycaemia), CYP2D6 inhibitors (increase levels)',
                monitoring: 'Heart rate, blood pressure, signs of heart failure, ECG as needed',
                pregnancy: 'Use with caution—can cause fetal bradycardia and growth restriction',
                sideEffects: 'Bradycardia, fatigue, cold extremities, sleep disturbance, impotence',
                pharmacokinetics: 'Hepatic metabolism (CYP2D6); variable bioavailability; half-life ~3-7h (longer for extended-release formulations)',
                clinicalPearls: 'Cardioselective at low doses; useful for rate control in AF/flutter and post-MI management',
                indication: 'Hypertension, angina, rate control in atrial fibrillation, secondary prevention post-MI'
            },
            'propranolol': {
                name: 'Propranolol',
                class: 'Non-selective beta-blocker',
                mechanism: 'Non-selective β1 and β2 antagonist reducing heart rate, myocardial contractility and peripheral vasodilation',
                dosing: 'Hypertension/angina: 40-320mg daily in divided doses or as extended-release; anxiety/thyrotoxicosis use lower doses as needed',
                contraindications: 'Asthma/COPD with active bronchospasm, severe peripheral vascular disease, uncontrolled heart failure',
                interactions: 'CCBs/antiarrhythmics (additive bradycardia), insulin (masks hypoglycaemia), CYP2D6 inhibitors',
                monitoring: 'HR, BP, signs of heart failure, respiratory status',
                pregnancy: 'Use with caution; fetal growth restriction reported with long-term use',
                sideEffects: 'Bradycardia, fatigue, bronchospasm, vivid dreams, impotence',
                pharmacokinetics: 'Hepatic metabolism; high first-pass effect; lipid soluble (crosses BBB)',
                clinicalPearls: 'Useful for migraine prophylaxis, essential tremor, thyrotoxicosis symptoms; avoid in reactive airways disease',
                indication: 'Hypertension, angina, arrhythmias, migraine prophylaxis, essential tremor'
            },
            'trametinib': {
                name: 'Trametinib',
                class: 'MEK inhibitor (targeted anticancer therapy)',
                mechanism: 'Inhibits MEK1 and MEK2, blocking MAPK pathway signalling in tumours with BRAF/MEK pathway activation',
                dosing: 'Oral 2mg once daily (usually in combination with other targeted agents); oncology dosing varies',
                contraindications: 'Known hypersensitivity; caution with cardiac disease and retinal disorders',
                interactions: 'CYP3A4 inducers/inhibitors may alter levels; many anticancer drug interactions possible',
                monitoring: 'LVEF, blood pressure, skin toxicity, ocular symptoms, LFTs',
                pregnancy: 'Contraindicated - teratogenic',
                sideEffects: 'Rash, diarrhoea, peripheral oedema, cardiomyopathy, ocular toxicity (retinal events)',
                pharmacokinetics: 'Oral agent with hepatic metabolism; refer to oncology guidance for specifics',
                clinicalPearls: 'Specialist oncology drug - use as part of targeted therapy in selected cancers; not a routine ward antimicrobial or cardiovascular drug',
                indication: 'Metastatic melanoma and other BRAF/MEK pathway-driven malignancies as per oncology guidance'
            },
            'pravastatin': {
                name: 'Pravastatin',
                class: 'Statin',
                mechanism: 'HMG-CoA reductase inhibitor reducing cholesterol synthesis',
                dosing: '10-40mg once daily (start 10-20mg and titrate)',
                contraindications: 'Active liver disease, pregnancy, breastfeeding',
                interactions: 'Fewer CYP interactions than many statins; caution with fibrates and cyclosporine',
                monitoring: 'LFTs at baseline and when clinically indicated, CK if muscle symptoms',
                pregnancy: 'Contraindicated',
                sideEffects: 'Myalgia, hepatotoxicity (rare), new-onset diabetes (small risk)',
                pharmacokinetics: 'Hydrophilic statin with less drug interaction via CYP system',
                clinicalPearls: 'Useful when drug interactions with CYP3A4-metabolised statins are a concern',
                indication: 'Hyperlipidaemia, cardiovascular risk reduction where appropriate'
            },
            'hydralazine': {
                name: 'Hydralazine',
                class: 'Vasodilator (direct arteriolar dilator)',
                mechanism: 'Direct relaxation of arteriolar smooth muscle reducing afterload',
                dosing: 'Start 25mg BD/TDS; titrate as needed (usual 50-200mg/day in divided doses)',
                contraindications: 'Coronary artery disease, mitral valve rheumatic disease (use with caution), severe tachycardia',
                interactions: 'Other antihypertensives (additive hypotension), MAOIs (sympathomimetic interactions)',
                monitoring: 'BP, HR, signs of lupus-like syndrome (long-term), renal function',
                pregnancy: 'Can be used in pregnancy for severe hypertension under specialist guidance',
                sideEffects: 'Tachycardia, fluid retention, headache, flushing, lupus-like syndrome with long-term use',
                pharmacokinetics: 'Hepatic acetylation (slow vs fast acetylators affect response and side effects)',
                clinicalPearls: 'Often used in combination with a β-blocker and diuretic to counter reflex tachycardia; consider in pregnancy with severe hypertension under guidance',
                indication: 'Severe hypertension (including in pregnancy under specialist care), refractory hypertension'
            }
}

// Make drugDatabase available globally
window.drugDatabase = drugDatabase;

